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Abstract
Oestrogens are essential regulators of both male and female fertility as well as
playing an important role in other tissues including the cardiovascular system and
bone. Oestrogen action is mediated via high affinity nuclear receptors expressed in
target tissues. The first oestrogen receptor (ER) was cloned in 1986 however, ten
years later a second ER was identified. The two ERs are known as ERa and ERp
and are encoded by genes on different chromosomes. Splice variants of ERp have
been described in human; one of these variants (known as ER|32 or ERpcx)
contains an alternatively spliced exon at the 3' end. The resulting ERp2 variant
protein has a truncated C-terminal when compared to the ERp wild type (WT)
protein, resulting in the absence of a functional AF-2 region and part of the ligand
binding domain, leaving intact the AF-1 domain which may be a target for
phosphorylation.
The aims of this project were a) to determine whether ERp WT and ERp variant
(ER(32) forms exist in primates as well as in humans and to determine the ER
localisation in reproductive tissues, b) to examine the localisation of FP-tagged ER
protein constructs (ERa, ERp WT and ERp2) within cells using a confocal
microscope in the presence or absence of different oestrogenic ligands, c) to
examine the functional dose response of ER proteins to different ligands using
transient transfections in the presence of ERE-luciferase reporter constructs, d) to
investigate an alternative activation mechanism for ERp2 via a growth factor
signalling pathway.
RT-PCR results demonstrated that mRNA for ERp WT and the ERp2 variant were
differentially expressed in tissues from the human, Old World (stump-tailed
macaque) and New World (common marmoset) primates. Immunohistochemical
analysis resulted in detection of ERp WT protein in both human and primate tissues
but ERp2 variant protein immunostaining was only positive in the human tissues.
Sequence analysis revealed that the peptide used to raise the anti-hERp2 antibody
was not conserved in either primate. In human tissues, ERp WT and ERp2 had
differential but overlapping patterns of expression so that formation of homo- or
heterodimers might occur. In the absence of ligand the FP-tagged ERs were
diffusely distributed within the nucleus of transfected cells. Addition of oestrogenic
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ligands induced rapid redistribution of both the ERa and ERp WT receptors so that
they adopted a 'focal' nuclear pattern. The ER|32 variant remained in a diffuse
distribution throughout the nucleus even in the presence of ligand. Transient
transfection studies revealed differences in the extent to which ERa, ERp WT and
ER(32 variant can stimulate gene transcription of ERE-luciferase reporter constructs
following addition of oestrogenic ligands. ERa and ERp WT were both able to
stimulate reporter gene expression in a dose-dependent manner, whereas the ER|32
variant was not able to activate the ERE-luciferase reporter. Co-transfections of
ERa or ERp WT with ER(32 suggested a possible dominant negative effect of ERp2
on ERa but this was abolished when the co-activator SRC-1 was present. The ER(32
variant did not respond to ligand by showing a change in subnuclear localisation nor
did it activate the ERE-luciferase consistent with the absence of a functional AF-2
region but it did appear to be activated by epidermal growth factor acting via the
MAP kinase phosphorylation pathway.
In conclusion, ERp WT and ER|32 variant proteins are expressed in reproductive
tissues in human and primate. The ERp2 variant cannot be activated by binding
oestrogens but appears to be a target for phosphorylation via growth factor
stimulated pathways. The ability of this receptor to form heterodimers with ERa or
with ERp WT thereby altering target cell responsiveness to oestrogens may have an
impact on cell function. Further studies are required to elucidate the relative
contributions of ERa, ERp WT and ERp variants in the response of tissues to
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Appendix to Materials and Methods
Chapter 1
Literature Review
1.1 Oestrogens and Human Health
Oestrogens influence cell function in a wide range of tissues including bone (Turner
et al., 1994), the cardiovascular system (Farhat et al., 1996), brain and central
nervous system (McCarthy, 1996) and have an important role in both male and
female reproductive function (Clarke et al., 1992; Manolagas and Kousteni, 2001)
(see Figure 1.1).
Figure 1.1. Figure to demonstrate oestrogen target tissues within the male and female.
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1.1.1 Oestrogen Action in the Female
A key focus of oestrogen action in the female is within the reproductive system. The
menstrual cycle in the female has two distinct phases; 1) the oestrogenic (follicular)
phase in which the ovary prepares the female for receipt of spermatozoa and
fertilization of the oocyte, 2) the progestagenic (luteal) phase when the ovary
prepares the female to receive and nuture the conceptus should fertilisation be
successful. See Figure 1.2. for details of the hormone levels throughout the cycle.
Ovulation
Figure 1.2. Figure to show the levels of oestradiol, progesterone, LH and FSH throughout
the human reproductive cycle. Taken from Carlson (1994).
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1.1.2 Oestrogen Action in the Male
Oestrogens have an impact on the reproductive and non-reproductive tissues in
males (see Figure 1.1) and are believed to play a significant role in maintaining
fertility (reviewed by O'Donnell et al., 2001). The primary function of the testis is to
synthesise and secrete steroid hormones, notably testosterone and to release
mature spermatozoa (Figure 1.3).
Spermatogenesis involves four basic processes: spermatogonia! development (stem
cell and subsequent cell mitotic divisions), meiosis (DNA synthesis and two meiotic
divisions to yield haploid spermatids), spermiogenesis (spermatid development
involving differentiation of head and tail structures) and spermiation (the process of
release of mature sperm into the tubule lumen). The organisation of
spermatogenesis is essentially the same in all mammals and has been described at
the morphological level (Sharpe, 1994) and recently reviewed by McLachlan et al.,
(2002). In rodents and some primate species (e.g., Macaca fascicularis), germ cell
development occurs in orderly and recognizable cell associations (or stages) along
the seminiferous tubule, such that a single stage can be seen within a tubule cross
section (Russell et al., 1990). However, in humans and some other primates (e.g.
Callthrix jacchus, the common marmoset), the stages are arranged in an
intertwining helical pattern such that a single tubule cross section may have up to
six identified stages represented (Millar et al., 2000; Schulze and Rehder, 1984).
Such an arrangement makes the systematic stage-based counting of germ cell
populations, as well as the stage-specific detection of proteins or mRNA species of
interest, difficult although possible (McLachlan et al., 2002) and means the
marmoset is considered a useful model for human spermatogenesis.
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Figure 1.3. Schematic picture of the testes and spermatogenesis (Cooke and Saunders,
2002). A cross section through the testis (a) showing the localisation of the seminiferous
tubules, the vas deferens and the epididymis. A diagrammatical cross-section through a
testicular tubule (b) showing the germ cells (green) at different stages of maturation within
the Sertoli cell (outlined in red). Leydig cells (LC) present in the interstitium, are the sites of
testosterone synthesis. Maturing sperm are shown in the lumen of the tubules. PTM;
Peritubular myoid cells. A single Sertoli cell (c) with its associated germ cells. Tight junctions
between Sertoli cells (arrowhead) define two compartments; the stem cells and the pre-
meiotic cells (spermatogonia) are found on one side of the junction whereas meiotic
(spermatocytes) and the post-meiotic (round and elongated spermatids) are found organised
in order of maturation towards the lumen (cytoplasm is shown in dull green). DNA is shown
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1.2 Steroidgenesis
Oestrogen biosynthesis is dependent on the expression of the cytochrome p450
aromatase enzyme. In females high levels are found in human placenta and the
granulosa cells of the mature ovarian follicle (Simpson and Davis, 2001; Turner et
al., 2002). This is consistent with the finding that in non-pregnant pre-menopausal
females the ovaries are the primary source of oestradiol (Simpson, 2000).
In males, oestrogens are synthesised from testosterone or oestrone via the
aromatase or 17|3-hydroxysteroid dehydrogenase (17(3-HSD) enzymes in the brain
and the testis (de Ronde et at., 2003). The total oestradiol production rate in the
human male has been estimated to be 35-45p,g per day, of which approximately 15-
20% is directly produced within the testis (Baird et al., 1969). Therefore oestrogen
levels within the reproductive tract of the male are higher than the rest of the
circulation (Hess, 2000). The site of oestrogen synthesis in the male was initially
thought to be the Leydig cells (Payne, 1990). However more recent data has
demonstrated aromatase was also associated with the cytoplasm surrounding
elongate spermatids in human, marmoset and rat (Turner et al., 2002) and in
rodents, aromatase activity has been found in mature germ cells and spermatozoa
(Hess et al., 1995; Nitta et al., 1993).
1.3 Nuclear Receptor Gene Superfamily
Nuclear hormone receptors are a class of transcription factors whose activity
depends on the binding of a ligand (Parker, 1990). The oestrogen receptor (ER)
belongs to the nuclear receptor superfamily, of which there are 83 subgroups
identified (NUREBASE; www.ens-lyon.fr/LBMC/laudet/nurebase). These include the
receptors for testosterone, progesterone, corticoids, thyroid hormone, vitamins A
and D, and a large group of proteins referred to simply as "orphan" receptors for
which the specific ligands are still to be determined (Enmark and Gustafsson, 1999).
The mechanism of action of these steroid hormones is that upon ligand binding the
nuclear receptor undergoes a conformational change which promotes dimerisation,
recruitment of co-activator proteins and high affinity binding to specific palindromic
DNA response elements, for example the oestrogen response element (ERE)
located within the regulatory region of target genes (Beato and Klug, 2000;
Mangelsdorf et al., 1995).
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1.3.1 Introduction to Steroid Receptor-Group III
Members of the steroid hormone receptor (SHR) family share significant sequence
homology with each other and have been classified as subgroup A of the nuclear
receptor subfamily 3 (NR3) (reviewed in Beato and Klug, 2000). All the members of
the SHR share a common arrangement of five structure-function domains denoted
A-F (as pictured in Figure 1.4) (Beato et at., 1995; Beato and Klug, 2000;
Mangelsdorf et al., 1995), the roles of which have been defined by techniques such
as domain switching and site directed mutagenesis (reviewed in Carson-Jurnica et
al., 1990). Some domains have high homology between the receptors (e.g. the DNA
binding domain), however the A/B and F functional domains are poorly conserved
between the family members (Scobie et al., 2002) (see Figure 1.4).
Figure 1.4. A diagram to illustrate the nuclear receptor domains. Adapted from Nilsson et al.,
(2001).
A/B D E
AF-l DNA Ligand AF-2
1.3.2 Oestrogen Receptor Genes
The oestrogen receptor family of steroid hormone receptors is multifaceted (Hall,
2001) and more complex than initially thought. The "classical" oestrogen receptor
(ERa) was discovered by Elwood Jensen in 1958 and cloned in 1986 from a human
breast cancer cell line (Green et al., 1986). For many years it was thought that this
was the only ER, until an ERa knockout (ERKO) mouse model was produced and
exhibited specific oestrogen binding in some tissues (Lubahn et al., 1993)
suggesting that a second oestrogen receptor must exist. In 1996 a second ER
(ERp) was cloned from rat prostate cDNA (Kuiper et al., 1996).
Both oestrogen receptors (ERa and ERp) are encoded by eight exons, however
they are the products of two different genes located on different chromosomes
(Enmark et al., 1997). Human ERp has been mapped to band q22-24 of
chromosome 14 (Enmark et al., 1997; Lakaye et al., 1998) whereas human ERa
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has been mapped to the long arm of chromosome 6 (Enmark and Gustafsson,
1999).
The ERa and ER|3 isoforms have distinct roles in oestrogen action, independent of
each other (reviewed in Couse and Korach, 1999) as well as being able to directly
interact due to heterodimerisation which may occur when the receptor proteins are
expressed together in the same cell (Cowley etal., 1997; Enmark etal., 1997).
1.3.3 Domains
ERa and ER|3 have six domains named A-F from the N- to C-terminus, encoded by
8-9 exons (Kuiper et at., 1998) (See Figure 1.4). The three major functional domains
of the ER are (i) a variable N-terminus (domains A and B) which contains the
activation function-1 (AF-1) (Enmark and Gustafsson, 1999; Mclnerney and
Katzenellenbogen, 1996), (ii) a highly conserved DBD, also referred to as the C
domain (Enmark et at., 1997) and (iii) a less conserved LBD (E domain) that
contains the activation function-2 (AF-2) (Klinge, 2001).
The variable A/B domain modulates transcription by directly interacting with
components of the core transcriptional machinery or with co-activators that mediate
signalling to downstream proteins in a gene- and cell- specific manner through the
AF-1 (Enmark and Gustafsson, 1999).
The DNA-binding domain (C) is the most conserved region between ERa and ER(3,
sharing 97% homology (Enmark et at., 1997) and is comprised of two functionally
distinct zinc fingers through which the ER interacts directly with the DNA helix. The
positions of the cysteine residues within this domain, that co-ordinate the two zinc
fingers are very highly conserved. The sequence EGCKAF (hER(3 amino acids 122-
127) at the base of the first zinc finger is essential for specific binding to oestrogen
responsive elements on target genes. The region of the second zinc finger
contributes to the receptor dimerisation (CPATNQC; hER(3 143-150). Both zinc
fingers are identical in both ERa and ER|3 (reviewed in Pettersson and Gustafsson,
2001). As human ERa and ER(3 have a conserved DBD it has been proposed that
both ERa and ER(3 are able to bind to identical oestrogen response elements
(EREs) on the DNA (Ogawa et at., 1998a).
The hinge (D) domain contributes flexibility to the DNA and the ligand binding
domain and has been shown to influence the DNA binding properties of individual
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receptors (Enmark and Gustafsson, 1999). It has also been proposed that the D
domain serves as an anchor for certain co-repressor proteins (Enmark and
Gustafsson, 1999).
Domain E is located within the C-terminal and contains regions of homology (53%)
between ERa and ER|3. It is this region which determines the ligand specificity of the
receptor proteins. The LBD also harbours the activation function-2 (AF-2) which is a
complex and conserved region whose structure and function are determined by the
binding of ligands (Feng et a/., 1998; Henttu et at., 1997; Klinge, 2001; Shiau eta!.,
1998). The C-terminal F domain has been shown to contribute to the
transactivational capacity of the receptor via the AF-2 region (Enmark and
Gustafsson, 1999).
1.4 The Oestrogen Receptor alpha (ERa)
The ERa protein is approximately 67kDa (Kuiper et a!., 1997). The ERa gene
(located on chromosome 6) is very large with the translated exons spanning more
than 140kb (Enmark efa/., 1997; Ponglikitmongkol efa/., 1988). The human ERa
gene has been shown to have at least three separate promoters (Enmark et at.,
1997).
1.4.1 ERa Variants
There are numerous variants of ERa, either with point mutations at a single amino
acid or with insertions, or more commonly deletions, which have been identified as
mRNAs (Fuqua efa/., 1993; Taylor efa/., 1998; Zhang efa/., 1996).
Examples of ERa isoforms include one with exon 3 deleted (ERaA3) and which is
therefore missing the second zinc finger of the DBD. This isoform inhibits oestradiol
dependent transcriptional activation in a dominant negative fashion when it is co-
transfected with the wild type ERa (Wang and Miksicek, 1991). Inuoe et at reported
a mutated ERa with deleted exons 4 and 5, this also inhibited wild type ERa activity
when they were co-transfected (Inoue efa/., 1996).
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1.5 The Oestrogen Receptor beta (ERp)
The intron/exon organisation of both the mouse and the human ERp genes has
been determined (Enmark et al., 1997). The translated exons of the mouse ERp
gene span approximately 40kb which is considerably smaller than the ERa gene
(Enmark, 1998). Multiple non-coding exons upstream (5') from exon 1 have also
been identified (Enmark etal., 1997; Peng et al., 2003).
Homology between ERp and ERa is particularly high in the DNA-binding domain
(95% amino acid identity) and in the ligand binding domain (55% amino acid
identity) (Enmark and Gustafsson, 1999) as shown in Figure 1.5.
Figure 1.5. Percentage amino acid homology between human ERa and ERp.
1 185 251 355 549 595
A/B 0BD Hinge LBD AF-2 hERa
17% 97* 4 30% 59% 18% hERp
148 214 304 500 530
1.5.1 ERp Variants
Since the cloning of the human homologue of ERp was first reported by Mosselman
efa/(1996) additional sequence information has become available and led to the
identification of several variant isoforms of human ERp (Inoue et al., 2000; Lu et al.,
1998; Moore etal., 1998; Ogawa etal., 1998b; Ogawa etal., 1998c). The molecular
weights of the human ERp variant proteins are given in Table 1.1.
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Table 1.1. Human oestrogen receptor variants identified in the human for which there is
evidence for protein expression. Taken from Scobie et al., (2002).
Abbreviated name Protein size (kDa) References
Beta 1 "long" (wild type) 59.2 Ogawa et al., 1998b
Beta 1 "short" 53.3
54.2
Mosselman et al., 1996;
Enmark et al., 1997
Beta 2/cx "long" 55.5 Ogawa et al., 1998c;
Moore et al., 1998
Beta 2/cx "short" 51 Ogawa et al., 1998c
B1/B2 exon 5 deleted 36 Lu et al., 1998;
Inoue et al., 2000
Beta 4 8 (?) Moore et al., 1998
Beta 5 7 (?) Moore et al., 1998
Bold indicates the ER(3s studied in this thesis.
1.5.1.1 Alternate Start Sites
The original human ER|3 cDNA published (X99101: Mosselman et al., 1996)
encoded a protein (~53kDa) that was eight amino acids shorter than the rat ER(3
cDNA (Kuiper et al., 1996). The human sequence was extended to include extra
nucleotides and it was confirmed that it contained an ATG start site corresponding
to the original rat clone (Enmark et al., 1997). The size of the human ER(3 protein
was determined to be approximately 54.2kDa. The hER(3 sequence was further
extended to include a further 45 amino acids resulting in a protein size of 59.2 kDa
(AB00659: Ogawa et al., 1998b). Saunders et al have found that proteins
corresponding to both the "long" and the "short" forms of ER|3 can be detected on
Western blots (Saunders et al., 2002b and unpublished data).
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1.5.1.2 Splice Variants and Loss of Exons
Several splice variants have been described for both the human (Figure 1.6) and
rodent ER(3.
Figure 1.6. Illustration of the splice variants of human ER|3. Exons 1-8 are utilised in wild type
ER(3 (ER|31) but the ER|32 splice variant has exon 8 replaced by the alternative exon (exon
9) labelled ex. Adapted from Weihua et al., (2003).
hER[?65
hERpS5,6 1 2 3 4 7 8
1 2 3 4 6 7 8
1.5.1.3 Identification ofN- or C-terminal Variant Isoforms of ER/3
In 1998 a novel human ER(3 variant was identified and named ER|32 (also referred
to as ER|3cx) (Moore et al., 1998; Ogawa et at., 1998c). The open reading frame of
the hER[32 protein (55kDa) was found to be identical to ER(31 from amino acids 1 to
468, the hER(32 sequence then diverges at the C-terminus (see Figure 1.6). The last
61 C-terminal amino acids of ER|31 are replaced by a unique 26 amino acid residue
in ER|32, due to the exchange of the last exon. ER|32 therefore lacks some amino
acids important for ligand binding and all of those that constitute the AF-2 core
domain in helix 12 (Weihua et al., 2003).
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Moore et al have described five ERp isoforms (ERpi-5) detected by RT-PCR from
human tissues (Moore et al., 1998). The human ER(33 is also identical to hERpi up
to amino acid 468 and then diverges containing another 5 novel amino acids (see
Figure 1.6). Therefore both the hER(32 and hER|33 variants are truncated at the C-
terminus, have a disrupted helix 11, and are missing helix 12. They are therefore
are unable to bind ligand or have AF-2 mediated transcriptional activity (Peng et at.,
2003).
Human ERp5 mRNA has been found to contain a sequence between exon 7 and
part of exon 9 which are not present in either hER|31 or hER(32 mRNA (Moore et al.,
1998; Peng et al., 2003). These specific ERp5 mRNA sequences can be found
immediately following exon 7 sequences of intron 7 of the human ER|3 gene, 28
nucleotides downstream of those present in hER|32. Thus suggesting that a cryptic
splice acceptor is present within exon 9 and that the normal splice donor site is not
recognised (Peng et al., 2003).
RT-PCR using specific primers has detected mRNA specific for ER|32 in multiple
tissues (Moore et al., 1998; Scobie et al., 2002). This isoform seems to be
particularly abundant in testis (Makinen et al., 2001; Moore et al., 1998). The ER|34
and ER|35 mRNAs have also been detected in the testis and ovary as well as in
several other tissues and human cell lines (Moore et al., 1998). ER(34 has generally
been found to be expressed to a lesser extent than ER|35 except within the testis
(Moore eta!., 1998; Scobie et al., 2002).
1.5.1.4 LossofExons
Lu et al detected ERp mRNAs lacking exons 5 (ER|3A5) and/or 6 (ER|3A5/6) in
human breast, ovary, uterus and breast cancer by RT-PCR with primers located in
exons 4 and 8 (Lu et al., 1998). Messenger RNA for the exon 5 deleted form of ERp
has also been identified in a breast cancer cell line using RT-PCR and RNase
protection assays (Vladusic et al., 1998) and isolated from human testis cDNAs
(Inoue et at., 2000). Exon 5 deletion results in a frame shift in the reading frame of
the protein and the introduction of five alternative amino acids followed by a stop
codon (Inoue et al., 2000).
Isoforms of rat ERp lacking exon 3 (Price et al., 2001) and isoforms containing an
insertion of 54 nucleotides encoding an additional 18 amino acids between exons 5
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and 6 (Chu and Fuller, 1997) have both been documented to modulate gene
transcriptional activation by ERa and the ER|3 wild type. However these splice
variants have not been detected in human (Chu and Fuller, 1997; Chu et al., 2000).
1.6 Oestrogen Receptor Ligand Binding Domain
The ligand binding domain (E domain) mediates ligand binding, receptor
dimerisation, nuclear translocation and transactivation of target gene expression.
The LBD shares 53% homology between ERa and ERp (Weihua et al., 2003).
Crystallographic studies have shown that the overall tertiary structure of the ligand-
binding domain of human ERa (Brzozowski et al., 1997) and ERp (Pike et al., 1999)
are similar and contain 12 helices (Figure 1.7). Studies in the rat ERp have shown
that there are key amino acids within the ligand binding domain which are
conserved between the ER subtypes and that amino acids surrounding the LBD
cavity are very similar (Kuiper et al., 1997). Alignment of the E domain sequences
of human ERa and ER|3 has revealed two regions of the protein with significant
homology; hERp 260-343/hERa 353-431, and hERp 418-453/hERa 511-547
(Enmark et al., 1997) which include helix 12 (Figure 1.7). Therefore it is not
surprising that some oestrogenic compounds that have been tested bind to rat ERa
and ERp with similar affinities (Kuiper et al., 1998) or have similar potencies in
activation of ERE reporter mediated gene transcription.
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Figure 1.7. Schematic representation of the hERa, illustrating the helices upon receptor
dimerisation. Taken from Tanenbaum et al., (1998).
Agonists induce a conformational change in ERa so that the AF-2 core helix (helix
12) completes the formation of a hydrophobic groove (Nilsson et al., 2001) (Figures
1.7 & 1.8) which is important in binding to LXXLL motifs (NR box) found in p160 co-
activator proteins (Brzozowski et al., 1997; Shiau et al., 1998). When ERa is bound
to an antagonist, helix 12 is displaced from this position and instead occupies the
hydrophobic co-activator binding groove, formed by helices 3, 4, and 5, therefore
precluding co-activator binding (Brzozowski et al., 1997; Kraichely et al., 2000;
Shiau et al., 1998). The conformations adopted by the receptor following agonist
and antagonist binding are illustrated in Figure 1.8. The position adopted by helix 12








Chapter 1 Literature Review 25
Figure 1.8. Diagram to show the receptor conformation upon ligand binding with agonist or
antagonists (eg.raloxifene). Taken from Nilsson ef a/., (2001).
1.6.1 Importance of the AF-2 Domain
The ligand dependent transactivation domain AF-2 is of particular interest because it
provides a mechanistic explanation for the observed differences between agonism
and antagonism of the ER. The AF-2 recruits co-factors upon ligand binding and it is
these proteins which act to inhibit or increase transcriptional activity by binding with
the pre-initiation complex. The ERP2 lacks the AF-2 domain and part of the ligand
binding domain, therefore it is unable to bind correctly to ligands or to recruit co-
factors.
The AF-2 is part of the LBD and the conformation of the LBD has been shown to be
of vital importance for AF-2 function. The AF-2 region was initially identified in the
mouse ERa where detection analysis demonstrated a large segment of the LBD to
be important for ligand binding (Lees et al., 1990). Mutation and deletion studies of
LBDs revealed a conserved segment in the very C-terminus of the LBD that was
shown to be essential for ligand dependent activation of transcription (reviewed in
Warnmark et al., 2003). This conserved segment has been shown by
crystallographical studies to be an amphipathic helix (helix 12) within the ER. This
helix projects away from the core structure whereas in a ligand-bound ER, helix 12
is folded up against the core creating a lid over the ligand binding pocket. This
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amphipathic, a-helical structure is critical for AF-2 function and mutagenesis studies
suggest that co-activator interactions with ER may depend on the integrity of this
activation region (Danielian et al., 1992). Therefore, structural data together with
transcriptional activation data imply that the positioning of helix 12 is crucial for
receptor activation.
There is a conserved tyrosine residue located immediately before the AF-2 domain
(White et al., 1997). This residue is conserved in the ER sequence of every species
examined to date (Smith, 1998). The importance of this tyrosine, Tyr537, in human
ER a (Tyr541 in mouse ERa) for ER function is highlighted by site-directed
mutagenesis studies in which amino acid substitutions (serine or alanine for tryosine
537) in human ERa resulted in a constitutively active ERa mutant (Weis et al.,
1996). In contrast to wild-type ERa, the mutant receptor interacts with co-activators
to a lesser extent in the absence of hormone (Weis et al., 1996). Therefore data has
demonstrated that the conserved tyrosine (Tyr537) and the adjacent amphiathic
helix form a conformation-dependent interaction surface for co-activators and that
this region is important for ER transcriptional activity.
1.6.2 Oestrogen Receptor Dimerisation
Dimerisation of the ER upon ligand binding is necessary for DNA binding and hence
gene transcription. Transcriptional activity of the dimer complex has been found to
be dependent on a functionally intact AF-2 region within both ERa and ER(31
(Warnmark et al., 2003). The complex is able to initiate transcription when only one
ER subunit interacts with a ligand, albeit to a lower extent than if both subunits
interacted with a ligand (Pettersson et al., 1997).
1.6.2.1 Domains Involved in Dimerisation
Mutations that interfere with the dimerisation of steroid receptors generally result in
receptors that are transcriptionally inactive (Tamrazi et al., 2002). Human ERa and
hER(3 have almost identical DBDs and the regions of the LBDs involved in
dimerisation also share a significant degree of similarity (Pettersson and
Gustafsson, 2001). The region of the second zinc finger within the DBD is thought to
contribute to specific receptor dimerisation via the CPATNQC sequence and this
sequence is identical in hERa and hER|3 (Pettersson and Gustafsson, 2001).
Residues 507-514 have been identified as vital for dimerisation activity of mouse
Chapter 1 Literature Review 27
ERa and are largely conserved in rodent and human ERp (Ekena et al., 1997;
Fawell et al., 1990; Lees etal., 1990).
1.6.2.2 Homodimers and Heterodimers
A variety of techniques have been used to demonstrate the ability of ERa and ER|5
to form homodimers (ERa/ERa or ERp/ERp) and heterodimers (ERa/ERp) (Figure
1.9). These include gel shift assays (Cowley et al., 1997), GST pull down assays
(Cowley et al., 1997; Ogawa et al., 1998b; Pettersson et al., 1997),
immunoprecipitation (Pettersson etal., 1997) and a mammalian two hybrid system
(Pettersson et al., 1997).
Figure 1.9. Diagram to demonstrate ER homodimerisation and heterodimerisation.
ERE ERE ERE
Heterodimer formation between hERa and ERp means that in vivo they may
cooperate in regulating oestrogen-responsive gene expression in cell types in which
they are co-expressed (Pettersson et al., 1997). Co-expression of ERa and ERp
results in the preferential formation of receptor heterodimers, instead of ERa and
especially ERp homodimers in vitro (Enmark and Gustafsson, 1999; Hall and
McDonnell, 1999). In binding assays, human ERa/ERp heterodimers bind to the
consensus ERE with an affinity similar to that of ERa homodimer (2nM Kd) and is
greater than that of the ERp homodimer (~8nM Kd) (Cowley et al., 1997). Similar
results were observed in transient transfections in human cell lines (Hall and
McDonnell, 1999; Pettersson et al., 1997).
The molecular basis for the reduced DNA binding activity of ERp/ERp homodimers
is unclear. Differences within the DBD of the two receptors are unlikely to account
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for the variation since they differ by only two residues, neither of which seems to be
in a position that is likely to affect their DNA binding properties. An alternative
possibility is that the receptors differ in their ability to dimerise. It seems likely that
the residues required to form the homodimer interface in ERa and ERp dimers are
distinct. Although precise dimerisation interfaces in these two receptors have yet to
be identified, functional analysis of a series of mutations in helix 10 of ERa indicate
that the residues are similar but not identical to those required for ERa/ERp
heterodimerisation (Cowley et al., 1997).
The truncated ERp2 splice variant contains the DBD and most of the LBD including
the conserved dimerisation sequence. It is able to form heterodimers with ERa or
with ER(31 in gel shift assays (Cowley et al., 1997) and in GST Pull down assays
(Ogawa et al., 1998c) (as illustrated in Figure 1.10 with ERpi). ERp2 shows
preferential heterodimerisation with ERa rather than with ERpi and therefore may
act to inhibit ERa's binding to DNA (Weihua et al., 2003).
Figure 1.10. Diagram to demonstrate ERp1/ERp2 heterodimerisation.
1.7 DNA Binding and Gene Activation
Gene activation occurs once the ligand has bound and homo- or heterodimers have
formed. In the classical pathway, the receptors bind to an oestrogen responsive
element (ERE) on the DNA and activate transcription of the target gene.
ERpi ERp2
ERE
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1.7.1 Structure of the DNA Binding Domain
The most conserved region of the ERa and ERp isoforms is the DNA binding
domain (DBD) in the C functional region (96% homology). The DBD contains two
functionally distinct zinc fingers co-ordinated by eight highly conserved cysteine
residues which are involved in ERE sequence recognition and dimerisation of the
ER DNA binding domains (Loven et a/., 2001; Scobie et al., 2002). Amino acids
near the C-terminus of the first zinc finger in the P-box determine the half-site ERE
sequence to which the receptor binds while the amino acids in the D-box (near the
terminus of the second zinc finger) provide important protein-protein contacts in the
receptor dimers (Pace et al., 1997). Each ER monomer is bound to DNA in the
major groove with the ER dimer located predominantly on one face of the DNA helix
(Klinge, 2001). Outside the DNA binding domain, specific contacts between the ER
dimer and the sugar phosphate backbone of the ERE play a role in sequence
recognition and high affinity binding. These regions are highly conserved between
the ERa and ERp isoforms, particularly the P and D-boxes (Vanacker et al., 1999)
and are critical for target DNA recognition and specificity (Loven et al., 2001).
Therefore it is not surprising that both receptors bind to similar EREs (Nilsson et al.,
2001).
1.8 Activation Pathways
Oestrogen receptors can regulate gene transcription via four pathways as shown in
Figure 1.11 (Hall et al., 2001). ERs can either bind directly to the promoter of target
genes (EREs) in the classical pathway (1) or by binding indirectly through an ERE
independent mechanism involving other transcription factors such as Sp1, NFkB or
AP-1 (2) (Nilsson et al., 2001; Shang and Brown, 2002). There is also a ligand
independent activation mechanism involving phosphorylation of the ERs via a
phosphorylation cascade (3) and a non-genomic pathway (4).
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Figure 1.11. The multifaceted mechanisms of oestradiol and ER signalling. Taken from Hall
eta!., (2001).
1.8.1 Classical Gene Activation (ERE)
In contrast to the wide variety of actions that oestrogens have in various organs,
tissues and cells, relatively few genes have been defined that are directly regulated
by oestrogen treatment. Using ER-binding fragments isolated from human genomic
DNA, Northern blot analysis and screening, ER binding fragments were found to
contain consensus oestrogen binding elements (EREs) (Inoue et al., 1993). The
ERE sequences were identified by aligning sequences with shared homologies in
the 5' flanking regions of the oestrogen regulated vitellogenin genes A1, A2, B1 and
B2 from Xenopus laevis and the chicken apo-VLDLII gene (Walker et al., 1984).
Since then it has been demonstrated that the minimal consensus ERE sequence is
a 13 base pair palindromic inverted repeat; 5-GGTCAnnnTGACC-3' where "n" is
any nucleotide (Klinge et al., 1997; Klinge et al., 2001). However, most oestrogen
regulated genes contain imperfect, non-palindromic EREs (Driscoll et al., 1998).
In her review Klinge listed 38 oestrogen-responsive genes whose promoters contain
functional EREs (Klinge, 2001), for example those encoding Xenopus vitellogenin
A1 and B1, chicken apo VLDII, and human genes including pS2, oxytocin, c-fos, c-
myc, TGF-a, lactoferrin, prolactin, the progesterone receptor, cathsepin D and
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complement 3 (Inoue et a/., 1993; Klinge, 2001). Some genes, for example the
Xenopus vitellogenin A2 (referred to here as Vit ERE), and the human oxytocin
genes, contain a single perfect or sequence variant copy of the consensus ERE.
Other oestrogen responsive genes, for example Xenopus vitellogenin B1,
ovalbumin, prolactin, the rat progesterone receptor and human c-fos contain
multiple copies of the ERE but not the palindrome. These genes usually have one or
more base changes compared to the consensus ERE and function synergistically to
induce oestradiol dependent gene activation (Klinge et al., 1997; Sathya et a/.,
1997). It has been documented that differences in ERE sequence impact on ER
binding affinity and transcriptional activation (Klinge, 2001). It has been
demonstrated that if the ERE sequence deviates from the consensus sequence by
even a single base pair, the receptor exhibits a reduced affinity for the ERE and a
decreased transcriptional activity (Wood et al., 2001).
The change of one nucleotide in the ERE can determine the formation of a different
interconnected hydrogen bond network. This suggests that each ERE sequence can
induce a unique conformational change in the DBD structure (Wood et al., 1998)
and may induce different transcriptional responses. The orientation of a consensus
or imperfect ERE relative to the TATA sequence within the DNA can have profound
effects on the expression of an oestrogen responsive reporter plasmid when it is
transfected in MCF-7 cells (Sathya et al., 1997). For example, location of single or
tandem copies of ERE sequences upstream of the luciferase gene promoter was
demonstrated to be more effective in inducing reporter expression than if it were
located downstream (Sathya et al., 1997).
Using gel mobility shift, DNase I footprinting and methylation interference assays it
has been demonstrated that the DBD bound only as a dimer to the A2 ERE (Wood
et al., 1998). Spacing between EREs is also important because when the ER dimer
binds to an ERE a conformational change is induced within the DNA resulting in a
bend of 65°. The helical separation between the EREs and the TATA box may
influence the bending induced and therefore the interaction of transcription factors
with the TATA box (Nardulli et al., 1996). Conformational changes vary for different
EREs. For example, the Vit ERE maximally activates transcription when it is
separated from the TATA sequence by 2.6 or 3.6 helical turns, whereas the pS2
ERE maximally activates transcription when it is separated by 3 helical turns (Wood
eta!., 1998).
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The length and spacing of the ERE palindrome is also critical for high affinity ER-
ERE binding. ERa does not bind to ERE half sites in which the palindrome is
separated by 2, 4 or 5 base pairs (Klinge, 2001). It has been argued that the
minimal length of the ERE containing sequence should be considered to consist of
15 base pairs (Klinge, 2001) and not 13 as reported previously (Klein-Hitpass et a/.,
1988). Extension of the ERE thus resulting in a 17 or 19 base pair sequence did not
further increase affinity for either ERa or ER(3 (Klinge, 2001). The consensus
Xenopus vitellogenin A2 ERE palindrome is 19 base pairs in length.
1.8.2 ERE-independent Gene Activation
For many years it was considered that the only mechanism through which the
oestrogen receptors affected transcription of oestrogen sensitive genes was by
direct binding of the ERs to EREs. However, it is now understood that ERa and
ERpi can activate gene expression through alternative, non-classical pathways as
pictured in Figures 1.11 & 1.12.
Figure 1.12. Models representing various modes through which ERs can modulate
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Both ERa and ER|31 can interact with the transcription factors Fos and Jun,
influencing their function at AP-1 sites to stimulate gene transcription (as shown in
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Figures 1.11 & 1.12) (Olefsky, 2001; Paech eta/., 1997). ER action can proceed
through the AP-1 sites via two pathways; (i) ERa acts through an activation function
dependent pathway, which does not require the DBD but does rely on an intact AF-1
or AF-2 and allows activation with agonists (Price et at., 2001), (ii) ERpi activates
AP-1 responsive transcription through an AF-1 independent pathway that requires
an intact DBD and allows activation of AP-1 sites with ER antagonists. Flence, in the
presence of ERa, agonists such as E2 and DES, as well as the antagonist
tamoxifen, function as agonists in the AP-1 pathway. In the presence of ER(31,
raloxifene and tamoxifen act as full agonists in the AP-1 pathway whilst E2 acts as
an antagonist (Paech et at., 1997). The ER(3 DBD sequesters co-repressors from
the AP-1 transcription complex, releasing it from the suppression and resulting in
AP-1 dependent transcription (Webb et at., 1999).
Several well known gene promoters are regulated by AP-1 sites and in opposite
directions by ERa and ER|31 (Cowley et at., 1997; Mosselman et at., 1996;
Pettersson et at., 1997). For example, on the AP-1 site of the collagenase promoter,
E2 elicits transcriptional activation via ERa but represses it with ER|31 (Ogawa et al.,
1998c). Therefore, ERa and ER|3 have been shown to respond differently to certain
ligands at an AP-1 element demonstrating the different regulatory functions for the
two ER isoforms.
ERa and ER|3 can also modulate the expression of genes without directly binding to
DNA. One example is the interaction between ERa and the c-rel subunit of NFkB
complex (Nilsson et at., 2001) as pictured in Figure 1.12. Genes containing GC-rich
promoter sequences can be activated via an ERa-Sp1 complex (Hall et al., 2001) in
a ligand independent manner (Nilsson et al., 2001) (Figure 1.12).
1.9 Importance of the AF-1 Domain
The N-terminal A/B domain of the ER includes a ligand-independent activation
function (AF-1) (Kraus et al., 1995; Mclnerney et al., 1998b). However, ERa and
ER|3 have little or no sequence homology within their A/B domains. Comparison of
the functional activity of the AF-1 domains of the two ERs has revealed that in ERa,
the domain is very active in stimulating reporter gene activation of target gene
expression from a variety of EREs in different cell lines (Cowley and Parker, 1999).
However the activity of the AF-1 domain in ER(31 is negligible under the same
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conditions. Anti-oestrogen agonism has been reported to be via the AF-1 region of
ERa and is not supported by AF-1 region of ER(31 (Mclnerney et al., 1998b).
Therefore these differences in the amino-terminal regions of ERa and ER(3
contribute to the cell and promoter specific differences in transcriptional activity of
the receptors and their ability to respond to different ligands, providing a mechanism
for differentially regulated transcription by these two ERs (Mclnerney etal., 1998b).
Fluman ERa contains serine residues within the AF-1 region which become
phosphorylated with ligand binding (Weis et al., 1996) as well as being regulated by
phosphorylation via kinase signalling pathways (Sadovsky et al., 1995). Mouse
ER|31 has been found to contain serine residues also within the AF-1 (Tremblay et
al., 1999b), but with slightly different positions compared to hERa.
1.10 Co-factors
To regulate transcription, ligand bound ERs interact with the general transcriptional
machinery and form the transcription pre-initiation complex at the transcription start
site of the target gene. This can be achieved either by direct contact between the
ER and the transcription factors, or by means of co-activators (Beato and Klug,
2000).
Ligand binding of ERa or ER|3 induces a conformational change in the structure of
the protein resulting in the recruitment of interacting proteins (co-activators or co-
repressors) (Figures 1.13 & 1.14) that can have a profound effect on ER-mediated
gene transcription (reviewed in Klinge, 2000). Ligand binding induces a change in
the position of helix 12, next to the AF-2 domain and results in the exposure of
critical residues required for co-activator recruitment (Klinge, 2000; Pike et al., 1999;
Routledge et al., 2000; Warnmark et al., 2001). There are differences between the
conformational change in ERa and ER|31 upon ligand binding which therefore lead
to variations in recruitment of co-factors.
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It has been shown that the ER interacts with a number of nuclear proteins in vitro,
some of which have functional consequences for transcriptional activation (Klinge,
2000). Over the last few years at least nineteen different receptor interacting
proteins (co-factor proteins) have been identified (Klinge, 2000). These include
SRC-1/NCoA1 (Onate et at., 1995), GRIP-1/T!F-2/NCoA2 (Voegel eta!., 1996),
p/CIP/AIB1/ACTR (Anzick et at., 1997) and CBP/p300 (Chrivia et at., 1993)
(reviewed in McKenna et a!., 1999).
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Co-activators act by turning on target gene transcription (Figure 1.13) whilst co-
repressors act to turn off activated target genes (Figure 1.14). The majority of these
co-factors exist as multi-protein complexes which upon binding to the LBD of the
receptor, bridge the ER to either chromatin compartments such as histones or to
components of the basal transcription machinery, or to both.
Co-activators interact with the agonist bound LBD and AF-2 interaction surface of
the receptor dimers (Feng et al., 1998) via a conserved region known as the NR box
(Heery et al., 1997; Onate et al., 1998). Domain-mapping experiments reveal that a
region (amino acid 535 to 554) that contains helix 12 (amino acid 538 to 546) in the
crystal structure of the ERa LBD (Brzozowski et al., 1997) is required for SRC
recruitment. The co-activator NR box consists of three conserved motifs each
consisting of LXXLL, where L is leucine and X is any amino acid (Heery et al.,
1997). The LXXLL motif forms an amphipathic a-helix that binds a hydrophobic cleft
formed in the LBDs of ERs after ligand binding (Shiau et al., 1998). It has been
demonstrated that the central motif 2 is sufficient for in vitro binding to the ER.
However for the optimal potentiation of ER-mediated transcription in transiently
transfected cells three motifs are required (Kalkhoven et al., 1998).
The length and orientation of these helical motifs in the co-activators are important
for high-affinity interaction with the receptor's AF-2 domain (Nolte et al., 1998). The
recruitment of SRCs depends not only on their LXXLL motif but also the adjacent
basic residues, especially those in the C-terminal region surrounding the
hydrophobic groove which are involved in the recognition of charged residues in the
receptor's LBD (Chang et al., 1999; Mak et al., 1999; Mclnerney et al., 1998a).
Thereafter specific hydrophobic and electrostatic interactions between the motif and
the receptor occur, resulting in stable interactions of the co-activator with the
receptor. Not all co-activator LXXLL motifs are identical and receptor binding
selectivity can be achieved by altering sequences flanking the LXXLL core motif
(Chang et al., 1999). To add to the complexity of the receptor co-activator
complexes, different ligands induce different helix 12 conformations and therefore
alter the ER's ability to recruit these SRC NR boxes (Mclnerney et al., 1998a;
Torchia et al., 1997).
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1.10.1 The Steroid Receptor Co-activator (SRC)
The SRC was the first steroid co-activator to be identified (Onate et al., 1995). Once
bound to the ER, co-activators such as the SRC are thought to enhance NR-based
transcription by several mechanisms (Jenster, 1998). Many co-activators including
SRC possess intrinsic histone acetylase activity (HAT) suggesting that chromatin
remodelling plays a role in transactivation. The HAT domain in SRC was mapped
out to the C terminus of the protein, between amino acids 1107 and 1441 (Spencer
et al., 1997). SRC HAT activity may not be essential for ER directed initiation of
transcription as site-directed mutations to the C-terminal region do not significantly
affect its co-activation function (Spencer et al., 1997). Although SRC may play a role
in chromatin remodelling and the assembly of general transcription factors through
direct and indirect recruitment of other co-activators (Leo and Chen, 2000).
There are three isoforms of the SRC (SRC-1, -2, -3) (Xu and O'Malley, 2002) all of
which interact with the ERs and activate transcription. SRC-1 gene expression has
been identified in the testes as well as in other oestrogen target tissues (Xu et al.,
1998). SRC-1 knockout mice have been shown to exhibit nearly normal male and
female reproductive behaviours and fertility (Apostolakis et al., 2002; Xu et al.,
1998). However, oestrogen target organs such as uterus, prostate, testes and
mammary gland exhibited decreased growth and development in response to
steroid hormones (Xu et al., 1998). The SRC-1 knockout model may not reveal the
full activity of SRC-1 as it has been documented that SRC-2 and SRC-3 proteins
can compensate for the loss of SRC-1 (Xu and O'Malley, 2002; Xu et al., 1998).
1.10.2 Other Co-activators and Co-repressors
There are several other co-activators involved in nuclear receptor activation,
including CBP/p300 complexes, which are viewed as general co-activators and co-
integrators involved in multiple signalling pathways. They are ubiquitously
expressed, possess acetyltransferases activity and contain docking sites for ERs via
N-terminal NR-boxes (Nilsson et al., 2001). The TRAP/DRIP is another co-activator
complex which is thought to connect ERs directly to the basal transcription
machinery (Kang et al., 2002). ERa is less effective than ER|3 in recruiting the
TRAP/DRIP complex in vitro (Montano et al., 1997). The RIP-140 co-repressor
interacts with the AF-2 domain, but exhibits inhibitory coregulatory functions
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because it can antagonise SRC-1 in vivo and compete for binding to the AF-2
(Treuter et a/., 1998).
1.11 Activation of Steroid Receptors via a Ligand Independent Pathway
All of the steps involved in transcriptional activation of ER-dependent genes, i.e.
ligand binding, ER dimerisation, DNA binding, and the interaction with co-activators
appear to be influenced by phosphorylation of the ER (Nilsson et at., 2001). In the
absence of ligand, alternative signalling pathways can also modulate ERs through
phosphorylation. These alternative pathways include regulators of the general
cellular phosphorylation state, such as mitogen activated protein kinase (MAP
kinase) (Figure 1.15) protein kinase A (PKA), or protein kinase C (PKC) (Ignar-
Trowbridge et al., 1996; Ince etal., 1994).
Figure 1.15. Schematic diagram to show activation of gene transcription through the MAP
kinase pathway. Taken from Lonard and Smith (2002).
MAP Kinase/cAMP MAP Kinase/cAMP
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1.11.1 The MAP Kinase Signalling Cascade
MAP kinases are activated through several distinct signalling pathways, one of
which is mediated through tyrosine kinase-type cell membrane receptors activated
by growth factors such as EGF, IGF-1 and TNF-a (Kato et al., 2000). Upon binding
of a growth factor to the receptor extracellular's domain, the receptor undergoes
autophosphorylation on tyrosine residues and subsequently acquires the potential to
activate a number of intracellular enzymatic activities, as schematically represented
in Figure 1.16 (reviewed in Smith 1998).
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Figure 1.16. A schematic representation of the MAP Kinase signalling pathway, adapted
from Smith (1998).
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1.11.2 Phosphorylation of the Oestrogen Receptor
All steroid receptors including ER are phosphorylated after binding their respective
ligands (reviewed in Weigel and Zhang, 1998). In addition, ERa and ER|3 can be
phosphorylated and activated in the absence of ligand binding (Tremblay et al.,
1999b; White etal., 1997).
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Using a combination of direct (amino acid and radiolabel sequencing) and indirect
(deletion and site-directed mutagensis) approaches, five phosphorylation sites have
been mapped within the human ER (Figure 1.17). Four of these sites (Ser104,
Ser106, Ser118 and Ser107) are located in the A/B domain while the fifth site
(tyrosine 537) is located within the LBD (reviewed in Smith, 1998).
Figure 1.17. Full length hERa is composed of 595 amino acids, with five known
phosphorylation sites (A). Adapted from Smith (1998). Full length hER(31 is composed of 530
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The AF-1 region within the ER's N-terminus contains several conserved serine
residues which are targets for phosphorylation. Deletion mapping and mutagenesis
of human ERa have revealed that phosphorylation of Serine 118 is required for full
activity of AF-1 (Kato et al., 1995). Phosphorylation of Ser118 in human ERa is
induced by growth factors such as the epidermal growth factor (EGF) and is
dependent on the MAP kinase (mitogen activated protein kinase) pathway
(Pettersson and Gustafsson, 2001). Oestradiol can induce phosphorylation of
Ser118, but this appears to be independent of MAP kinase (Joel et al., 1998)
indicating that alternative signalling pathways can act on the same residue,
depending on the amount of oestradiol present in the cell.
Serine residues in the mouse ER|3, for example Ser124, are also phosphorylated by
the MAP kinase pathway (Tremblay et al., 1999a). In human, ER(3 contains two
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serine residues which are phosphorylated; Ser106, which has previously been
shown to mediate Ras activation of mouse ER(31 (Tremblay et al., 1999a) and
Ser106 which is part of a motif shared with other steroid receptors (Rochette-Egly,
2003).
1.12 Oestrogenic and Anti-oestrogenic Ligands
Steroid hormones are widely distributed small, lipophilic molecules that participate in
intracellular communication and control of a wide spectrum of developmental and
physiological processes (Beato and Klug, 2000).
Oestrogen receptors are unique in that they have the ability to bind to a wide variety
of oestrogenic ligands that exhibit remarkably diverse structural features (Kuiper et
al., 1997). Some compounds act as receptor agonists, such as 17(3-oestradiol (E2)
and certain phytoestrogens (Barkhem et al., 1998; Enmark and Gustafsson, 1999;
Kuiper et al., 1998), whilst others function as pure antagonists such as ICI 164,384.
Another category termed "selective ER modulators" (SERMs) have the ability to act
as both agonists and antagonists depending upon the subtype of the receptor and
the cellular and promoter context (Lonard and Smith, 2002; Paech et al., 1997).
Binding studies have provided a description of the binding affinity relationships of
different ligands for the receptors and a model for the ligand binding site (Anstead et
al., 1997). Each ligand produces distinct conformational differences, confirmed by
crystallographic studies, in the receptor's LBD (McDonnell et al., 1995). The
oestrogenic potency of different compounds is determined by a number of factors
such as the binding affinity, the induced conformational change, differential effects
on the transactivation functionalities of the receptor, the particular co-activators
recruited and the cell- and target gene promoter context (Kuiper et al., 1998).
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Table 1.2. Table to show the binding affinities of ERa and ERp (EC50 nM) for a range of
oestrogenic ligands.







Harris et al., 2002a;







Kuiper et al., 1997 & Harris et al., 2002a;
Miller et al., 2003
Tamoxifen 197 nM 206 nM Human Harris et al., 2002a
Raloxifene 7.9 nM 44.0 nM Human Harris et al., 2002a
ICI 6.4 nM 5.8 nM Human Harris et al., 2002a
ppt™ 0.98 nM - Human Sun et al., 2002
dpn™ 66 nM 0.85 nM Human Meyers et al., 2001
NB. 3(3Adiol EC50 has not been documented.
1.12.1 17p-Oestradiol
Oestradiol is the most potent oestrogen produced in the body and is considered the
"classical" ligand for the oestrogen receptor. It is synthesised from testosterone or
oestrone by the aromatase or 17(3-hydroxysteroid dehydrogenase (HSD) enzymes.
The two receptor subtypes, ERa and ER(31 have a similar affinity for 17p-oestradiol
(Enmark and Gustafsson, 1999; Harris et at., 2002a) (see Table 1.2), despite
sequence differences within their LBDs (Kuiper et al., 1996; Ogawa et al., 1998b).
Figure 1.18 shows the chemical structure of 17|3-oestradiol. The aromatic A-ring, the
B- and C-rings and the OH-group in the D-ring all contribute significantly to the
receptor binding (Anstead et al., 1997).
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Figure 1.18. Chemical structure of 17|3-oestradiol.
1.12.2 5a-androstane-3p,17p-diol (3pAdiol)
The potent 5a-dihydrotestosterone (DHT) androgen is converted to two metabolites
in rodents; 5a-androstane-3a,17p-diol (3aAdiol) and 5a-androstane-3p,17p-diol
(3pAdiol) (Figure 1.19) (Weihua et al., 2003). Whereas in human it is thought only
3pAdiol is formed (unpublished observation by Ian Mason). Both are epimers but
have very different biological actions; 3aAdiol is androgenic whereas 3pAdiol is
oestrogenic (Weihua et al., 2003). 3aAdiol functions as a weak androgen by itself
and through the action of 3a-hydroxysteroid dehydrogenase (3pHSD) is reconverted
to the potent androgen DHT (Pilven et al., 1976), however it has no oestrogenic
activity or effects. The oestrogenic activity of 3pAdiol has been well documented
and the ligand has been shown to displace E2 from ERa (Hackenberg et al., 1993;
Ho and Ofner, 1986). The hydroxylation enzyme, CYP7B1, terminates 3pAdiol's
oestrogenic activity (Weihua et al., 2003). Compared to E2, 3pAdiol's affinity is 10-
fold lower for ERp and 20-fold lower for ERa (Kuiper et al., 1997).
In vivo studies have been performed with mice although it has been difficult to show
the oestrogenic activity of 3pAdiol (reviewed in Weihua et al., 2003). In rats high
doses of 3pAdiol were observed to have an effect on uterine growth and vaginal
stratification, however at lower doses there were no uterotrophic effects but a delay
of ovulation was recorded (Kramer and Meijs-Roelofs, 1982). These in vivo data had
led endocrinologists to believe that 3pAdiol did not perform physiological functions
by itself (Kramer and Meijs-Roelofs, 1982). However recently the regulation of
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3|3Adiol by CYP7B1 has been proposed to be a key factor in regulation of prostatic
growth (Weihua et al., 2003).
Figure 1.19. Chemical structure of 3|3Adiol.
OH
In the prepubertal female rat the serum 3|3Adiol levels are high, around 100ng/ml,
after the first ovulation levels are decreased to 10pg/ml (Eckstein, 1974). The origin
of 3(3Adiol in the immature animal is the ovary. In mature male rats serum levels of
3pAdiol are around 200pg/ml, this is about 20 times higher than the oestradiol level.
Even though the binding affinity for 3|3Adiol is 10-fold lower than that of E2, 3|3Adiol
could still serve as a physiological ligand for ER|3. For example, it has been
proposed that 3|3Adiol binds to ER|3 with agonistic affects and in the prostate this
results in the inhibition of androgen receptor expression (Weihua et al., 2002).
1.12.3 Genistein
Phytoestrogens are a diverse group of non-steroidal polyphenolic oestrogenic
compounds produced by plants primarily as bacterial and fungicidal agents. They
represent the major natural exogenous source of oestrogenic molecules
(Adlercreutz and Mazur, 1997; Pettersson et al., 2000). The presence of such
compounds in the human diet appears to be beneficial and may even reduce the
risk of certain cancers and heart disease (Adlercreutz and Mazur, 1997; and
reviewed in Strauss et al., 1998).
Genistein is an iso-flavonoid phytoestrogen that is found in significant levels in soya
bean and soy products. It has a similar structure to oestradiol (see Figure 1.20).
Upon binding, genistein is completely buried in the hydrophobic core of the ERa's
LBD and induces conformational changes within the AF-2 region, similar to that
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observed with E2 (Pike et al., 1999). There have been many studies analysing the
binding affinities of genistein for ERa and ER|31, with a number of different values
being obtained (An et al., 2001; Barkhem et at., 1998; Harris et at., 2002a) (see
Table 1.2). Overall, genistien shows full agonism for ERa and only partial agonism
for ER(31 (Liu et al., 2003; Pettersson and Gustafsson, 2001). In the ERp-genistein
complex helix 12 does not adopt the distinctive agonist position, but instead forms
an intermediate position in a similar orientation to that induced by other ER
antagonists (Lonard and Smith, 2002; Pike et al., 1999). This was unexpected as
the structures of E2 and genistein are similar (Pike et al., 1999). However, the
difference in binding affinity of genistein for ER(31 does not translate directly into the
observed transcriptional activation of a 1x vitellogenin ERE reporter because
genistein is over 1000-fold more potent at triggering transcriptional activity via ERpi
compared with ERa in U937 cells (An et al., 2001; Barkhem et al., 1998). It has
been suggested that the molecular mechanism for ERpi selectivity by genistein
involves the receptor's capacity to create an AF-2 surface that has a greater affinity
for co-activators than that formed in ERa-genistein complexes (Tremblay et al.,
2001).
Figure 1.20. Chemical structure of genistein.
1.12.4 Synthetic Oestrogen Receptor Modulators (SERMs)
Synthetic oestrogen receptor ligands such as tamoxifen and raloxifene produce
biological responses which can be either oestrogenic or anti-oestrogenic, depending
upon the tissue in which their action is examined (Lonard and Smith, 2002). These
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ligands have therefore been termed selective oestrogen receptor modulators
(SERMs). They are able to exert different effects through ERa and ER(3 due to their
differential ability to alter the ER's LBD conformation and thereby affecting the
receptor's ability to bind to EREs and recruitment of co-factors (Norris et al., 1999;
Paige et al., 1999).
Both raloxifene and tamoxifen inhibit AF-2 activity of ERa and ER|31. Tamoxifen is
thought to stimulate ERa mediated transcription through the N-terminal AF-1 in
certain cellular or promoter contexts (Metzger et al., 1995). Evidence from studies in
Hep G2 cells suggests that this activity can be supported through the classical
mechanism of ERa action, namely through the interaction of the ligand bound
receptor with an ERE-containing DNA response element (Hall and McDonnell,
1999). Tamoxifen acts as a pure antagonist on ER(31 as it inhibits transcriptional
activation via AF-2 and the AF-1 domain in ER(31 is reported to possess negligible
transcriptional activity (Brzozowski etal., 1997; Hall and McDonnell, 1999).
It is uncertain whether raloxifene can stimulate gene transcription through the AF-2
or AF-1 domains in the classical pathway of ER dependent gene expression
(McDonnell et al., 1995).
1.12.5 Specific ERa or ERp1 Synthetic Ligands
ERa and ER|3 only share 56% amino acid homology within their LBDs and although
the residues that surround the ligand are nearly identical ER subtype selective
ligands have been developed (Meyers et al., 2001; Sun et al., 2003; Sun et al.,
2002). Such subtype selective ligands could prove to be useful tools in probing the
physiological functions of each ER subtype.
1.12.5.1 PPT™
Propyl pyrazole triol (PPT™) is a nonsteroidal ligand, with the highest affinity for
ERa of all the pyrazole compounds (Stauffer et al., 2000) (Figure 1.21). PPT™ is a
potent agonist on ERa, with a high relative binding affinity (49%+/-12% that of E2)
but is reported to be inactive when incubated with ERp, having a very low binding
affinity (0.12%+/-0.4% that of E2) (see Table 1.2) (Kraichely et at., 2000). PPT™
stabilizes ERa to the same extent as E2 upon binding and is believed to induce a
similar agonist-like conformation, recruit co-activators such as SRC-1 and therefore
Chapter 1 Literature Review 47
initiates gene transcription to a similar extent to E2 (Kraichely et al., 2000). However
as PPT™ is reported not to be an agonist for ER(31 as it fails to induce recruitment
of co-activators and does not stimulate gene transcription (Kraichely et al., 2000).
Figure 1.21. Chemical structure of PPT
■TM
TM1.12.5.2 DPN
Meyers et al recently prepared a non-steroidal ER[31 potency-selective ligand; 2,3-
bis(4-hydroxyphenyl)propionitrile (DPN™) (Meyers et al., 2001) (Figure 1.22).
DPN™ acts as an agonist on both ERa and ERp 1 subtypes, but has a 70-fold
higher relative binding affinity (see Table 1.1) and a 170-fold relative potency in
transcription assays with ER(31 compared to ERa (Meyers et al., 2001). This is a
substantially higher level of ER(31 affinity and potency selectivity than observed with
the partial agonist genistein (Meyers et al., 2001).
Site-specific mutagenesis and DNA shuffling has demonstrated that one relatively
conserved residue in the LBD between hERa and hER(31 (L384 in ERa and M336 in
ER(31) is important in DPN™ binding and that the hERfH selectivity for DPN™ can
be significantly altered (Sun et al., 2003). This one amino acid change can affect not
only the local interaction with ligand, but it also has a long-range influence on other
parts of the binding pocket (Sun et al., 2003). However other residues at the
beginning of helix 3 of the LBD are also very important. Hence a limited number of
critical interactions of DPN™ with the ER(31 LBD underlie its ER subtype selective
character (Sun et al., 2003).
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Figure 1.22. Chemical structure of DPN™.
1.13 Tissue Specific Patterns of Expression of Oestrogen Receptors
As shown in Figure 1.1 oestrogens have an effect on a wide range of tissues, and
consistent with this, oestrogen receptors are widely distributed throughout the body.
1.13.1 Expression of ERa and ERp
The ovaries are the main source of oestrogen in non-pregnant premenopausal
women, consistent with the expression of high levels of cytochrome P450 in the
granulosa cells of the preovulatory follicles (Simpson and Davis, 2001). Oestrogens
are essential for normal follicular maturation in the human as well as in the primate
(Palter et al., 2001). Messenger RNAs for both ERa and ER|3 have been detected in
ovarian extracts from a wide range of species including rodents (Byers et al., 1997),
primates and humans (Misao et al., 1999). ERa and ER|3 mRNAs have been
reported to be differentially expressed within the ovary. For example in rodents ER|3
mRNA is predominantly expressed within granulosa cells (Byers et al., 1997)
whereas ERa mRNA has been detected in human corpus luteum (Brandenberger et
al., 1998). Overall, total ovarian mRNA for ER|3 is more abundant than for ERa
(Drummond et al., 1999; Saunders et al., 2000).
In the rodent ovary immunohistochemical analysis has detected ERa protein in
stromal nuclei, germinal epithelium and theca but not in granulosa cells (Sar and
Welsch, 1999; Saunders et al., 1997; Suzuki et al., 1994). Saunders et al were the
first to immunolocalise ER|3 protein to rodent granulosa cells of all stages of follicular
maturation (Saunders et al., 1997). Others have confirmed and extended these
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results (Fitzpatrick et al., 1999; Sar and Welsch, 1999). In humans and primates
ERa has been immunolocalised to granulosa cells of mature antral follicles
(Saunders et al., 2000). ERp protein has been detected in granulosa cells and cells
within the corpus luteum (Saunders et al., 2000). ERa and ERp proteins have also
been localised to the surface epithelium of the ovaries (Henderson et al., 2003;
Saunders et al., 2000). This is consistent with detection of mRNAs for ERa and ERp
in cultured ovarian epithelial cells (Hillier etal., 1998).
The uterus is a target for oestrogen action and all the cellular components of the
endometrium (the epithelial, stroma, endothelium and bone-marrow derived cells in
the stroma) express one or both of the oestrogen receptors (Saunders, 2002). The
cyclical event of menstruation follows the sequential exposure of the endometrium
to oestrogen and progesterone. Messenger RNAs for both ERa and ERp have been
detected within glandular epithelial cells, stromal cells and the smooth muscle of the
uterine wall at every stage of the menstrual cycle (Critchley et al., 2002). During the
proliferative phase ERa mRNA may be approximately 300-fold higher than ERp
mRNA (Matsuzaki etal., 1999). Henderson et al confirmed that mRNAs for ERpi
and the ERp2 variant were both present in human endometrial extracts across the
menstrual cycle, increasing during the late secretory phase (Henderson et al.,
2003).
Immunohistochemistry has localised ERa to glandular and stromal cell nuclei in the
endometrium and a decline in immuno-intensity of ERa has been reported in the
superficial layer in the secretory phase (Henderson et al., 2003; Lecce et al., 2001;
Saunders, 2002). In contrast, ERp protein expression does not decline during the
secretory phase (Critchley et al., 2001; Lecce et al., 2001). There was a difference
in ERa and ERp immuno-expression in the vascular endothelium and the
perivascular cells surrounding the endometrial blood vessels. Only ERp protein was
detected in the endothelial cell population, although both ERa and ERp were found
in perivascular cells (Critchley et al., 2001; Critchley et al., 2002; Lecce et al., 2001;
Saunders, 2002).
Human decidual cells from early pregnancy contain positive nuclear immunostaining
for ERa protein (Wu et al., 1993); ERp has been detected in the decidualised
stromal cells (Lecce et al., 2001). However, in the third trimester ERa protein has
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not been detected in decidual tissue (Noci et al., 1994). In agreement with this
Saunders et al reported expression of ER|3 but not ERa in the nuclei of cells of the
syncytiotrophoblast of the placenta during the second trimester and at term
(Saunders, 2002).
It has been proposed that oestrogens play a role in regulating spermatogenesis
(reviewed by O'Donnell et al., 2001). Levels of oestrogens within the male
reproductive tract are higher than in the general circulation (Hess et al., 1997). The
distribution of ERa and ER(3 mRNAs within the male reproductive tract are tissue
and cell specific (Enmark et al., 1997; Williams et al., 2001). Messenger RNA for
ER|3 has been found in developing spermatids of human testis, suggesting that
oestrogens participate in the regulation of spermatogenesis (Inoue et al., 2000),
however ERa is absent (Scobie et al., 2002). In the rodent some studies have
claimed that ERa is present in Leydig cells and some peritubular cells (Zhou et al.,
2002). Whereas Saunders et al reported that the expression of ERa was confined to
rodent Leydig cells (Atanassova et al., 2000; Fisher et al., 1997; Saunders et al.,
1998).
In the human and primates some studies report that ERa is not expressed in the
testis (Makinen et al., 2001; Saunders et al., 2001), although others have reported
detection of protein using squash preparations (Pentikainen et al., 2000). High
levels of expression occur in the efferent ductules and in the initial segment of the
epididymis that lie adjacent to the testis (Saunders et al., 2001). The detection of
ERa mRNA in human testis extracts may occur if the tissue is not dissected
carefully with the efferent ducts separated from the testis (Saunders et al., 2001).
1.14 Mouse Models of Receptor Knockouts
Recently four mouse strains have been created in which either ERa or ER(3 or both
receptors, or the hormone; oestradiol, have been eliminated (Enmark and
Gustafsson, 1999). The two oestrogen receptors were inactivated through targeted
disruption of the respective ER genes, and oestradiol was removed by inactivation
of the aromatase enzyme (cyp19) which converts testosterone to oestradiol (Fisher
eta!., 1998).
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1.14.1 aERKO Mice
Female aERKO mice become infertile by four or five weeks of age (Lubahn et al.,
1993). They initially exhibit normal follicular development, but in adulthood the
follicles tended to become atretic after the antral stage with no apparent corpora
lutea, finally resulting in haemorrhagic cysts. The development of these cysts
appears in part to be due to elevated levels of gonadotrophins (LH and FSH)
caused by a loss of negative feedback at the level of the pituitary (Schomberg et al.,
1999). In agreement with this, prevention, using a GnRH antagonist inhibits
development of these cystic structures (Couse and Korach, 1999). The uteri of
aERKO female mice are immature in appearance and lack development in
adulthood (Lubahn et al., 1993).
Male aERKO mice undergo apparently normal prenatal development to produce
internal and external structures that are indistinguishable from wild type males.
However as adults there is a significant reduction in testis weight compared to wild
type litter mates (Couse and Korach, 1999). Within the testis hyperplastic Leydig
cells are observed, consistent with increased LH levels. The adults are infertile, with
a significantly reduced sperm count and decreased sperm mobility (Couse and
Korach, 1999). Their rete testis and efferent ductules are dilated (Hess et al., 2000).
Detailed investigations suggest that infertility in aERKO males is a result of reduced
fluid resorption within the efferent ductules. This leads to an increased back
pressure and collapse of the seminiferous tubule resulting in the loss of germ cells
(Hess et al., 2000).
The sperm from aERKO males have a lower percentage mobility, beat less
vigorously and show less forward progression than sperm from wild type mice
(Lubahn et al., 1993; Mahato et al., 2000). Mahato et al suggested that ERa does
not regulate genes in the germ cells, required for their development in the testis or
maturation in the male duct system, but rather affects sperm function indirectly
through somatic cells that support spermatogenesis and/or epididymal function.
1.14.2 pERKO Mice
Female pERKO mice contain all stages of follicular development, however as adults
ovulation rate is reduced (Krege et al., 1998). In addition, litter size is reduced and
substantially fewer litters are produced (Krege et al., 1998). Histological analysis of
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(3ERK0 ovaries showed an increase in number of early atretic follicles and few
corpora lutea (Couse et al., 1999). This is consistent with a role for ER(3 in the
granulosa cells (Dupont et al., 2000). The uteri of (3ERKO female mice appear to be
comparable to those of wild type animals and although they exhibit subfertility, they
are able to carry pregnancies successfully to full term (Krege et at., 1998).
Male (3ERKO mice are fertile (Couse and Korach, 1999). The lack of a phenotype in
|3ERKO mice appears at odds with the observation that germ cell loss occurs in
male ARKO mice appearing to be consistent with oestrogen action via ER(3,
expressed in spermatocytes and spermatids (de Ronde et al., 2003).
1.14.3 apERKO Mice
The ovaries of a|3ERKO mice are distinctly different from the single knockouts with
some abnormal follicles, no corpora lutea and the presence of large cells with
abundant cytoplasm and a prominent nucleus (Dupont et al., 2000). Follicles with a
normal morphology decreased with age as those with an unusual appearance
increased. The abnormal follicles lacked an oocyte and contained cells which
shared morphological characteristics with Sertoli cells. For example, there was
evidence of the formation of unique junctional complexes as well as the synthesis of
anti-Mullerian hormone and Sox9 mRNAs (Couse et al., 1999). It has been
suggested that follicles are initially normal but begin to "trans-differentiate" into
seminiferous tubule-like follicles as the oocyte degenerates. The uteri of a(3ERKO
mice do not exhibit sensitivity to oestrogens and normal growth is prevented (Couse
et al., 1999).
Male a|3ERKO mice are infertile (Dupont et al., 2000). They exhibit a loss of germ
cells in the seminiferous tubules and a marked dilation of straight tubules and the
rete testis.
1.14.4 ARKO Mice
Female ARKO mice become infertile and display disturbances in ovarian
development with follicular arrest, hyperplastic stroma and the formation of
haemorrhagic cysts by one year of age (Britt et al., 2000; Fisher et al., 1998). The
ovaries contained numerous follicles with abundant granulosa cells and evidence of
antrum formation that appeared to be arrested before ovulation.
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Male ARKO mice display more or less normal fertility when young, but a decrease in
litter siring is apparent with advancing age (Fisher et al., 1998). Adult onset of
infertility observed in male ARKO mice is consistent with a role for oestrogens in the
male as well as in the female (Robertson et al., 1999). Analysis of the testes from
the ARKO mice has revealed that round spermatids undergo apoptosis, display
disturbances in acrosome formation and fail to differentiate into mature elongate
spermatids (Robertson et al., 2001). These results suggest oestrogens are essential
for normal spermatogenesis and for a direct impact of oestrogens on male germ cell
development and hence fertility.
Characterisation of the phenotypes exhibited by these knockout models has
extended our understanding of the physiological processes governed by oestrogens
and their phenotypes are summarised in Table 1.3.
Table 1.3. Details of the knockout mice phenotypes.
E2 levels LH levels FSH levels Fertility References
ARKO Decreased Decreased Increased Infertile females
Infertile males
Fisher et al., 1998
aERKO Increased Increased Increased Infertile females
Subfertile males
Couse and Korach, 1999
pERKO Increased Normal Normal Subfertile females
Fertile males
Hewitt and Korach, 2003
apERKO Increased Increased Increased Infertile females
Infertile males
Couse et al., 1999;
Dupont et al., 2000
Data to support the importance of oestrogen mediated gene expression within the
female reproductive tract also comes from mice that have had the co-activators
SRC-1 or SRC-3 disrupted. In these mice there is partial hormone resistance and
reduced female reproductive function (Wu et al., 2002; Xu et al., 1998).
1.15 ERE-Reporter Mice
As an alternative technique to analyse oestrogen's action in vivo, Ciana et al
engineered the mouse genome to express an ERE linked to a luciferase reporter
gene ubiquitously (Ciana et al., 2001). They showed that oestrogen action via the
ERE reporter was localised to a number of different tissues including the
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reproductive tract and bone (Ciana et al., 2001). Nagel et al also developed a
transgenic mouse that functions as a reporter of ER activity. This model was used to
identify target tissues that contain active ERs and thus aid in the evaluation of the
contributions of the cellular environment, rather than promoter context (Nagel et al.,
2001). They incorporated the 3x Vitellogenin ERE linked to a minimal TK promoter
with a beta-galactosidase reporter, and termed it an ER action indicator (ERIN)
model. Evaluation of ER activity in the ERIN female demonstrated oestrogen-
inducible expression of the reporter gene in the uterus, pituitary and hypothalamus
as well as in non-classical oestrogen target tissues such as the kidney, liver, adrenal
and thyroid gland. However there are other potentially important ER-mediated
actions that function through pathways besides direct binding to ERE, for example,
interactions with AP-1 (Paech et al., 1997) to consider.
1.16 Human Cases
The roles played by oestrogens in normal human testes function are less clear than
animal models due to the difficulty in obtaining tissue samples. There has been one
case reported of a young male patient with an inactive ERa, who had apparently
normal testes, normal sperm density but decreased sperm viability (Smith et al.,
1994).
There are currently four men world wide who are characterised with aromatase
deficiency (taken from Simpson 2003, Abstract 85th Meeting Endo Soc. Philadelphia
p40). These individuals have a range of phenotypes including tall stature due to
failure of epiphysial closure, delayed bone age and a "Metabolic Syndrome". The
testicular phenotype is confusing due to markedly variable penetrance and ranges
from moderate oligospermia to cryptorchidism.
To date, no patients lacking expression of the ER|3 gene have been identified.
1.17 Conclusions
Oestrogens have a key role in regulation of many biological processes including
reproduction. The "simple" oestrogen receptor pathway has become extremely
complex as our understanding of receptor isoforms and splice variants, receptor
localisation, different ligands, co-factor proteins, classical EREs and non-classical
alternative pathways and the activation of the receptor via a MAPK phosphorylation
pathway have become apparent.
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1.18 Aims
The aims of this project are; i) to determine whether ER|3 wild type (ER(31) and ER(3
variant (ER|32) forms exist in primates as well as human and to determine the ER
localisation in reproductive tissues (Chapter 3); ii) to examine the localisation or
absence of fluorescently tagged ER constructs (ERa, ER|31 and ER|32) in live cells
in the presence or absence of different ligands (Chapter 4); iii) to examine the
functional dose response of ER proteins to different ligands in the presence of ERE-
luciferase reporter constructs (Chapter 5); iv) to investigate an alternative, non-
classical activation mechanism for ER(32 via a growth factor signalling pathway
(Chapter 6).
Chapter 2
General Materials and Methods
2.1 Cell Lines
Two different cell lines were used; Hek 293 and Hep G2. Both were purchased from
European Collection of Cell Culture (ECACC). The Hek 293 cells were derived from
human embryonic kidney cells, they were previously transformed with sheared
human Ad5 DNA. The Hep G2 cell line was isolated from a liver biopsy of a male
Caucasian aged 15 years, with a well differentiated hepatocellular carcinoma. Cos 7
(African Green Monkey), Ishikawa (human endometrium), LnCap (human prostate)
and Hela (human ovarian cancer) cells were obtained from stocks at the MRC
Human Reproductive Sciences Unit.
2.2 Ligands
Different ligands were selected to stimulate the transiently transfected cells.
2.2.1. Natural Oestrogenic Ligands
The natural oestrogen; 5 alpha-androstane-3-beta,17 beta-diol (3|3Adiol) is a
metabolite of dihydrotestosterone. It was purchased from Sigma (Catalogue
Number; A-7630). 17|3-Oestradiol (E2) was purchased from Sigma (Catalogue
Number; E-8875). Both were reconstituted in 100% ethanol, serial dilutions (10"3M to
10"11M) made in 100% ethanol and stored at -20°C. 4',5,7-Trihydroxyisoflavone
(Genistein) was a synthetic powder purchased from Sigma (Catalogue Number; G-
6649). The powder was reconstituted in DMSO, serial dilutions produced (10~3M to
10"11M) with DMSO and stored at -20°C.
2.2.2 Receptor Selective Synthetic Ligands
DPN™ and ppj™ were purchased from Tocris Cookson Ltd. 2,3-bis(4-
Hydroxyphenyl)-propionitrile (DPN™) is marketed as a highly potent ER(31 agonist
with a 70-fold selectivity over ERa (EC5o values are 0.85 and 66nM repectively)
(Meyers et a/., 2001). The ligand 4,4',4"-(4-Propyl-[1 H]-pyrazole-1,3,5-triyl)trisphenol
(PPT™) is marketed as a highly potent ERa agonist which displays a 410-fold
selectivity for ERa over ER|3 (Kraichely et al., 2000; Stauffer et at., 2000). Both of
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the compounds were reconstituted in 100% ethanol and serial dilutions produced
(10"3M to 10'11M) with 100% ethanol and stored at -20°C.
2.2.3 Growth Factors
Epidermal Growth Factor (EGF) fragment was purchased from Sigma (Catalogue
Number; E9384). The lyophilised powder was reconstituted in PBS and serial
dilutions made in PBS (10"3M to 10"11M). Aliquots were stored at -20°C. Insulin-like
Growth Factor-1 (IGF-1) was purchased from Sigma (Catalogue Number; I-3769).
The IGF-1 was a human recombinant single chain polypeptide of 70 amino acid
residues cross-linked by three disulphide bridges, expressed in E.coli. The
lyophilised powder was reconstituted in 10mM HCI to a concentration of 2.0mg/ml,
serial dilutions made (10"3M to 10"11M) in 100% ethanol and stored at -20°C.
2.3 RNA Extraction
A typical mammalian cell contains about 10"Vg RNA, 1-5% is mRNA, which is
heterogeneous in both size and sequence. The other 80-85% is rRNA and 15-20%
is low molecular weight tRNAs, nRNAs etc. (Sambrook et al., 1989). The mRNA
was extracted from cells or tissue samples using the commercial Tri Reagent
purchased from Sigma (Chomczynski, 1993).
2.3.1 RNA Extraction from Cells
A cell suspension was prepared from a single confluent 75cm2 flask by adding 2mls
1x trypsin (Sigma, Catalogue Number; T-4424) and incubating at room temperature
until the cells detached from the flask. The trypsin was neutralised by the addition of
fresh media (section 2.10.1), the cells were counted using a haemocytometer and
centrifuged at 1000 rpm for 5 minutes at room temperature to pellet. The
supernatant was discarded and RNA was extracted from the pellet using Tri
Reagent (Sigma) according to manufacturers instructions. In brief, 1ml Tri Reagent
was added to the cell pellet on ice and thoroughly mixed by pipetting, followed by
the addition of 200pil chloroform, the sample was mixed on a vortex and left to stand
at room temperature for 5 minutes. The aqueous and organic layers were separated
by centrifugation at 12,000 rpm for 10 minutes at 4°C. The aqueous layer
(approximately 600^1) containing the RNA was transferred to a fresh chilled
Eppendorf tube (1.5ml) which was placed on ice and 500^1 isopropanol (pre-chilled
to -20°C) added to induce the precipitation of RNA. The sample was mixed gently
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by inverting the tube and left to stand for 10 minutes on ice. The sample was
centrifuged again at 12,000 rpm at 4°C for 10 minutes, the supernatant removed
and the RNA pellet washed with 75% ethanol, air-dried and re-suspended in RNA
storage solution (Ambion). The concentration and purity of the RNA was measured
using a Pharmacia Biotech Genequant (section 2.6.2). The sample was aliquoted
and stored at -70°C.
2.3.2 Extraction of RNA from Tissues
Frozen tissue samples were ground to a fine powder under liquid nitrogen using a
pestle and mortar. The sample was divided up into approximately 50mg aliquots and
stored at -70°C. For RNA extraction approximately 50-1 OOmg tissue was required.
Extraction of RNA was performed using Tri Reagent as in 2.3.1 and the RNA re-
suspended in RNA storage solution.
2.4 Preparation of Complementary DNA (cDNA) by Reverse Transcription (RT)
The cDNA was synthesised from total RNA using oligo dT primers (Invitrogen) and
pools of each dNTP (Invitrogen). An aliquot of total RNA (5pg) prepared using the
methods in section 2.3, was mixed with 2pil RNasin (Promega) and the volume
adjusted to 21 p.l using RNAse-free water (Promega). Oligo dT (2pl, 200pM) primers
were added to the reaction and the sample incubated at 75°C for 3 minutes to
reduce secondary structure within the RNA. Thereafter the reaction was placed on
ice to encourage annealing of the oligo DT primer to the poly A+tail at the 3' end of
mRNAs. In a separate tube 4pl 100mM DTT (Roche), 8pl 5x RT buffer (50mM Tris-
HCI, 100mM NaCI, 1mM EDTA, 10mM DDT, 0.05% polydocanol (v/v), 50% glycerol
(v/v); pH 8.4), 4pl 10mM total dNTPs (dATP, dCTP, dGTP and dTTP) and 1pl
DNase (Sigma) were mixed together. 2pl Expand RT™ was added to the master
mix (19pl final volume) which was then added to the RNA sample to give a final
reaction volume of 40pl. A control was included using pure water (Promega) to
replace the RNA. The RT reaction was incubated at 42°C for 2 hours, thereafter the
reaction was terminated by heating at 99°C for 5 minutes. A volume of 1pl RNase
was added to the single stranded cDNA and incubated at 37°C for 15 minutes to
remove RNA. The cDNAs were separated from unincorporated nucleotides and
primers using "High Pure Purification columns" (Roche) following manufacturers
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guidelines (section 2.7.2) and analysed using a Pharmacia Biotech Genequant
(section 2.6.2).
The quality of the cDNA pool was checked by using PCR (section 2.5) with primers
specific for the housekeeping gene GAPDH. PCR products were separated on a 1%
agarose gel stained with ethidium bromide and photographed (section 2.6.1).
2.5 Amplification of Specific cDNAs by Polymerase Chain Reaction (PCR)
The single stranded cDNA pools synthesised from section 2.4 were used in PCR
reactions with oligonucleotide primers specific to target sequences to determine
whether specific RNA messages were present within the cell or tissue used for RNA
extraction.
The PCR reactions are dependent upon the synthesis of DNA by a thermostable
DNA polymerase (Saiki et a/., 1988). The Thermus aquaticus (Taq) enzyme can
survive extended incubation at 95°C and therefore is not inactivated by the heat
denaturation step in each cycle. The buffer used in the reaction contains 50mM KCI,
10mM Tris-HCI; pH 8.3, and 1.5mM MgCI2. During the 72°C amplification step the
pH decreased by more than a full unit producing a buffer with a pH of approximately
7.2. The presence of divalent cations was essential for the reaction, Mg++
concentration was fairly low (1.5mM) therefore it was necessary to ensure that the
concentration of chelating agents such as EDTA were kept minimal. The dNTPs
were used at saturating concentrations (200pm for each dNTP) to ensure they didn't
become depleted and the efficacy of the reaction was not reduced after multiple
cycles.
2.5.1 Oligonucleotide Primers
Oligonucleotide primers (17-24mer) were synthesised by Sigma-Genosys and MWG
Biotech. The primers were suspended in either TE (10mM Tris-HCI; pH 7.5, 1mM
EDTA) or pure water (Promega) to obtain a concentration of 50pmol/pl.
The primers were chosen to contain approximately 50% G+C content and an
annealing temperature within the range of 55-62°C. In the current studies primers
were chosen to sequences within the open reading frame of the mRNAs but in the
case of large gene families such as the steroid receptors regions with significant
sequence homology between family members e.g. the DNA binding domain, were
Chapter 2 General Materials and Methods 60
avoided. The length of the primer and its GC content determines both the specificity
and the annealing temperature used during the PCR reaction. A primer of 17-24
nucleotide bases is sequence specific as long as the annealing temperature is set
within a few degrees of the dissociation temperature for the template/primer
duplicate. Using primers of a minimal length (17 bases) ensured a melting
temperature of around 54°C or higher and a high probability of sequence specificity.
Table 2.1. Screening primers used to detect cDNAs in pools prepared from cells or tissues.
5' primer 3' primer Product size
ERpi GGCATCTCCTCCCAGCAGCA CACTGAGACTGTGGGTTCTGGA 240 bp
ER|32 GGCATCTCCTCCCAGCAGCA CACTGCTCCATCGTTGCTTC 135 bp
EGFr GTGTGCCCACTACATTGACGC GTTGGACAGCCTTCAAGACC 237 bp
IGFr ATGCTGTTTGAACTGATGCG TCTCCATGTTCTCTGGCTCC 166 bp
SRC-1 CATGCTTATGAGGCAGCAAA ATTCCAGTGCCAAACTGTCC 247 bp
Table 2.2. Primers used to amplify full length cDNAs.
5' primer 3' primer Product size
hER[31 CCACGAATCTTTGAGAACATTAT GTGGGCCAGTTCACCTCAGG 1698 bp
hER|32 CCACGAATCTTTGAGAACATTAT GTGAAAATGTTACCCAAGAT 1615 bp
ATG start sites are approximately 66 bp downstream from the 5' primers
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Table 2.3. Primers used for cloning using ECHO Vectors.
5' primer 3' primer Product
H ER(31 GACATGGATATAAAAAACTCACC CACTGAGACTGTGGGTTCTGGGA 1591 bp
H ER|32 GACATGGATATAAAAAACTCACC CACTGCTCCATCGTTGCTTC 1489 bp
Mm ERpi GACATGGATATAAAAAACTCACC CACGGAGACTGTGGGTTCTGGGA 1590 bp
Mm ER(32 GACATGGATATAAAAAACTCACC CAATCTCCATCTTCCATTCCAAA 1458 bp
Mc ER|31 GACATGGATATAAAAAACTCACC CACTGAGACTGTGGGTTCTGGGA 1590 bp
Mc ER|32 GACATGGATATAAAAAACTCACC GCGAAGGTCACAGATCCATCCGT 960 bp
ATG Start Sites
Table 2.4. ER|3 primers used for sequencing.
Primer
100 Anti Sense (3') GCTATAGAATGTCATGGCTGGA
1760 Sense (5') GGCATCTCCTCCCAGCAGCA
CMV (5') CGCAAATGGGTAGGCGTG
BGH (FP) (5') TAGAAGGCACAGTCGAGG
Table 2.5. Control primers to determine PCR quality.
5' primer 3' primer Product size
GAPDH CTGCACCACCAACTGCTTAGC ATGCCAGTGAGCTTCCCGTTC 280 bp
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ATG Start Site, Hindtll Restriction Site. BamHI Restriction Site




Important ERE region,Nhe I restriction site, Kpn I restriction site
2.5.2 PCR Reactions
Two different sets of reagents for PCR reactions were used at different times during
these studies; ABgene Extensor High-Fidelity PCR Master Mix (Advanced
Biotechnologies) and Mega Mix (Microzone Ltd).
2.5.2.1 ABgene Extensor High-Fidelity PCR MasterMix
Using the ABgene Extensor High-Fidelity PCR Master Mix; 5fxl 10x reaction buffer
(22.5mM MgCI2), 1pl Extensor Hi-Fidelity PCR Enzyme mix (Taq included) and 19pl
pure water (Promega) were mixed together (total volume 25pl). Another mix was
made up containing 5pl 50mM dNTP mix, 5-1 Ong cDNA, 100pM of each primer and
made up to 25pl with pure water. Both these master mixes were added together
(total volume 50pl) in a 0.2pl thin walled tube (ABgene) on ice.
2.5.2.2 Mega Mix Containing Reaction Mix
Using Mega Mix (consisting of Taq polymerase, dNTPs, 2.5mM MgCI2, buffer, and
enzyme stabiliser) 50pM of each primer and 2-5ng cDNA were mixed to a total
volume of 10(il with the Mega Mix on ice in a 0.2pl thin walled tube.
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2.5.3 PCR Cycle
For a typical PCR the reactions were subjected to an initial denaturing incubation at
95°C in a PTC-200 Thermal Cycler (MJ Research) for 2 minutes followed by 35
cycles of: 94°C for 30 seconds, annealing of primers with the thermostable DNA Taq
polymerase at 60°C, 58°C or 55°C for 30 seconds depending upon the primer used,
72°C for 2 minutes, and a final 10 minute incubation at 72°C. The PCR machine had
a hot lid so it was not necessary to add mineral oil to prevent evaporation. The
machine was programmed accordingly with the volume of the PCR reaction. A
negative control was always included, using pure water (Promega) instead of the
cDNA.
2.6 Product Analysis
To ensure the product of a PCR, cloning or purification reaction was correct aliquots
(5-10 pi I) of each sample were either visualised on a gel or the purity and
concentration determined using a Pharmacia Biotech Genequant.
2.6.1 Agarose Gel Analysis
Agarose gels were used to check the size and purity of PCR products, plasmids and
to determine whether ligations had worked. Size and conformation of the plasmid
construct influences the migration of the DNA during electrophoresis, superhelical
DNA migrates the slowest, whereas linear DNA migrates faster.
Agarose gels were prepared using 1xTAE buffer (2M Tris acetate, 50mM EDTA pH
8.0) with the addition of 1% (w/v) agarose (Roche). The percentage of agarose used
was increased to 2% when the expected size of the DNA to be visualised was
smaller than 300bp. The agarose was melted in a microwave oven and 1:2000
dilution of ethidium bromide solution (stock solution at 1mg/ml, Sigma) added to
allow UV visualisation of the product bands. The gel was poured into a gel tray and
a comb used to form the wells for the samples.
PCR products (5pil) to be run on the gel were mixed with 1pl 5x blue loading dye
(0.25% bromophenol blue and 30% glycerol). When cloning products were run on a
gel, an approximate 100ng concentration was loaded in a maximum volume of 15ptl
with the dye. The blue dye ran at approximately 600bp, therefore if the product to be
run was the same size as the blue dye it was mixed with 2x Orange G (50% 1xTAE,
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20% glycerol, and 0.25% Orange G; Sigma, Catalogue Number; 3756) loading dye
instead which runs at approximately 50bp. Size markers were run in one lane of all
gels. For PCR products (100-800bp), 5p.l of a 100bp DNA ladder (Promega) was
mixed with 1pl blue dye or 5^1 orange dye. For larger products (plasmids/full length
cDNAs) 2p,l Lambda marker cut with Hindlll (Promega) was used. Once the samples
were loaded into the gel wells, submerged in 1xTAE in the electrophoresis tank
(Bio-Rad Equipment), the gel was run at 100 volts for 30-60 minutes depending
upon the product migration and gel size. The gel was visualised using a UV
transilluminator (GRI Syngene) and photographed with a BioRad camera and
integration control unit. When PCR products were analysed a band of a certain size,
depending upon the primers used, was visible. Pure plasmid DNA appeared as two
bands, one for circular DNA and the other representing supercoiled DNA. Other
cloning products were analysed by comparing their size to known markers or
controls. The approximate concentration of a sample was also determined by
running a plasmid sample of known concentration i.e. 200ng, on the gel to compare
intensity of the sample band.
2.6.2 Genequant Analysis
The Pharmacia Biotech Genequant spectrophotometer was used to determine the
concentration and purity of the sample RNA, double or single stranded DNA. The
blank reference was set first, using either pure water (Promega) or TE depending on
the sample content and the Genequant was programmed to analyse RNA, dsDNA
or sDNA samples, with an OD set at 260nm. A small volume (7-10pl) of the sample
was pipetted into the cuvette and the product's concentration, ratio and absorbance
reading noted. A ratio reading of 1.9 was taken to be pure; a higher ratio indicated
the sample was degraded, a lower ratio indicated there was protein present in the
sample. The absorbance reading should be approximately 10-fold more than the
concentration reading.
2.6.3 Sequencing
All sequencing was performed using an ABI 373 or the newer ABI 377 Sequencer.
Samples were run by the Sequencing Service within the MRC Human Reproductive
Sciences Unit. Analysis and alignments were performed using GeneJockey II
Sequence Processor (P. Taylor BIOSOFT).
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2.7 Subcloning of cDNA Constructs
Purified PCR products were cloned into plasmid vectors so that they could be
expressed in bacterial cells, or introduced into eukaryotic cells by transient
transfections, for Luciferase assays and protein expression studies.
2.7.1 Amplification and Cloning of Full Length ERp cDNAs
Primers 5' of the human ATG start and 3' of the human TGA stop were chosen and
used to amplify full length ERp 1 and ER|32 cDNAs from human, macaque and
marmoset testes using the PCR reagents detailed in section 2.5. However, a
reduced primer annealing temperature and an increased extension time of 1 minute
30 seconds was used to amplify up the full length products. PCR products were
purified (section 2.7.2) and sequenced using the original PCR amplification primers
and a series of internal sequencing primers generated to human ER|3 sequence
(Table 2.4 and section 2.6.3) to ensure the sequence of the PCR product was
correct and that no base changes had been introduced during the PCR reaction.
Human ERa was purchased from the American Type Culture Collection (Catalogue
Number; 79762). The hERa cDNA was restriction digested out of the plC20H vector
it was supplied in, using BamHI and EcoRV restriction sites located in the vector's
multiple cloning site. In a total volume of 50|xl, 5p,g ERa-plC20H, 2.5ptl of each
enzyme (Promega) and 5ptl Buffer (Promega) was made up with water and
incubated for approximately 4 hours at 37°C to digest. The reaction mix was purified
by eluting it through a High Pure Purification column (section 2.7.2).
2.7.2 Purifiying cDNA and PCR Products Prior to Cloning
The cDNAs prepared as in section 2.7.1 and restriction digested products (section
2.8.2) used for cloning and ligations were purified to remove the Taq and other
contaminants which have a high salt content and may have inhibited cloning
reactions. In order to achieve this the product was passed through either a Chromo-
spin TE-400 column (Clontech) or a High Pure Purification column (Roche)
according to the manufacturer's instructions. Using the Chromo-spin TE-400
column, the column was centrifuged at 1800 rpm for 3 minutes and the flow through
discarded. The product to be purified was made up to 50pil by adding pure water
(Promega) and added to the column, this was centrifuged at 1800 rpm for 3 minutes
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and the flow through transferred into a fresh Eppendorf and stored at -20°C. Using
the High Pure columns, five times the PCR volume of High Pure binding buffer (3M
guaninidine-thiocynanate, 10mM Tris-HCI and 5% ethanol (v/v); pH 6.6) was added
and the mixture added to the spin column. This was centrifuged at 8000 rpm for 2
minutes, and the flow through added back to the column. This step was repeated to
ensure maximal binding of the PCR product to the column, and the flow through
discarded. The column was washed with 500pil High Pure wash buffer (20mM NaCI,
2mM Tris-HCI and 80% ethanol; pH 7.5), centrifuged at 8000 rpm for 2 minutes and
the flow through discarded, this step was repeated using 200fxl wash buffer. The
column was centrifuged at 12,000 rpm to ensure the column was completely dry
before 50ptl pure water (Promega) was added and the product eluted by
centrifugation.
2.7.3 Cloning of the cDNAs into Eukaryotic and Prokaryotic Vectors
Different vectors were used depending whether the contructs were to be used for
expression of recombinant protein in prokaryotic cells or transient transfections into
eukaryotic cells.
Table 2.8. Vectors used for each ER construct.
Vector Insert Experiment
pUni hER(31 & ER(32, MmER(31 & ER(32, McER(31 &
ERp2
Cloning and recombination




pcDNA3.1 hERa, ER(31 & ER(32, MmER|31 & ER|32, McER|31
& ER(32
Transient transfections
FP hERa, ER(f1 & ER[32 Protein expression
pUni, pRSET and pcDNA3.1 purchased from Invitrogen. FP vectors purchased from
Clontech.
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2.7.3.1 Sequence of Cloning Reactions
Figure 2.1. Flow diagram to show the sequence of cloning reactions performed.
Gene of Interest (cDNA)
TA Cloning into pUni Direct cloning into pcDNA3.1
cDNA amplified up to contain
3' -A overhangs to allow
cDNA, pcDNA3.1 & FP vectors





2.7.3.1.1 TA Cloning of cDNA into the pUni Vector
The amplified PCR product was inserted into the pUni vector into the sites shown in
Figure 2.2.
Figure 2.2. A diagram to show the TA cloning site in the pUni vector which the PCR product
was inserted into. Taken from Invitrogen product information.
Topoisomerase
CACC ATG NNN NNN AAG GG-





CCCTTCACC ATG NNN NNN AAG GG- --
GGGAAGTGG TAC NNN NNN TTC CC- --
J*
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2.7.3.1.2 Recombination ofpUni into the Acceptor Vector pRSET
Figure 2.3. Diagram to demonstrate how pUni and the gene of interest recombines with an
acceptor to produce the recombined plasmid. Taken from Invitrogen product information.
fox* = foxP or loxH depending on acceptor vector
Once the cDNA had been cloned into the pUni vector it was recombined with an
acceptor vector in the presence of Cre recombinase (Figure 2.3). The net result of
this reaction was the formation of a recombinant plasmid.
2.7.3.2 Preparation of ERfi1/ERf}2 Expression Constructs, Cloning into
pUniA/5-His TOPO (Invitrogen)
The ECHO cloning system (Invitrogen) was used to recombine the gene of interest
cDNA into a pUni vector (Figure 2.2), therefore creating a donor vector which was
used for subsequent recombinations with an ECHO adapted acceptor vector such
as pRSET.
Full length ER|31/ER|32 cDNAs were generated from human, macaque and
marmoset testes (section 2.7.1) and cloned into the pUni "donor" vector (pllniA/5-
HisTOPO® Echo Cloning System) following the guidelines outlined in Invitrogen's
ECHO cloning system. Specific primers (2.5.1) were used to amplify up the cDNA to
enable TA cloning into pUni's specific sites. The cDNA was purified as section 2.7.2
before cloning. A 2\i\ volume of the purified cDNA (approximately 100ng) was mixed
with 1pl NaCI (supplied by Invitrogen) and made up to 5pl with sterile water
(Invitrogen). To this, 1pl TOPO® vector (Invitrogen) was added and the reaction
incubated at room temperature for 15 minutes. The TOPO® reaction was
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transformed into "One Shot PIRI" cells (Invitrogen) on ice. Briefly, 2\x\ TOPO®
reaction was added to the cells and incubated on ice for 30 minutes. The cells were
heat shocked at 42°C for 30 seconds to facilitate entry of the construct into the cells.
The cells were returned to ice and 250pil SOC medium (2% bacto-tryptone, 0.5%
bacto-yeast extract, 10nM NaCI, 2.5 mM KCI, 10mM MgCI2, 10mM MgS04 and
20mM glucose) was added, after which they were shaken for 1 hour at 37°C at 225
rpm. A 50pil volume was removed and spread onto Luria Bertani (LB; 10b T1 bacto-
tryptone, 5g T1 bacto-yeast extract, 5g 1"1 NaCI pH 7.0 with NaOH) agar plates
containing 50pg/ml kanamycin and left in a 37°C incubator overnight. The next day
several colonies were picked and propagated overnight in kanamycin-containing LB
and the plasmid extracted (section 2.9). The constructs were assessed to ensure
the cloning was successful (section 2.6) and glycerol stocks produced for long term
storage (section 2.9.3).
2.7.3.3 Cloning into pRSET-E (Invitrogen)
Figure 2.4. Diagram of the pRSET vector. Taken from Invitrogen product information.
The pUni donor constructs were recombined into the pRSET-E "acceptor" vector
with a T7 promoter (Figure 2.4) following Invitrogen's protocol. Recombination was
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performed by mixing approximately 100ng of the donor vector (pUni) containing the
correct cDNAs of interest, with 100ng pRSET-E and 2pl Recombinase buffer
(Invitrogen). This was made up to 19pil with sterile water (Invitrogen) and 1pl Cre
Recombinase (Invitrogen) added. The reaction was incubated at 37°C for 20
minutes at room temperature and inactivated by heating to 65°C for 5 minutes. A
Cre recombinase from Clontech was also used for recombination reactions. In brief,
50ng pRSET, 50ng cDNA/pUni, 1pl 10x Cre buffer (Clontech), 1pl 0.05% BSA
(Promega), 2pl 10mM Tris (for human cDNAs) and 0.5pil Cre recombinase
(Clontech) was made to a total volume of 10pil with pure water (Promega). The
reaction was incubated for 20 minutes at room temperature and then at 65°C for 5
minutes to inactivate the enzymes.
A 5pJ volume of the recombination reaction was transformed into "One Shot TOP10"
competent E.coli cells (as in section 2.7.3.2). Kanamycin selective agar plates were
used and the colonies propagated in kanamycin-containing LB the following day.
The resulting constructs were screened for correct insertion (section 2.6).
2.7.3.4 Cloning into pcDNA3.1A/5-His TOPO (Invitrogen)
Figure 2.5. A diagram to show the pcDNA3.1 vector. Taken from Invitrogen product
information.
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The pcDNA3.1A/5-His (Invitrogen) allows direct ligation of the cDNA product into a
plasmid vector (Figure 2.5). These constructs can be directly transfected into cells
and their expression analysed using the Luciferase Assay (section 2.10.2.4), or
protein expression from the cells (section 2.10.2.6).
Human, macaque and marmoset cDNAs (section 2.7.1) were directly cloned into the
TA cloning site of pcDNA3.1A/5-His as directed by Invitrogen's guidelines. The
TOPO® cloning reaction was performed as in section 2.7.3.2 and 2pil transformed
into One Shot TOP10 competent E.coli cells (Invitrogen). Transformation of the
construct was carried out as in section 2.7.3.2, and 250pl cells plated out on
ampicillin-containing agar plates and incubated overnight at 37°C. Colonies were
propagated as section 2.7.3.2 and the resulting constructs analysed to ensure they
contained the correct insert (section 2.6). High quality caesium chloride preparations
(section 2.9.2.3) were produced for use in transient transfections (section 2.10.2).
Human ERa cDNA, which had been recovered from the plC20H vector (American
Type Culture Collection) (section 2.7.1) using BamHI and EcoRV restriction
enzymes, was purified as in section 2.7.2. It was ligated into pcDNA3.1, pre cut with
the same enzymes, using Ready to Go ligase (Amersham) as discussed in section
2.8.3.
2.8 Preparation of Fluorescent Protein-tagged Constructs
To be able to visualise ER|31 and ER|32 proteins in transfected cells the cDNAs were
tagged with fluorescent proteins (FP) using vectors purchased from Clontech. These
vectors were chosen so that the ER cDNA was inserted into the vector in frame with
the 3' end of the EGFP (Figure 2.5) and DsRed (Figure 2.6). The resulting protein
was therefore tagged with the EGFP or DsRed protein at its N-terminus. This
organisation was chosen to avoid disturbing the ligand binding or AF-2 domains at
the C-terminus of the steroid receptor.
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2.8.1 Preparation of the ER cDNAs and the EGFP and DsRed Vectors Prior to
Cloning
ER(31 and ERp2 cDNAs from pUNI and pRSET vectors (respectively) were amplified
by PCR (section 2.5) with ABgene Extensor annealing at 60°C for 30 seconds,
using sequence specific primers (section 2.5.2.1) which include Hindlll and BamHI
restriction sites. The net result was the generation of cDNAs with Hindlll and BamHI
sites upstream from the start site and downstream of the stop codon of the receptor
cDNA. The resulting cDNA was purified through the High Pure Purification Columns
(Roche) as section 2.7.2.
2.8.2 Restriction Digestion of the cDNA and FP Vectors
The EGFP and DsRed vectors and the cDNAs were all digested with both Hindlll
and BamHI restriction enzymes (Promega), following the manufacture's instructions.
In brief, 5pig sample was cut with 2.5p,l of each enzyme and a total of 5p.l enzyme
buffer in a 50^1 volume made up with pure water (Promega). These were left to
digest at 37°C for approximately 4 hours to ensure complete digestion had occurred.
The digested EGFP and DsRed vectors were incubated with Shrimp Alkaline
Phosphatase (SAP) to ensure the vector would not re-ligate to itself. For every Vg
DNA present, 1p,l SAP (Promega) and 1 pil SAP buffer was added, this was
incubated at 37°C for 15 minutes followed by de-activation by heating to 65°C for 20
minutes. Products were purified through High Pure Columns (Roche) as section
2.7.2.
2.8.3 Ligations of ERpi/ER02 in the FP Vectors
Using the calculation below to ensure the correct ratio of insert to vector was used,
ligations were performed to insert the cut and purified ER|31 and ER(32 cDNAs into
the cut and purified FP vectors (section 2.8.2).
10nq vector x insert size x 3
vector size 1
The Ready-to-Go T4 DNA ligase mix (Amersham) was purchased already aliquoted
into tubes. These tubes were mixed using a vortex and briefly centrifuged before
use. Approximately 63ng ER|31 or ER(32 was added to 37ng of the FP vector. The
volume was made up to 20pil with pure water (Promega) and the mix added to the
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Ready-to-Go T4 DNA ligase tube. The ligation mix was then incubated at room
temperature for 5 minutes and then at 16°C for 45 minutes, with occasional mixing
using a vortex.
2.8.4 Transformations of the Ligated Products
Transformations were carried out by adding 2\x\ of the ligation mix (approximately
10ng DNA) (section 2.8.3) to 50^1 competent XL1 Blue cells (Stratagene) in a chilled
tube and incubated on ice for 30 minutes. The plasmid was introduced into the cells
by heat shocking the tube at 42°C for 35 seconds. The cells were returned to ice for
two minutes, before 450pil SOC medium was added. The cells were incubated with
vigorous shaking (225 rpm) for 1 hour at 37°C, after which all of the 500^1 cells/SOC
medium was spread onto LB agar plates containing 50p,g/ml kanamycin, as the FP
vectors contain the kanamycin resistance gene. Plates were then inverted and
incubated at 37°C overnight when bacterial colonies appeared. Colonies were
propagated in 5ml kanamycin-containing LB overnight and a "mini plasmid prep"
performed to obtain the plasmid (section 2.9.2).
2.8.5 Plasmid Analysis
To ensure ER|31 or ER|32 cDNAs had been inserted correctly into the FP vector, the
plasmids obtained from the colonies grown overnight (section 2.8.5) were either
linearised with one or digested with both Hindlll and BamHI enzymes as previously
(section 2.8.2). The cut products were then run on an agarose gel (Section 2.6.1). If
the plasmid appeared to contain an insert of the appropriate size the plasmid was
sequenced (section 2.6.3) to confirm that no mutations had been introduced during
the PCR amplification or cloning reaction.
2.9 Plasmid Preparation
2.9.1 Plasmid Propagation
Plasmid stocks were prepared by picking a single colony off the agar plate and
propagating it overnight by shaking at 225 rpm at 37°C in 5ml LB broth containing
50[xg/ml ampicillin or kanamycin depending on which resistance gene the vector
contained.
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2.9.2 Plasmid Extraction
Three different methods were used to isolate the plasmid from the bacterial cultures,
the first method was using a kit purchased from Promega for purification of products
used for cloning and the second method was a crude preparation used to determine
if reactions such as cloning had been successful. The caesium chloride (CsCI)
preparation was a method used to obtain high quality DNA for transient
transfections.
2.9.2.1 Wizard ® Plus SVMinipreps DNA Purification System (Promega)
Plasmid DNA was isolated from 1.5ml of the bacteria culture using the alkaline lysis
method of the Wizard ® Plus SV Minipreps DNA Purification System. Briefly, the
culture was centrifuged for 1-2 minutes at 14,000 rpm and the pellet resuspended in
250pil "Resuspension solution" (50mM Tris-HCI pH 7.5, 10mM EDTA and 100ng/ml
RNase). The tube was inverted a couple of times, after addition of 250|xl "Cell Lysis
solution" (0.2M NaOH and 1% SDS) to lyse the cells and denature the chromosomal
DNA. 10ptl alkaline protease solution added and the contents again mixed by
inverting. The tube was left to incubate for 5 minutes at room temperature, after
which 350pil "Neutralisation solution" (1.32M KOAc and 6.4% glacial acetic acid, pH
4.8) was added. After inverting the tube again it was centrifuged at 14,000 rpm for
10 minutes, resulting in the sedimentation of bacterial genomic DNA, protein and
cell debris. The cleared lysate containing the plasmid DNA was passed through a
spin column by centrifuging at 10,000 rpm for 1 minute. The column was washed by
adding 500pil "Wash solution" (200mM NaCI, 20mM Tris-HCI, pH 7.5, EDTA and
47.5% v/v ethanol) and centrifuging at 10,000 rpm, the flow through was discarded.
This step was repeated and the column centrifuged at 14,000 rpm to dry. The spin
column was transferred to a sterile 1.5ml tube and 50pl pure water (Promega) was
added to the spin column. This was allowed to sit for 5 minutes to allow for
maximum elution of the DNA from the spin column into the water. The tube was
centrifuged for 1-2 minutes at 14,000 rpm, the DNA/water was spun through the
column for a second time to allow for complete elution. The plasmid flow through
was transferred into a fresh tube and stored at -20°C until analysis.
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2.9.2.2 Crude Alkali Preparation
The Crude Alkali Preparation method was taken from (Sambrook et al., 1989) and
modifications of the methods by (Birboim, 1979; Burke, 1981). The bacterial pellet
was re-suspended in 10Opil of ice cold Solution 1 (50mM glucose, 25mM Tris-HCI,
pH8.0 and 10mM EDTA, pH 8) by vigorously vortexing. To this, 200^1 freshly
prepared Solution 2 (0.2M NaOH and 1% SDS) was added. The contents of the
tube were mixed by inverting several times. The tube was placed on ice and 150p,l
ice cold Solution 3 (5M KOAc, glacial acetic acid and water) added. The tube was
mixed using a vortex to ensure Solution 3 was thoroughly dispersed through the
viscous bacterial lysate. The tube was left to stand on ice for 5 minutes before being
centrifuged at 12,000 rpm for 5 minutes at 4°C. The supernatant was transferred to
a fresh tube and the pellet discarded. An equal volume of phenol:chloroform was
added and the solution mixed using a vortex. The tube was centrifuged at 12,000
rpm for 2 minutes at 4°C and the top aqueous layer transferred to a fresh tube. The
double stranded DNA was precipitated by adding 2 volumes of 100% ethanol to the
tube and mixing with a vortex before being left to stand at room temperature for 2
minutes. The tube was centrifuged at 12,000 rpm for 5 minutes at 4°C and the
supernatant removed. The pellet was washed with 500pil 70% ethanol at 4°C and
the tube centrifuged as in the previous step. The pellet was left to air dry before
being re-suspended in 50pil TE (pH 8.0) or 50pil pure water (Promega) and stored at
-20°C.
2.9.2.3 CsCI Preparations
CsCI preparation of plasmids yields a high quality pure DNA which were used for
transfection studies. The method was taken from Sambrook et al., (1989).
2.9.2.3.1 Plasmid DNA Preparation
Bacterial culture was grown in a 10ml volume overnight at 37°C and transferred into
a larger 500ml volume over a second night at 37°C. The culture was split into two
centrifuge flasks (250ml in each) and centrifuged at 6000 rpm at 4°C for 10 minutes.
The supernatant was discarded and the pellet re-suspended in 36ml solution P1
(50mM glucose, 25nM Tris-HCI pH 8.0 and 10mM EDTA). To lyse the cells, 36ml
solution P2 (0.2M NaOH and 1% SDS) was added and the cell solution thoroughly
mixed. The SDS in the P2 solution complexes with proteins present. Solution P3
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(3M KOAc pH 4.8) was chilled prior to use and 36ml added to the cells, thus
precipitating the proteins and high molecular weight DNA. This mixture was left on
ice for 15 minutes or longer, before centrifuging at 7000 rpm at 4°C for 15 minutes.
The clear and glassy looking supernatant was immediately filtered through Miracloth
(Calbiochem) into a clear centrifuge tube. To the supernatant, 0.7 volumes of
Isopropanol was added and the solutions gently mixed, the tube was then
centrifuged at 7000 rpm at 4°C for 15 minutes. The supernatant was discarded and
the pellet re-suspended in 4 ml TE. To this, 2ml Tris saturated phenol was added
and the tube inverted vigorously several times, 2ml chloroform was added and the
tube inverted vigorously again. The tube was centrifuged at 2500 rpm for 5 minutes.
The aqueous layer was transferred to a fresh tube and 0.1 volume of 3M NaOAc,
pH 5.0 was added, followed by 2 volumes of 100% ethanol. The solution was mixed
and left at -20°C for at least 15 minutes to allow for the precipitation of the DNA. The
tube was centrifuged at 8000 rpm at 4°C for 5 minutes. The supernatant was
removed and the DNA pellet washed with 70% ethanol and centrifuged again. The
pellet was dried and resuspended in 2ml TE.
2.9.2.3.2 Preparation ofCsCI Gradient
The gradient was prepared in a 2ml Eppendorf tube. To the tube, 1.7g CsCI and
40pil ethidium bromide (10mg/ml) was added, along with 1.4ml of the DNA sample
(section 2.9.2.3.1). This mixture was transferred to a 2ml polyallomer Re-Seal™
tube (Kendro Laboratory), which was sealed with a plug and crown. The tube was
centrifuged in a Sorvall microultracentrifuge (Kendro Laboratory) for 2.5 hours using
a gradient spin starting at 150,000 rpm decreasing to 80,000 rpm all at 20°C. The
ethidium bromide intercalates with the plasmid DNA which could be visualised as a
band in the middle of the tube, with the RNA forming a pellet at the bottom of the
tube.
2.9.2.3.3 Recovery of Plasmid DNA
An 18 gauge needle was used to pierce the neck of the tube to allow air to pass
freely into the tube. Another needle was used to pierce the tube just below the DNA
plasmid band and a hypodermic syringe used to extract out the contents of the band
which was then transferred into two fresh tubes.
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2.9.2.3.4 Removal ofEthidium Bromide
Following transfer of the plasmid DNA an equal volume of CsCI-saturated
isopropanol was added and the contents shaken vigorously. TE was added if the
CsCI came out of solution. The organic and aqueous phases were left to separate
and the upper aqueous phase discarded. This process was repeated until the two
phases were completely clear. The lower organic phase was then transferred to a
fresh tube and 0.1 volume of 3M NaOAc, pH 5.0, and three volumes of 70% ethanol
added. This was gently mixed and precipitated at -20°C for 45 minutes or -70°C for
20 minutes. The tube was centrifuged at 7000 rpm at 4°C for 10 minutes and the
supernatant discarded. A 500pl volume of 70% ethanol was added to the pellet and
the contents of the tube mixed using a vortex before being centrifuged at 13,000
rpm for 10 minutes. The pellet was air dried and re-suspended in 1ml TE. To this,
250pil Tris-saturated phenol was added and the solution inverted vigorously, 250p,l
chloroform was added and the tube inverted again. The tube was centrifuged at
13,000 rpm for 5 minutes. The aqueous phase was transferred to a new tube and
500p,l chloroform added and inverted vigorously again and the tube centrifuged as
before. The aqueous phase was aliquoted to a fresh tube and 0.1 volume 3M
NaOAc; pH 5.0 and 3 volumes of 100% ethanol added. The solution was
precipitated at -20°C for 30 minutes and centrifuged at 13,000 rpm for 10 minutes.
The DNA pellet was washed in 70% ethanol, centrifuged and left to air dry. The
pellet was finally re-suspended in 500pl TE and the purity and concentration
determined by running the sample on an agarose gel (section 2.6.1) and Genequant
analysis (section 2.6.2).
2.9.3 Glycerol stocks
After plasmid preparation and analysis to ensure that the insert size, orientation and
sequence was correct, a stock of E.coli from which fresh plasmid could be
recovered at a later date was prepared. An 800pil aliquot of the bacterial culture was
added to 300pl 100% glycerol mixed using a vortex and stored at -70°C.
2.10 Cell Culture and Transfections
All cell culture work was carried out in a class 2 cabinet. Cells were maintained in an
incubator at 37°C with 5% carbon dioxide.
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2.10.1 Cell Culture
Cells were maintained in DMEM Phenol Red Free Media (Sigma, Catalogue
Number; D-5921) supplemented with 10% charcoal-stripped fetal bovine serum
(Gibco, Catalogue Number; 10106), 1% D-(+)-Glucose (45% solution, Sigma.
Catalogue Number; G-8769), 1% 2mM L-Glutamine (Sigma, Catalogue Number; G-
7513), 1% Non-Essential Amino Acids (Ambion), 1% Fungizone (Gibco) and 1%
Penicillin-streptomycin (Sigma, Catalogue Number; P-4333). For transfections, the
media contained the above, except the fetal bovine serum and antibiotics were
omitted.
The cells were split using 1x trypsin as in section 2.3.1. Briefly, the media was
removed from the cells in the 75ml flask, 2ml trypsin was added to cover the cell
layer and the flask incubated at room temperature until the cells had detached.
Media was added to neutralise the trypsin, making the volume up to 10mls and the
cells were counted using a haemocytometer so that they could be plated out at the
correct density.
2.10.2 Transient Transfections
The cell line to be used was plated out at the densities given in Table 2.9, 24 hours
prior to transfection. Two transfection reagents were used to introduce the DNA into
the cells; either Gene Porter (Gene Therapy Systems) or JetPEI (Cambridge
Biosciences).
Plates and Dishes Used:
• 12 well plates (Costar) for Luciferase assays (section 2.10.2.4)
• 35mm glass bottom microwell dishes (Plastik® Cultureware, MatTek
Coporation) for confocal microscopy (section 2.10.2.5)
• 60mm dishes (Cellstar ® Greiner bio-one) for protein extraction
(section 2.10.2.6)
• Chamber well slides, 8 well (Nalgene Nunc International) for cell
immunocytochemical analysis (section 2.10.2.7)
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Table 2.9. Details of the cell numbers plated onto different dishes.
Dish/Cell line 12 well plate Confocal dish 60mm dish Chamber well
Hep G2 1x105cells/well 2x105cells/dish 4x105cells/dish 0.3x105ceils/well
Hek 293 1.5x105cells/well 3x105cells/dish 6x105cells/dish 0.5x105cells/weli
2.10.2.1 Gene Porter
In brief, transfection media was aliquoted into two tubes according to the type of
dish to be used, using the volumes given in Table 2.10. Plasmid DNA was added to
one of the aliquots of media and Gene Porter was added at a ratio of 6fd Gene
Porter to Vg of plasmid DNA, to the other aliquot. These aliquots were mixed
together and incubated at room temperature for 45 minutes to allow for complexes
between the DNA and Gene Porter to occur. This was then added to the cells in the
media-free wells.
Table 2.10. Details of the volumes and concentrations used in transfections.
Reagent 12 well plate Confocal dish 60mm dish Chamber well
Gene Porter
(Total vol.)

















1.3fig 2 fxg 6fxg 0.5pg
2.10.2.2 JetPEI
The plasmid DNA was mixed with 150mM NaCI (volume determined by size of dish)
and a 2:1 ratio of JetPEI to p,g of plasmid DNA added to another aliquot of 150mM
NaCI (Table 2.10). These two aliquots were mixed together and left to incubate at
room temperature for 30 minutes before being added to cells with transfection
media present. See Table 2.10 for volumes.
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Four hours post transfection, a 1x volume of complete media was added to the wells
with an additional 10% charcoal stripped fetal bovine serum and the specified
ligand. Twenty-four hours after transfection the media was removed from the cells
and fresh media was added along with the ligand the cells had previously been
incubated with. The cells were harvested 48 hours after transfection using
Promega's Lysis Buffer as manufacturer's instructions. All experiments were carried
out in duplicate or triplicate and repeated a minimal of three times on separate
occasions.
2.10.2.3 Constructs for Transient Transfections
2.10.2.3.1 Oestrogen Response Elements (EREs)
The EREs used were tagged to the luciferase promoter construct so their response
to ER activation in transient transfections could be analysised using the Luciferase
Assay (section 2.10.2.4). The Oxytocin ERE was obtained from Norbert Walther
(Institute for Hormone and Fertility Research, University of Hamburg, Germany
(Adan et at., 1991)) already tagged to the luciferase promoter and cloned into the
pGL2 Basic Vector. The 3x ERE-TK-Luc reporter construct was a gift from S.C.
Nagel and D.P. McDonnell (Department of Pharmacology and Cancer Biology, Duke
University Medical Centre, North Carolina, USA. (Nagel et al., 2001)).
The vitellogenin ERE sequence (Klinge, 2001) was cloned into pGL2-Basic-
Luciferase vector (Promega), and the pTAL-Luciferase vector (Promega) to form Vit
ERE (pGL) and pTAL ERE respectively (work performed by Graeme Scobie, MRC
Human Reproductive Sciences Unit).
2.10.2.3.2 Oestrogen Receptors
Human, Macaque and Marmoset full length ER|31 and ERp2 that had been cloned
into pcDNA 3.1 (section 2.7.3) and Human ERa (section 2.7.3) were used for
transient transfection.
2.10.2.3.3 SRC-1 Preparation
SRC-1e and SRC-1 a constructs were a kind gift from M. Parker (Molecular
Endocrinology Laboratory, Imperial Cancer Research Fund, London. (Kalkhoven et
al., 1998)) supplied in the pSG5 vector. The constructs were reconstituted in TE,
transformed into XLI Blue cells (Stratagene) and plated onto ampicillin-containing
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agar plates (section 2.8.5). Prior to use in transient transfection studies the plasmids
were purified using the CsCI technique (section 2.9.2.3).
2.10.2.3.4 Renilla Internal Control
The pRL-CMV vector (Promega) contains the CMV enhancer and early promoter
elements which provide a high level expression of Renilla luciferase. When co-
transfected with the ERE-luciferase constructs this provides an internal control for
the luciferase assay. The pRL-CMV vector was transformed into XL1 Blue cells
(Stratagene), plated out onto agar plates and propagated in LB (section 2.9.1). A
CsCI preparation (section 2.9.2.3) was performed so that the construct was ready
for transfections.
2.10.2.4 Luciferease Assay
The Dual-Luciferase® Reporter Assay (Promega) was used to measure the level of
transcriptional activity. The experimental ERE-Luc reporter activity was corrected
against the Renilla internal control. This normalisation of the luciferase activity was
essential as it minimises the experimental variability caused by the differences
between cell viability or transfection efficiency. The results were expressed as a fold
increase in activity over the control, ie. the luciferase value given for constructs
transfected into the cells in the absence of ligand.
2.10.2.4.1 Harvesting the Cells
The media was removed from each of the wells in the 12 well plate and 250pil 1x
Passive Lysis Buffer (Promega) added. The plate was gently rocked at room
temperature for 15 minutes to ensure the cells were lysed. Using a pipette, the cells
were aspirated from the wells and into an Eppendorf. Where necessary, the cells
were scraped from the plate using a cell scraper (Nalgene Nunc International). The
tube of cells was then left to sit at room temperature for a further 5 minutes to
ensure complete lysis, before being centrifuged at 14,000 rpm at 4°C for 2 minutes.
2.10.2.4.2 Assaying the Cell Lysate Solution
The Luciferase Assay Buffer II was added to the Luciferase Assay Substrate
(lyophilized product) in the glass bottle and briefly mixed using a vortex. A 200p,l
volume of Renilla Stop & Glo ® Reagent was added to the Stop & Glo ® Substrate
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(dried product) in the small vial and mixed for 10-20 seconds using a vortex. This
was then added to the Stop & Glo ® Substrate Solvent.
The microplate luminometer (Berthold Laboratories) was primed through injector M,
with the Luciferase Reagent before being programmed to read the samples. Each of
the cell lysate samples was aliquoted in 20pil volumes in duplicate into a white 96
well plate (Costar). The plate was read and the data generated saved for analysis.
Once all of the samples had been read for their Luciferase activity, the luminometer
was washed with water and injector M was primed with the Renilla Reagent. The
plate was read again, exactly as for the Luciferase reagent, and the data saved.
2.10.2.5 Transient Transfections for Confocal Analysis
The cells were plated out onto 35mm glass bottom microwell dishes as section
2.10.2 and transfected with the appropriate fluorescent construct. The media was
removed from the cells 48 hours after transfection and the cells were washed with
PBS. The cells were maintained in 1ml PBS with 25mM Hepes buffer (Sigma,
Catalogue Number; H-0887) to give them a minimal amount of nutrients. The cells
were then observed under a confocal microscope (LSM 510, Zeiss) on a warm plate
set to 37°C and treated with the appropriate ligand diluted in PBS/Hepes to 10"8M.
2.10.2.6 Transient Transfections for Protein Analysis
Cells were plated out as section 2.10.2 into 60mm dishes and transfected with the
appropriate constructs (2.10.2.3).
2.10.2.6.1 Extraction of Proteins
Forty-eight hours post transfection, the cells were harvested and the protein
extracted using three different methods. The RIPA extraction (method taken from
Sambrook et al., 1989) is a crude method which does not extract the nuclear
proteins, the Crude Whole Cell Protein Extraction (Maudsley et al., 2000) method
extracts the nuclear and cytoplasmic proteins and the Nuclear Extraction (Active
Motif) can extract the cytoplasmic and nuclear fraction separately. Typically, there
were 4x106 cells present in the 60mm dish, therefore the following methods are
given for this amount of cells.
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2.10.2.6.1.1 RIPA Extraction
The media was removed from the cells in the 60mm dish and the cells incubated
with 500^ils 1x trypsin to detach them from the dish. The trypsin was neutralised with
media and the cells gently centrifuged at 7000 rpm for 5 minutes. The media was
removed from the cells and 400p.l 1x RIPA Buffer (5x RIPA {5M NaCI, 1M Tris-HCI;
pH7.4, 0.5M EDTA. 1% deoxycholate sodium, 0.1% SDS}, 50x Protease Inhibitor
and water) added. The cells were mixed using a vortex and passed through a
hypodermic syringe with a fine needle to shear the genomic DNA. The tube was
then incubated on ice for 15 minutes before being centrifuged to pellet the cell
debris at 14,000 rpm for 15 minutes at 4°C. The supernatant was aliquoted into a
fresh pre-chilled Eppendorf tubes and stored at -70°C.
2.10.2.6.1.2 Nuclear Extraction
Using the Nuclear Extract kit (Active Motif) the nuclear, whole-cell or cytoplasmic
extracts were obtained from cells. The cells were collected from the dishes by
addition of 2.5ml ice cold PBS in the presence of Phosphatase Inhibitors (Active
Motif) after the removal of media. If required, the cells were scraped from the bottom
of the dish using a cell scraper (Nalgene Nunc International). Once the cells were
aspirated from the dish, the cell suspension was centrifuged at 5000 rpm for 5
minutes at 4°C. The supernatant was discarded and the cells re-suspended in 250p1
1x Hypotonic Buffer (Active Motif) to swell the cell membrane and to render it fragile.
The cells were pipetted up and down several times before 15pil Detergent (Active
Motif) was added. The tube was mixed using a vortex for 10 seconds to ensure the
cytoplasmic proteins leaked out into the supernatant. The tube was centrifuged at
14,000 rpm for 30 seconds at 4°C and the supernatant (cytoplasmic fraction) was
collected and stored at -70°C. The nuclear pellet was re-suspended in 25pl
Complete Lysis Buffer (Active Motif) with Protease Inhibitor Cocktail, aided by
mixing with a vortex for 10 seconds. The tube was left on ice for 30 minutes on a
rocking platform so that the nuclei were lysed and the nuclear proteins were
solubilised. The contents of the tube were mixed with a vortex and centrifuged at
14,000 rpm for 10 minutes at 4°C, the supernatant (nuclear fraction) was transferred
to a fresh tube and stored.
Chapter 2 General Materials and Methods 85
2.10.2.6.1.3 Crude Whole Cell Protein Extraction
The media was removed from the cells and the dish placed on ice. The cells were
washed gently by adding 3ml ice cold PBS to each plate and carefully aspirating it
off. A volume of 0.3ml NP40-based lysis buffer (Stock solution: 5M NaCI, 1M Hepes,
10% glycerol. 0.5% NP40 and 1M EDTA; pH 8, plus 0.5mM Na3V04, 10^g/ml
leupeptin and 100mM PMSF added on the day of use) was added to each dish. The
dish was then rocked for 15 minutes on ice before the cells were scraped and
aspirated off into an ice cold Eppendorf tube. The tube was centrifuged at 15,000
rpm for 15 minutes at 4°C and the supernatant transferred to a fresh pre-chilled
tube. The sample was stored at -70°C. On day of use, an aliquot was taken and
added to an equal volume of Laemmli buffer (10% SDS, 0.01% (3-mercaptoethanol,
10% glycerol and 1M Tris; pH 7.0).
2.10.2.6.2 Measuring Protein Concentration
The concentration of the cell lysate was measured using the BioRad Protein Assay
(Bio-Rad Laboratories). BSA protein standards (0.125mg/ml to 1.5mg/ml) were
made up, using the appropriate lysis buffer according to the sample to be measured.
To each ml of Reagent A (BioRad) required, 20pil Reagent S (BioRad) was added.
Using a clear 96 well plate, 5(o.l of the standards and 5pl of each sample were
aliquoted out in duplicate. To these, 25pil Reagent A/S (BioRad) was added followed
by 200^1 Reagent B (BioRad). The plate was then incubated under a cover to
prevent evaporation, for 15 minutes at room temperature. The colour absorbance
was then measured at 650nm in a plate reader (Multiscan EX Labsystems). The
results were analysed by calibrating the protein samples with the standards.
2.10.2.6.3 Protein Electrophoresis, Transfer and Detection
The extracted proteins were subjected to Western analysis and their presence
detected by specific antibodies. Western blotting detects specific proteins resolved
using SDS-PAGE. The technique uses the specificity of antibody/protein
interactions.
2.10.2.6.3.1 Polyacrylamide Gels
Protein analysis was performed using 12% gels made up as follows. The resolving
gel was made up of 6ml 30% acrylamide, 3.8mls 1.5M Tris; pH 8.8, 0.15ml 10%
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SDS, 0.1ml 10% APS (ammonium persulphate) and 0.01ml TEMED made up to
15mls with water. This was poured into a cassette (Invitrogen) and left to set. The
4% stacking gel consisted of 0.65mls 30% acrylamide, 0.63ml 1.0M Tris; pH 6.8,
0.05ml 10% SDS, 0.05ml APS and 0.005ml TEMED made up to 1.5ml with water.
The stacking gel was poured into the cassette once the resolving gel had set and a
comb inserted so that loading wells were formed. The gels were stored at 4°C. Pre¬
cast 12% denaturing polyacrylamide gel (Invitrogen) were also used.
2.10.2.6.3.2 Protein Samples and Electrophoresis
A known concentration of the sample to be run on the polyacrylamide gel was mixed
with 5x SDS loading dye (50mM Tris-HCI; pH 6.8, 100mM DTT (dithiothreitol) 2%
SDS, 0.1% bromophenol blue and 10% glycerol with 0.01% |3-mercaptoethanol) or
an equal volume of Laemmli buffer (section 2.10.2.6.1.3) and boiled for 2-3 minutes.
The sample was then loaded onto the gel immersed in 1x electrolyte running buffer
(25mM Tris, 250mM glycine; pH 8.3 and 0.15% w/v SDS) in an X Cell Sure Lock
electrophoresis tank from Novel Experimental Technology. An aliquot of pre-stained
SDS-Page standards (BioRad) was run alongside the sample. The gel was run at
120 volts over approximately two hours until the dye front had run to the bottom of
the gel.
2.10.2.6.3.3 Protein Transfer
Once electrophoresis was complete, proteins were transferred onto an Immobilion
transfer membrane (Millipore) in blotting buffer (48mM Tris, 39mM glycine and 20%
methanol) using an electrophoresis unit from Hoefer Scientific Instruments as
pictured in Figure 2.7. This was performed either overnight run at 20 volts or over
four hours run at 40 volts.
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The gel was stained with Coomassie blue (0.1% w/v Coomassie blue R250 in 50%
v/v methanol and 7.5% v/v acetic acid) overnight to observe whether the proteins
had run properly. The transferred membrane was removed from the tank and
incubated with 1% (w/v) dried semi-skimmed milk in TBST (50mM Tris-HCI, 150mM
NaCI; pH 7.4, and 0.05%Tween-20) for 1 hour at room temperature. The membrane
was washed with TBST and then incubated overnight at 4°C with the primary
antibody made up in TBST to the correct dilution (Table 2.11).
Table 2.11. Details of the antibodies used in Western analysis.
Antibody code/supplier Raised in Dilution










As above (Catalogue Number;
9102)
Rabbit polyclonal 1:1000
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The following day, the Coomassie dye was removed from the gel with de-stain (50%
methanol and 5% acetic acid) so that the protein samples were visible. The primary
antibody was washed off the membrane by washing 3 times for 20 minutes with
TBST and then incubated for 2 hours with the appropriate HRP-conjugated
secondary antibody in TBST at room temperature. The membrane was washed 3
times for 20 minutes with TBST, with a final wash with TBS (50mM Tris-HCi, 150mM
NaCI; pH 7.4) before being subjected to ECL Plus Western Blotting Detection
System (Amersham Life Sciences). The chemiluminescence was detected using X
ray films (XLS, Kodak) which were developed using developer and fixer solutions.
2.11 Cell Immunocytochemistry
Cells were plated out into 8-well chamber well slides as section 2.10.2, and
transfected with the appropriate construct. After 48 hours post transfections, the
media was removed and the cells fixed in ice cold methanol for 10 minutes.
Immunocytochemical analysis was carried out on the cells (section 2.12).
2.12 Tissue immunohistochemistry
Tissues embedded in paraffin wax blocks (Histology department, MRC Human
Reproductive Sciences Unit) were cut into 5fxm sections using a Lecia hand
operated microtome RM 2135 (Leica). Sections were floated in ice cold water and
then warm (42°C) distilled water and placed onto charged slides. To remove the
wax after the slides were dry, they were immersed in xylene for 5 minutes. They
were re-hydrated in decreasing percentages of alcohol (100%, 95% and 70%) and
rinsed in water.
2.12.1 Retrieval
To visualise the receptor, antigen retrieval was performed as detailed in (Norton et
at., 1994; Saunders et at., 2000). Retrieval was performed to reduce cross-linking
between proteins that are formed by fixing the tissue. This was carried out by
pressure cooking (Tefal) the slides in glycine/EDTA (50mM glycine and 0.01%
EDTA) or Citrate.
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50mM Glycine/EDTA 3.5 5 minute pressure cook
Sit for 20 minutes after
ER|32
(Ab:57)
50mM Glycine/EDTA 3.5 5 minute pressure cook
Sit for 20 minutes after
EGF receptor
(Ab:Sigma)
Citrate 1 minute boiling
After retrieval, the slides were incubated in 3% hydrogen peroxide in methanol for
30 minutes to decrease endogenous peroxidase activity and therefore decrease
background staining. The slides were washed in tap water and washed three times
for 5 minutes in TBS (50mM Tris-HCI, 150mM NaCI; pH 7.4).
2.12.2 Avidin-Biotin Blocking
An avidin-biotin (Vector SP-2001) block was carried out to block endogenous biotin
therefore reducing background. Four drops of avidin per ml of rabbit blocking serum
(Diagnostics Scotland) in TBS/BSA was used on the slides and incubated for 30
minutes at room temperature, followed by three washes in TBS. The biotin (4 drops
per ml TBS) was added to the slides for 15 minutes, after which the slides were
washed again.
2.12.3 Primary and Secondary Antibodies
Table 2.13. Details of the antibodies used for immunohistochemistry.
Antibody Raised in Dilution
ERpi M9, raised to P7
Saunders et ai, 2002a
Mouse monoclonal 1:500
ER(32 M57, raised to P8
Saunders et at., 2002a
Mouse monoclonal 1:40
EGF receptor Sigma (Catalogue
Number: E3138)
Mouse monoclonal 1:50
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The slides were incubated with the appropriate dilution of the primary antibody
overnight at 4°C (Table 2.13). The excess primary antibody was then washed off
with TBS as before. The secondary biotinylated antibody was made up to the
correct dilution in blocking serum accordingly with the primary antibody used and
added to the slides for an hour at room temperature. This stage was excluded for
the EGF receptor antibody which was detected using DAKO mouse Envision kit
(section 2.13.5).
2.12.4 Horse-Radish Peroxidase
After TBS washes to remove the secondary antibody, the ABC-HRP detection
system (DAKO) was used to amplify the signal obtained from the primary antibody.
This ABC-HRP was added to the slides for 30 minutes at room temperature. Or
Envision (DAKO) was added to the slides in place of the secondary antibody and
the ABC-HRP for the EGF receptor (section 2.12.5).
The slides were washed and developed using Diaminobenzidene (DAB) substrate
(1 drop/ml, DAKO, Catalogue Number; K3468). After DAB staining, the slides were
counterstained with haematoxylin, differentiated in acid-alcohol and the blue colour
in the nuclei or cell membrane (depending upon protein stained for) developed in
Scotts tap water. The slides were dehydrated in increasing concentrations of alcohol
and cleared in xylene before mounted under glass coverslips using pertex.
2.12.5 Envision
Instead of ABC-HRP and the secondary antibody, one drop of mouse Envision
(DAKO, Catalogue Number; K4006) was added to the section and incubated for 30
minutes at room temperature before washing, DAB development, counterstaining
and mounting as described in section 2.13.4 above.
2.13 Photomicroscopy
Tissue sections were examined using an Olympus Provis microscope (Olympus
Optical Co.) and images were captured using a Kodak DCs330 camera (Eastman
Kodak Co.). Captured images were stored on an Apple Macintosh and images were
compiled using Photoshop 7 (Adobe Systems).
Chapter 3
Cell Specific Patterns of Expression of Oestrogen Receptor
Beta (ER(31 and ER|32) in Human and Primate Tissues,
and in Cell Lines
3.1 Introduction
Oestrogens are essential regulators of both female and male fertility as well as
playing a role in other tissues such as the cardiovascular system and bone.
Oestrogen action is mediated via specific receptors (ER). The first oestrogen
receptor was cloned from a human breast cancer cell line in 1986 (Green et al.,
1986). In 1996 a second ER was cloned, this time from rat prostate (Kuiper et al.,
1996) and its human homologue was cloned shortly thereafter (Mosselman et al.,
1996). The two receptors are known as oestrogen receptor alpha (ERa; NR3A1)
and oestrogen receptor beta (ER(3; NR3A2). ERa and ER|3 receptors are the
products of two genes located on different chromosomes (Enmark et al., 1997).
Splice variant isoforms of the ERp gene have been identified in a number of species
including human (Inoue et al., 1996; Lu et al., 1998; Moore et al., 1998; Ogawa et
al., 1998c), bovine (Walther et al., 1999) and rodents (Chu and Fuller, 1997; Lu et
al., 2000; Lu etal., 1998).
3.1.1 Oestrogen Biosynthesis
Oestrogen biosynthesis is dependent upon expression of the aromatase complex in
females and in males. This enzyme complex is a product of the cyp19 gene and is
composed of a specific cytochrome p450 aromatase and a ubiquitous NADH-
cytochrome P450 reductase (Simpson et al., 1994). The aromatase complex is
located in the endoplasmic reticulum of the cells and is present in numerous tissues
(reviewed in de Ronde et al., 2003). Cytochrome P450 is found at the highest levels
in the human placenta and the granulosa cells of the mature ovarian follicle
(Simpson and Davis, 2001; Turner et al., 2002). In the testis aromatase has been
localised to the Leydig cells, immature Sertoli cells, in the mature germ cells and
spermatozoa (Payne and Youngblood, 1995; Turner et al., 2002).
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3.1.2 Rodent Knockout Models
A number of studies on the role played by oestrogens in reproductive function have
been undertaken either using rodent models in which the oestrogen receptor is
disrupted and therefore oestrogen cannot activate its intended target, or by applying
selective antagonists. The advent of gene deletion has allowed the generation of
mice lacking ERa (aERKO) (Lubhan et al., 1993), ERp (PERKO) (Krege et al.,
1998) or both ERa and ERp (a|3ERKO) (Couse et al., 1999; Dupont et al., 2000), as
well as mice lacking the ability to synthesise oestrogens due to deletion of the
aromatase gene; cyp19 (ARKO) (Fisher et al., 1998). All knockout models are
discussed in detail in the literature review, along with the ERE-Luciferase
engineered reporter mice which demonstrate the tissues in which the ER acts upon
the ERE-reporter gene (Ciana et al., 2001; Nagel et al., 2001).
These knockout mouse models give indications of the overall physiological effect of
oestrogens acting via ERa or ERp in rodents, but they do not shed light on cell
specific patterns of receptors. The discovery of a number of ERa and ERp splice
variants in both rodent (Chu and Fuller, 1997; Lu et al., 2000; Lu et al., 1998) and
human (Inoue et al., 2000; Lu et al., 1998; Moore et al., 1998; Ogawa et al., 1998c;
Petersen et al., 1998) has introduced a new level of complexity in potential cellular
responsiveness to oestrogens. Sequence comparison reveals that the ERp variants
in human are not identical to rodents (Enmark and Gustafsson, 1999) therefore the
rodent models may not be directly comparable to humans or primates.
3.1.3 Oestrogen Receptor Beta (ERp) Isoforms and Localisation
The current study has focused on human ERpi, the full length wild type receptor
and the ERp2 (also known as ERpcx) splice variant isoform, the mRNA's of which
have previously been reported to have differential expression in different tissues and
cell lines (Moore et al., 1998; Ogawa et al., 1998c). In normal tissues RT-PCR
analysis suggests the highest levels of expression of mRNAs for human ERpi is
found in testis and ovary, with lower levels of expression in the heart, brain,
placenta, liver, skeletal muscle, spleen, thymus, prostate, colon, bone marrow,
mammary gland, uterus and fat. In contrast, human ERp2 mRNA was detected at
highest levels in spleen, thymus, testis and ovary, with lower levels of expression in
skeletal muscle, prostate, colon, small intestine, leukocytes, bone marrow,
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mammary gland, uterus and fat (Moore et al., 1998). Differential expression of other
ER|3 splice variant mRNAs; hER|33, hER|34, hER(3A5 and hER|35 has also been
documented (Inoue et al., 2000; Moore et al., 1998; Scobie et al., 2002).
In addition to normal tissues, transformed cell lines derived from prostate, uterus,
bone, liver, colon, breast and ovarian tumours have been analysed for expression of
hER|3 isoforms (Moore et al., 1998). Human ER(31 was detected in prostate, uterine,
bone, breast and ovarian tumour cell lines but not in colon and liver tumour cell
lines. Human ER|32 was detected in a wide range of cell lines including those
derived from prostate, uterus, breast, and endothelial cells.
In this chapter studies are described in which the human and non-human primates
are used to investigate localisation of ER(31 wild type and the ER|32 variant at an
mRNA and protein level. The Common marmoset is a New World primate (Callthris
jacchus) and the stump-tailed macaque is an Old World primate (Macaca arctodies).
The experiments performed complement studies from our laboratory which have
shown that these primates are good models for studying the expression of the
oestrogen receptors in reproductive systems (Saunders et al., 2000; Saunders et
al., 2001).
3.1.4 Aims
The aims of the studies in this chapter were to determine if the ER|3 variant mRNAs
and proteins exist in primates and if they do, whether they were similar to human or
rodent variants. The aim was also to determine the specific localisation of the ERpi
and ER(32 variant within reproductive tissues of the human and primates.
Chapter 3 Immunolocalisation of ER(31 and ERp2 94
3.2 Methods
3.2.1 Identification of mRNAs by RT-PCR
Cells and tissues were collected, total RNA extracted, oligo DT primed and cDNA
synthesis performed with oligo DT primers as described in sections 2.3 and 2.4
respectively. A human cDNA testis library was purchased from BD Biosciences and
used as a positive control.
3.2.1.1 Screening Primers
Specific primers were chosen, as outlined in section 2.5.1, to amplify regions of the
human ER(31 wild type and human ER|32 variant cDNAs in order to be able to
determine whether mRNAs with specific sequence homology were expressed in
tissue extracts or cell lines (Table 3.1).
Table 3.1. PCR primers used for detection of ER|31 and ER|32 and the GAPDH positive
control.
5' primer 3' primer Product size
ERpi GGCATCTCCTCCCAGCAGCA CACTGAGACTGTGGGTTCTGGG 240 bp
ER|32 GGCATCTCCTCCCAGCAGCA CACTGCTCCATCGTTGCTTC 135 bp
GAPDH CTGCACCACCAACTGCTTAGC ATGCCAGTGAGCTTCCCGTTC 280 bp
3.2.1.2 RT-PCR
PCR was carried out using Mega Mix (Microzone) as described in section 2.5.2.3.
The PCR reactions were annealed at 58°C for 30 seconds using the ER(31, ER(32
and GAPDH oligonucleotide primers (Table 3.1)] DNA fragments were analysed by
migration on agarose gel (section 2.6.1).
3.2.2 Antibodies for Immunohistochemical Analysis
Monoclonal antibodies to detect full length ER|31 and ER(32 proteins were prepared
as described previously (Saunders et al., 2000; Saunders et al., 2002a). Briefly, the
ERpi specific antibody (M9) was raised against the peptide P7
(CSPAEDSKSKEGSQNPQSQ) located at the C-terminus of human ER|31
(Saunders et al., 2000). The human ERp2 antibody (M57) was raised against
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peptide P8 (CMKMETLLPEATMEQ) located at the C-terminus human ERp2
(Saunders et al., 2002a) (Figure 3.1).
Figure 3.1 Figure to show the regions of the proteins that the antibodies were raised to. Note
the P4 peptide which has been used previously to immunolocalise ER[3 to human and




Marmoset tissues were previously collected from adult captive bred animals
(Callthrix jacchus) maintained in a colony which has been closed since 1973.
Tissues were also previously collected from adult stump-tailed macaques (Macaca
arctodies, n=3). These tissues had already been fixed and embedded in paraffin
wax blocks and along with tissues from human, were held in an archive in the
histology section at the MRC Human Reproductive Sciences Unit (Edinburgh). Fixed
sections of human endometrium were a gift from Professor Hilary Critchley and
Teresa Henderson (University of Edinburgh).
Immunohistochemical studies were carried out on tissues using anti-hER|31 and
anti-hER|32 specific monoclonal antibodies using methods described in section 2.12.
Slides were subjected to a heat induced retrieval stage (section 2.12.1) to reduce
cross-linking between proteins formed during the fixation (Norton etal., 1994).
Sections stained for ER(31 using the M9 antibody were pressure cooked for 5
minutes in a 50mM glycine/EDTA buffer at pH 3.5. Sections stained for ERf52 with
the M57 antibody were also pressure cooked in a 50mM glycine/EDTA buffer at pH
3.5, whereas endometrial sections were pressure cooked at pH 8.0 for 5 minutes.
An avidin-biotin block was carried out as section 2.12.2, however 6 drops per ml of
blocking serum (5% NRS in TBS/BSA) were used when looking at marmoset
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The primary antibodies were diluted in NRS/TBS/BSA (anti-ER(31 1:500; anti-ER|32
1:40) and added to the slides after the biotin had been washed off, they were
incubated overnight at 4°C (section 2.12.3).
The following day an anti-mouse biotinylated secondary antibody diluted (1:5000) as
described in section 2.12.3 was incubated on slides for 1 hour at room temperature.
ABC-HRP (DAKO) was used to amplify the antibody signal. This was incubated on
the slides for 30 minutes before being washed off and DAB used to develop the
signal. The slides were counter stained with haemotoxylin, dehydrated and mounted
with pertex, then photographed as described in section 2.13.
3.2.2.2 Cell Monolayer Immunocytochemistry
Immunocytochemical analysis was performed on the cell lines (Hek 293 and Hep
G2) that were used in the transient transfection studies described in Chapter 5. The
cells were plated out as in section 2.10 onto chamber well slides (Nalgene Nunc
International). The cells were either left to grow on their own or transfected with the
ER|3-containing plasmid constructs (prepared as described in Section 2.7) as a
positive control.
After 48 hours the cells were fixed in ice-cold methanol (section 2.11) and
immunocytochemistry performed as section 2.12, but without the de-waxing and
antigen retrieval stages. The anti-ER(31 and anti-ER|32 antibodies were used as
described above (and in section 3.2.1).
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3.3 Results
3.3.1 Detection of ERpi and ERp2 mRNA in Samples from Human, Macaque
and Marmoset Tissues and Cell Lines
Primers specific for ERpi and ERp2 isoforms were used to amplify cDNAs from
pools of cDNA prepared by RT of total RNA from cell lines and tissues and from
commercially available human testis RNA (BD Biosciences). Following PCR
amplification products of the expected sizes were observed on gels: ERpi gave a
band at 249bp, ERp2 at 135bp and GAPDH at 280bp. ERpi was detected in all
human and marmoset tissues, only the kidney was negative (Figure 3.1; top panel).
ERp2 mRNA expression was detected in heart, ovary and testis in both human and
marmoset (Figure 3.1; middle panel). However, ERp2 mRNA was not detected in
human and marmoset brain, liver, kidney or placenta. Results are summarised in
Table 3.3.
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Figure 3.1. Detection of ER(31 and ER(32 mRNAs in cDNAs pools prepared from human,
macaque and marmoset tissues. RT-PCR was performed on reproductive tissue cDNA from
human, and marmoset. Specific primers were used to detect ER(31 (top panel, 240bp), ER(32
(middle panel, 135bp) and GAPDH (lower panel, 280bp) as a positive control. Tissues tested
were (1) blank, (2) human brain, (3) human heart, (4) human liver, (5) human kidney, (6)
human ovary, (7) human placenta, (8) human testis library (BD Biosciences), (9) human
testis, (10) marmoset brain, (11) marmoset heart, (12) marmoset liver, (13) marmoset
kidney, (14) marmoset ovary, (15) marmoset placenta, (16) marmoset testis and (17)
marmoset testis. 100 bp marker was run on all gels.
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Table 3.3. Summary of ER[31 and ER(32 mRNA expression in tissues.
Tissue ER|31 ER|32
Human Brain + -
Human Heart + +
Human Liver + -
Human Kidney - -
Human Ovary + +
Human Placenta + -
Human Testis Library + +
Human Testis + +
Marmoset Brain + -
Marmoset Heart + +
Marmoset Liver + -
Marmoset Kidney - -
Marmoset Ovary + +
Marmoset Placenta + -
Marmoset Testis Pure + +
Marmoset Testis + +
RT-PCR analysis of RNA from different transformed cell lines also showed a
difference in ER|31 and ER|32 mRNA expression (Figure 3.2). Hek 293, Hep G2 and
Cos 7 cells were negative for both ER|31 and ER(32, whereas Ishikawa, LnCap and
Hela cells contained detectable ER(31 and ERp2 mRNAs. Results are summarised
in Table 3.4.
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Figure 3.2. Detection of ERpi and ERf32 mRNAs in cDNAs pools prepared from cell lines.
RT-PCR was performed using specific primers to detect ER|31 (top panel, 240bp), ERp2
(middle panel, 135bp) and GAPDH (lower panel, 280bp) as a positive control. The cell lines
tested were (1) blank, (2) Hek 293, (3) Hep G2, (4) Cos 7, (5) Ishikawa, (6) LnCap, and (7)
Hela. 100 bp marker was run on all gels.
Table 3.4. Summary of ERpi and ER(32 mRNA expression in cell lines.
Transformed Cell Line ERpi ERP2
Hek 293 (human kidney) - -
Hep G2 (human liver) - -
Cos 7 (monkey kidney) - -
Ishikawa (human endometrium) + +
LnCap (human prostate) + +
Hela (human cervical cancer) + +
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3.3.2 Immunohistochemical Analysis of Reproductive Tissues
3.3.2.1 Immunohistochemical Analysis of the Ovary
Using the anti-hER|31 antibody, ER|31 protein was immunolocalised to nuclei of
granulosa cells at all stages of follicular maturation, and in some cells of the corpus
luteum in the human, macaque and marmoset ovaries (Figure 3.3a, c, e). ER[32
immunopositive staining was detected only in the human ovary (Figure 3.3.b), with
no staining in either the macaque or the marmoset ovaries. In the human tissue
ER|32 expression was very similar to that of ER|31 expression, with immunopositive
staining clearly visible in the nuclei of granulosa cells (G).
3.3.2.2 Immunohistochemical Analysis of the Endometrium
ER|31 and ER|32 proteins were detected in human endometrial tissue (Figure 3.4).
Both ER|3 isoforms were expressed in cells within the basal layer (not shown) of the
human endometrium, as well as in the stromal and glandular cells of the functional
layer (Figure 3.4a, b). In the macaque and marmoset endometrium ER(31
immunopositive cells were also detected (Figure 3.4c, e). In contrast, using the anti-
hER|32 antibody, immunopositive cells were not detected in the macaque or
marmoset endometrial tissues (Figure 3.4d, f), in contrast immunopositive cells were
detected in glands and stroma of human endometrium (Figure 3.4b).
3.3.2.3 Immunohistochemical Analysis of the Placenta
In the human, macaque and marmoset placental tissues ER(31 protein was detected
in the nuclei of the syncytiotrophoblast and in endothelial cells surrounding the blood
vessels (Figure 3.5a, c, e). No ER|32 protein was immunolocalised to placental
tissues from the human, macaque or marmoset (Figure 3.5b, d, f).
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Figure 3.3. Immunohistochemical analysis of ERp1 and ERfS2 protein expression in the
ovary of human, macaque and marmoset. Sections from human (a, b), macaque (c, d) and
marmoset (e, f) were stained with anti-hERpi or anti-hER|32 specific monoclonal antibodies.
Immunopositive staining of ER|31 was observed in the nuclei of granulosa (G), cumulus (C)
and thecal (T) cells (a, c, e). However when the same ovaries were stained for ERp2 only
the human ovarian granulosa cells were clearly immunopositive (b). Magnification is x40.













Figure 3.4. Immunohistochemical analysis of ERpi and ERp2 protein expression in the
endometrium of human, macaque and marmoset. Sections from human (a, b), macaque (c,
d) and marmoset (e, f) were stained with the anti-hERpi or anti-hERp2 specific monoclonal
antibodies. Positive staining for ERp1 was observed in the nuclei of endometrial cells both in
the stroma (S) and in the epithelium lining the glands (G) (a, c, e). When the endometrial
tissues were stained for ERp2 protein only human endometrium was immunopositive (b).
Magnification is x40.
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Figure 3.5. Immunohistochemical analysis of ERf31 and ER|i2 protein expression in the
placentas of human, macaque and marmoset. Sections from human (a, b), macaque (c, d)
and marmoset (e, f) placenta were stained with the anti-hER|31 or anti-hERf52 specific
monoclonal antibodies. Positive staining for ER(31 protein was observed in the nuclei of
syncytiotrophoblast (S) cells and in endothelial cells (a, c, e). However when the same
placental tissues were stained for the ERp2 protein none were immunopositive (b, d, f).
Magnification is x40.
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3.3.2.4 Immunohistochemical Analysis of the Testes
Immunohistochemical evaluation of human, macaque and marmoset testes (Figure
3.6) detected intense immunopositive staining for ERpi protein in germ cells
including pachytene spermatocytes and round spermatids (Figure 3.6a, c, e) with
less intense reaction in Sertoli cells and spermatogonia. In the human testis ER(32
protein immuno-stained most intensely in the Sertoli cells and in B type
spermatogonia; type A spermatogonia, preleptotene spermatocytes were also
immunopositive for ER|32 protein (Figure 3b). There was a low level of
immunopositive staining for ER(32 in human pachytene spermatocytes. Elongated
spermatids were immunonegative for both ER|31 and ER|32 proteins. Macaque and
marmoset testes did not stain immunopositive for ER|32 with the anti-human ER(32
antibody.
3.3.3. Immunocytochemcial Analysis of Cell Lines
Immunocytochemical evaluation of the Hek 293 and Hep G2 cell lines confirmed
RT-PCR results, with no detectable ER(31 or ER|32 protein within the cell nuclei of
either cell line (Figure 3.7a, b, c, d), although the antibody produced some overall
background staining. ER(31 and ER|32 proteins were expressed in some cell nuclei
following transient transfections with ER|3-containing constructs as positive controls
(Figure 3.7 e, f, g, h).













Figure 3.6. immunohistochemical analysis of ERpi and ERp2 expression in the testis of
human, macaque and marmoset. Sections from human (a, b), macaque (c, d) and marmoset
(e, f) were stained with the anti-hERpi or anti-hERp2 specific monoclonal antibodies.
Immunopositive ERpi staining was observed in the nuclei of germ cells including pachytene
spermatocytes (P) and round spermatids (R) (a, c, e). However when the testis sections
were stained for ERp2 protein only the human testis was immunopositive (b) with staining
detected in the nuclei of Sertoli cells (Sc) and spermatogonia. Testes from macaque (d) and
marmoset (f) were immunonegative. Magnification is x40.
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Figure 3.7. Immunocytochemical analysis of ER(31 and ER(32 expression in Hek 293 and
Hep G2 cell lines. Hek 293 cells (a, c, e, g) and Hep G2 cells (b, d, f, h) were stained with the
anti-hER(11 (a, b, e, f) and anti-hER(32 (c, d, g, h) specific antibodies. The cells were
transiently transfected with human ER(31 (e, f) or human ER[32 (g, h) containing expression
vectors as positive controls. Untransfected cells showed no immunopositive staining for
either ER|31 or ER|32 proteins (a, b, c, d), however, following transient transfection some
cells showed positive nuclear staining for ER(31 protein (e, f) and ER(32 protein (g, h).
Magnification is x20.
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3.3.4 Sequence Analysis of the Human, Macaque and Marmoset ERf51 and
ER|32
Cloning and sequencing of full length cDNAs corresponding to macaque and
marmoset ER|31 (Figure 3.8) and ER|32 (Figure 3.9) was previously performed by
Joseph Gaughan and Graeme Scobie (Accession numbers; macaque ER|32:
AF393815 and marmoset ER(31: Y09372, ER|32: AF393816) Alignment of human,
marmoset and macaque peptide sequences corresponding to the predicted open
reading frames is shown in Figure 3.8 and Figure 3.9.
The ER(31 proteins showed significant sequence conservation between the three
species (490 amino acids), with macaque having 96.6% and marmoset with 93.6%
homology to the human. The full length sequences of ER(32 of human, macaque
and marmoset demonstrated differences in the C-terminal region. Marmoset ER|32
cDNA encoded a full length protein (486 amino acids) with 91.1% homology to
human ER(32. In contrast the macaque ER|32 cDNA encoded a truncated protein
due to the inclusion of a short region of intrinsic DNA containing a stop codon, thus
resulting in a protein of 320 amino acids.
Figure 3.8 and Figure 3.9 show a comparison of the peptide sequences of human, macaque
and marmoset ER|31 and ER|32. The underlined human peptides are the ones used to raise
the antibodies.
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Figure 3.8. Comparison of the peptide sequences of human, macaque and marmoset ER(31.
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Figure 3.9. Comparison of the peptide sequences of human, macaque and marmoset ERf>2.
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3.4 Discussion
Moore et al published results in which they investigated the amounts of ERa, full
length ER|3 (ER(31) and ER(3 variant mRNAs in a wide range of human tissues.
Although results were semi-quantitative, they suggested that the amounts of ER|31
and ER|32 cDNAs present in different human tissues and cell lines varied, with
mRNAs most abundant in the ovary and testis (Moore et al., 1998). Other studies
have detected both ERJ31 and ER|32 mRNAs in samples extracted from human
testis, granulosa cells, endometrium, placenta and cells lines (Ogawa et al., 1998c;
Saunders et al., 2002a; Scobie et al., 2002). In the present study I found that the
levels of ERpi and ER|32 mRNAs in different tissues from human, macaque and
marmoset and in the cell lines were variable.
Information regarding the presence of mRNA for ERa, ER(31 wild type or ERp2
variant isoforms from RT-PCR is useful. However because a total tissue
homogenate extract is used cell specific expression of the receptors cannot be
evaluated, therefore immunohistochemical analysis was carried out to identify the
precise cells expressing the ER[31 and ER|32 proteins. It must also be taken into
account that even if there is a message for an ER it does not necessarily indicate
that the protein will be expressed.
In this and other studies from our laboratory, the use of fixed, paraffin-embedded
tissue combined with mild antigen retrieval resulted in the maintenance of tissue
structure and consistent staining results with the antibodies independently
generated against specific peptides within ERp (Atanassova et al., 2000; Critchley
et al., 2002; Saunders et al., 2000; Saunders et al., 2001). In all cases
immunopositive staining was specific to the nuclei of cells and detected in multiple
cell types within the ovary, uterus, placenta and testis, consistent with previous
studies (Fisher et al., 1997; Saunders et al., 1998; Saunders et al., 2000).
Using RT-PCR, ER(31 and ER|32 mRNAs were detected in Ishikawa, LnCap and
Hela cells, but were absent from Hek 293, Hep G2 and Cos 7 cells. Ishikawa cells
are transformed human endometrium cells, therefore the detection of ER(31 and
ER|32 mRNAs is consistent with the ERpi and ER|32 immunopositive staining in
human endometrium tissues. Hela cells are derived from cervical cancer cells,
LnCap cells are derived from human prostate; both cell lines were found to contain
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ER|31 and ERp2 mRNA. ERp mRNAs were not detected in Hek 293 (human
kidney), Hep G2 (human liver) or Cos 7 (African Green Monkey Kidney cells). The
absence of ERp from the Cos 7 cells maybe due to species specific primers used to
amplify the cDNA pools, or it may correspond to human and marmoset kidney cDNA
pools not containing mRNA for ER(31 or ER(32. Consistent with RT-PCR,
immunocytochemical analysis of the Hek 293 and Hep G2 cells did not detect ER(31
or ER|32 protein expression, however upon transfection with ERpi or ERp2
containing constructs some nuclei stained immunopositive.
ER|32 variant mRNA was detected in the testis, ovary and endometrium of human,
macaque and marmoset using RT-PCR, however the anti-human ER|32 antibody
used in these immunohistochemical studies did not detect ER(32 protein expression
in the macaque or marmoset. Sequence comparisons between the ER proteins
encoded by the human, macaque and marmoset cDNAs revealed that the peptide
sequence (P8) in the C-terminus used to raise the monoclonal antibody was not
present in the primate ER|32 sequences and this is consistent with the failure of the
anti-human ER(32 antibody to detect primate ERp2 proteins.
Previous studies using a polyclonal anti-ERp antibody detected ERp immunopositive
cells in all three species (data not shown and Saunders et al., 2000; Saunders et a/.,
2001). This antibody was raised against a conserved peptide between the species,
within the hinge domain of ERp (P4) (Figure 3.1) and therefore can detect both
ERpi and ERp2 in the human, macaque and marmoset. Comparisons between the
pattern of expression of ERp determined using the polyclonal antibody and those
obtained using the anti-human ERpi monoclonal antibody provide some supporting
evidence that ERp variant proteins are expressed in primate tissues. For example,
examination of the pattern of ERp expression in marmoset and macaque testis
illustrated in Saunders et al., (2001), reveals that Sertoli cells are immunopositive. In
the present study and a previous one (Saunders et al., 2002a) ERpi
immunoreactivity in Sertoli cell nuclei has been shown to be faint. In human, ERp2
is strongly expressed in Sertoli cell nuclei and it is therefore possible that some
reactivity seen in the primate Sertoli cell stained with the anti-ERp hinge antibody
may be attributed to expression of macaque or marmoset ERp2 proteins in these
cells.
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In the ovary ER|31 protein expression was intense in the granulosa cells of all three
species, however ER|32 protein was not detected in the macaque or marmoset
although ER|32 mRNA was detected in ovary cDNA pools. ER|31 protein was also
detected in thecal cells, the corpus luteum and the surface epithelium of the ovaries
(data not shown). Previous studies using the anti-ER|3 hinge domain antibody have
detected ER|3 protein in the nuclei of granulosa cells in ovaries taken from human
and marmoset during the early, mid and late stages of follicular phase and in some
cells of the corpus luteum (Saunders et al., 2000; Saunders, 2002). In those studies,
immunopositive cells were detected in follicles both before and after formation of an
antrum, but absent from cells within an atretic follicle. Therefore my results and
those previously published (Saunders et al., 2000) and reviewed in Saunders
(2002), demonstrate that ERp protein is expressed in multiple cell types within the
human and primate ovary. However, the issue of whether ER|32 is present in germ
cells of primates cannot be resolved as ER|31 present, therefore polyclonal data
could be due to either ER|31 or ER|32 or both.
Investigators have generally reported that the amounts of ER|3 mRNA in the
endometrium are lower than those of ERa (Critchley et al., 2002; Matsuzaki et al.,
2000) and that ER(3 mRNA levels are lower in the secretory phase compared to the
proliferative phase. Quantitative Taqman PCRs have been performed to detect the
levels of ER|31 and ER|32 in the human endometrium (Critchley et al., 2002). The
levels of both mRNAs were found to be significantly increased in samples obtained
during the late secretory phase of the cycle compared to other stages. The overall
pattern of both ER|31 and ER|32 variant mRNAs paralleled each other with the
lowest levels detected during the proliferative/early secretory stages. In the results
shown here, mRNA for ER(31 and ER|32 was present in the endometrium from all
three species analysed.
Immunohistochemistry has previously demonstrated that ERa protein is expressed
in the glandular and stromal nuclei in the endometrium (reviewed in Saunders,
2002) and that there is a difference in ERa and ER|3 expression in the vascular
endothelium and the perivascular cells surrounding the endometrial blood vessels,
with only ER|3 being detected in the endothelial cell population, although both ERa
and ERp are present in perivascular cells (Critchley et al., 2001; Saunders, 2002).
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ERp protein expression within the vascular endothelium is reported to increase in
the mid-late secretory phase (days 24-26) (Lecce et al., 2001).
Immunohistochemistry to determine the spatial and temporal expression of ER|31
and ER|32 proteins in human uterine tissues has detected expression of both
isoforms within the cells lining the glands and in some stromal cells within the
functional and basal layers (Critchley et al., 2002). The functional layer had the most
intense staining for ER|31 in the glandular epithelium and this was especially marked
in the mid secretory phase, whereas the ER|32 protein was less intense in the mid
secretory phase. Levels of ERpi expression within the basal layer were generally
more intense than those of ERp2, especially within the glandular epithelium. Levels
of ERpi and ER(32 protein did not appear to vary across the cycle (Critchley et al.,
2002).
The results in the present study were in agreement with a previous study on human
endometrium (Critchley et al., 2002). The macaque and marmoset endometrial
tissues were also found to express the ERpi protein in the endometrial cells, in the
stromal cells and those lining the glands. As expected, ER(32 protein was not
detected in the primate endometrium using the antibody raised to human ER|32.
Therefore it can be concluded from previous studies and the work presented here
that both ER|31 and ER|32 mRNAs and proteins are expressed within the
endometrium but at lower levels than ERa. The levels of expression of ER|31 and
ER|32 throughout the cycle do not change as dynamically as does ERa protein
expression. The immuno-staining for ER(31 is more intense compared to ER(32, but
both receptors are present in cell nuclei in the functional and basal layers. However,
it must be taken into account that immunohistochemical analysis is not quantitative
and therefore differences in the intensity of ER|31 or ER|32 protein expression may
not be accurate. Therefore quantitative RT-PCR is required to deduce the changes
in ER|31 and ER|32 mRNA levels throughout the cycle, although to determine relative
levels in stroma and glands this would need to be performed after laser capture
microscopy (Gaskell et al., 2003).
It has previously been shown that ERa protein is expressed in human decidual cells
of the placenta from early pregnancy (Wu et al., 1993). However, in the third
trimester ERa protein was not detected in the decidual tissue (Noci et al., 1994;
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Saunders, 2002). ER(3 protein has been detected in the decidualised stromal cells
and the syncytiotrophoblast in the second and third trimester human placenta
(Henderson et al., 2003; Lecce et at., 2001; Saunders, 2002). The results shown
here demonstrate for the first time that ER(31 protein is also expressed in placental
tissue from macaque and marmoset. ER|31 protein is expressed within the nuclei of
perivascular cells surrounding the blood vessels and the syncytiotrophoblast in
human, macaque and marmoset placenta. ERp2 protein was not detected in
human, macaque or marmoset placental tissues. These results were consistent with
the failure to detect ER(32 mRNA following RT-PCR analysis of RNA from human
and marmoset placenta.
Results in this study and others (Makinen et al., 2001; Scobie et al., 2002) using RT-
PCR analysis have demonstrated that ERpi and ER|32 mRNAs are both expressed
within the testes of humans, as well as macaques and marmosets. However, upon
closer examination immunohistochemical evaluation in this and previous studies has
shown that the localisation of ER(31 and ER|32 is very different. ERpi protein is
expressed in the nuclei of pachytene spermatocytes and round spermatids, faint
levels of expression are detected in Sertoli cells, spermatogonia, preleptotene,
leptotene, zygotene and diplotene spermatocytes (Saunders et al., 2002a;
Saunders, 2003). Highest levels of ERp2 protein were found to be present in human
Sertoli cells and spermatogonia with low or variable expression in preleptotene,
pachytene and diplotene spermatocytes, and most interstitial cells expressed more
ER(32 than ER|31 (Saunders et al., 2002a). ER|32 protein was not detected in
macaque or marmoset testes, however, ER|32 mRNA was detected in the macaque
and marmoset tissue. Immunohistochemical analysis using the polyclonal antibody
raised against the conserved hinge region (P4) has demonstrated the presence of
immunopositive cells within the testis in the primates, which do not stain
immunopositive for ER|31 (data not shown and Saunders et al., 2001).
ERa protein and mRNA is reported to be absent from testis of humans and primates
(Makinen et al., 2001; Saunders et al., 2001), but levels of oestrogen are higher in
the male testis than in the rest of the circulation (Hess et al., 1997), therefore ERp is
presumed to function as the target oestrogen receptor. However, as ER|32 is
present but differentially expressed compared to ER|31, the ER|32 variant may have
a specific role within the testis which still needs to be elucidated.
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Co-localisation studies of both ER|31 and ERp2 on the same human sections would
be valuable, however this has not been possible as both antibodies were raised in
mouse and although they were different monoclonal IgG subtypes, secondary
antibody specificity was poor. Localisation of the macaque and marmoset ER|32 with
a specific ER|32 antibody raised to their respective ER(32 peptide sequences instead
of the human ER(32 would be extremely useful. It would then be possible to observe
the specific localisation of ER|32 rather than assuming it's localisation by comparing
staining using the anti-ER|3 hinge antibody, which detects both ER(31 and ER|32
variant proteins, with that seen with the anti-ER|31 specific monoclonal antibody.
Patterns of expression in different tissues reveal potential complexity in response of
individual cells to oestrogens. For example, in the human ovary ER(31 protein is
expressed in all granulosa cells and it is assumed that ER|32 protein may also be
expressed in all granulosa cells. In the endometrium, ERa protein levels alter
throughout the cycle, ER|31 is present in vascular endothelial cells, whereas ER|32
protein is not detected in endothelial cells. In the placenta, only ER(31 protein has
been detected. In the human and primate testes, ERa is not detected, however
germ cells stain immunopositive for ERpi protein, and Sertoli cells stain
immunopositive for ER|32 protein. Therefore the differential distribution of the
oestrogen receptors may have an affect on the pattern of gene expression induced
by oestrogenic ligands the target tissues are exposed to.
It has been shown ERa and ER|3 are able to form heterodimers (ERa/ER|31) upon
ligand binding as well as homodimers (ERa/ERa, ER(31/ER|31) (Cowley et al.,
1997). In addition Moore et al used in vitro gel shifts assays to show that ER|32 can
form heterodimers with ERa or ER|31 as well as homodimers (Moore et al., 1998). In
the following chapters experiments defined to evaluate the impact of steroid ligands
on subcellular localisation of ER|31 and ER|32 proteins and reporter gene activation
are described.
Chapter 4
Investigations on the Functional Competence of ERa, ER01
and ER^2 Using FP-tagged Proteins
4.1 Introduction
In Chapter 3 the expression of ER|31 wild type and ER|32 variant were investigated.
Evidence was obtained demonstrating the differential expression of ERpi and ER|32
mRNA and protein in human and primate tissues. In several target tissues such as
the brain, ovary and mammary gland previous published data has shown that ERa
and ER|3 are co-expressed (Saunders et al., 2000; Saunders et a/., 2002b; Wang et
al., 2003), however in other tissues such as the human and primate testes ERa is
absent and ER|31 and ER|32 are abundant (Saunders et al., 2002a; Scobie et al.,
2002). Previous published work has also demonstrated that ERa and ER|3 can
heterodimerise upon ligand binding (Cowley et al., 1997; Pettersson et al., 1997)
and that the heterodimers are able to bind to an ERE with an affinity similar to that
of the ERa homodimer and greater than that of the ER|3 homodimer (Pettersson et
al., 1997). Understanding the distribution of the ERs is important as it has been
demonstrated that ligands bind to the ER isoforms with differing affinities and are
able to influence gene transcription to different extents (Hall and Korach, 2002; Hall
eta!., 2002).
4.1.1 Subcellular Oestrogen Receptor Distribution
In cells ERs have been detected in the nucleus by immunocytochemistry (Chapter 3
and Htun et al., 1996; Stenoien et al., 2000) and hormone binding assays (Beato
and Sanchez-Pacheco, 1996). Receptor movement in the nucleus is reported to be
highly dynamic with the receptors undergoing constant exchange between genomic
regulatory elements, multiprotein complexes with other transcription factors and
subnuclear structures which have not yet been fully identified (Hager et al., 2000).
The oestrogen receptor has been demonstrated to move from a chaperone complex
(8s) to a dissociated form (4s) in a ligand dependent fashion, but it is constantly
present within the nucleus (Hager et al., 2000). Hormone binding leads to a
conformational change in the receptor that results in the dissociation of the receptor
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from the chaperone and ultimately in the binding of the receptor as a dimer to
cognate sites in steroid responsive genes (Beato and Sanchez-Pacheco, 1996;
Htun et al., 1999; Tsai and O'Malley, 1994).
In the absence of ligand, ERa tagged to a fluorescent protein (FP) is distributed in a
reticular (network) pattern evenly distributed throughout the nucleus, therefore
suggesting that the majority of the unligand bound receptor is not freely diffusing in
the nucleus but is associated with nuclear meshwork (Htun et al., 1999). Upon
addition of ligand there is a dramatic redistribution of the receptors to give a
punctate or focal pattern. These discrete focal clusters of hERa are associated with
the nuclear matrix and co-factors within the nucleus (Htun et al., 1999). The two
distinct nuclear localisation patterns provided the first visual evidence of the
changes in receptor activity by hormones and reflect the loose and tighter binding
nuclear forms (Greene and Press, 1986).
ERs control the expression of specific genes by binding to regulatory DNA
sequences (EREs) located at the promoter or enhancer regions of the genes,
however it has been shown that ERa foci are not mainly localised at the sites of
nascent mRNA transcription (Matsuda et al., 2002). This ligand-dependent
intranuclear reorganisation of the oestrogen receptor into accumulation centres
involves more complex events than simple recognition of specific chromosomal
DNA binding. Therefore a highly organised and dynamic subnuclear environment
provides the framework for receptor function (Stenoien et al., 2001 b).
Ligand binding, dimerisation, DNA binding, binding with co-factors and binding with
the nuclear matrix are all required for ERs to form discrete foci (Matsuda et al.,
2002). The C-terminal region of the ER (E/F domain) plays an important role in the
receptor function because this region is essential for ligand binding and ligand
dependent transcriptional activation through binding with co-activators and
dimerisation. In recent studies deletion of the N-terminal region encoding the AF-1
domain required for co-factor regulation prevented discrete clusters forming
(Matsuda et al., 2002). Co-expression of a mutated ERa-tagged to an FP with an
intact FP-ERa restored the capacity to form discrete clusters, therefore indicating
that one AF-1 region within the receptor dimer was sufficient for the cluster
formation (Matsuda et al., 2002). A single DNA binding (C) domain was also found
to be sufficient for cluster formation with ER dimers (Matsuda et al., 2002).
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However, truncated forms of the hERa that lack the E/F and therefore the AF-2
domain do not have the ability to form discrete clusters shown using different FP
constructs (Matsuda et al., 2002), therefore suggesting two functional AF-2 domains
within the ER dimer are required for transcriptional activity (Matsuda et al., 2002;
Tremblay et al., 1999a). Weatherman et al also demonstrated that ER dimer
interactions are wholly dependent upon AF-2 in hERa (Weatherman etal., 2002).
4.1.2 Ligands
This chapter examines the distribution of the ER isoforms tagged to a fluorescent
protein and the alteration of the FP-ER distribution upon exposure to selected
ligands. Previous studies have concentrated on FP-ERa and its redistribution with
17|3-oestradiol (E2) (Htun etal., 1996; Stenoien et al., 2001b), tamoxifen (Htun etal.,
1999) and the antagonist ICI 182,780 (Htun et al., 1996). Several studies have
demonstrated that ERa and ERpi exhibit different affinities for ligands such as
3|3Adiol and genistein, (Harris et al., 2002a; Weihua et al., 2002), as well as for
novel ligands which act selectively as agonists or antagonists for ERa and ERpi
(Sun et al., 1999). Therefore in this study different ligands (E2, 3|3Adiol, genistein,
DPN™ and PPT™) were analysed for their abilities to activate the ERs, assessed by
their ability to redistribute the fluorescently tagged receptor within an individual live
cell.
Oestradiol is the classical ligand for the oestrogen receptor and the two receptor
subtypes have a similar affinity for E2 despite sequence differences within their
LBDs (Kuiper et al., 1996; Ogawa et al., 1998b). The metabolite of 5a-
dihydrosterone (DHT); 5a-androstane-3p,17pAdiol (3pAdiol) has been shown to be
a potent hormone (Weihua et al., 2002). The oestrogenic activity of 3pAdiol has
been documented previously and it has been found to displace E2 (Hackenberg et
al., 1993; Ho and Ofner, 1986). It has previously been reported that ERpi's affinity
for 3pAdiol is greater than ERa's and compared to E2, it's affinity is 10-fold lower for
ERpi and 30-fold lower for ERa (Weihua et al., 2002).
It has been demonstrated that certain phytoestrogens, such as the isoflaviniod
genistein, have the ability to activate transcription of ERpi to a greater extent
(approximately 30-fold) than ERa (An et al., 2001; Barkhem et al., 1998; Harris et
al., 2002a; Kuiper et al., 1997). Genistein alters the helix 12 conformation in ERa in
Chapter 4 FP tagged ERs 120
an agonistic manner, however with ER|31 the alteration in helix 12 conformation is
not the same as when the receptor is bound to agonists, but instead is only partially
altered (Liu et al., 2003). Therefore, the difference in binding affinity of genistein for
ERpi does not relate directly to the transcriptional activation because genistein is
over 1000-fold more potent at triggering transcriptional activity with ERpi compared
with ERa (An et al., 2001).
Attention has recently been focused on developing novel ligands that are capable of
activating either receptor isoforms in a specific manner. Two such commercial
ligands have been used in this study; Propyl pyrazole triol (PPT™) and 2,3-bis(4-
hydroxyphenyl)propionitrile (DPN™). PPT™ is a potent agonist for human ERa but
is inactive on hER(31, becoming an hER|31 agonist only at very high concentrations
(Kraichely et al., 2000; Stauffer et at., 2000). Following binding it has the ability to
stabilise hERa to the same extent as E2.
Meyers et al has recently developed a non-steroidal ER(31 -selective ligand;
diarylpropionitrile (DPN™). DPN™ acts as an agonist on both the hERa and hER(31
subtypes, but has a 70-fold higher relative binding affinity and a 170-fold relative
potency in transcription assays with hER(31 than with hERa (Meyers et al., 2001).
This is a substantially higher level of hER|31 affinity and potency selectivity than that
of the partial ER|31 agonist genistein (Meyers etal., 2001).
4.1.3 The Effects of Co-transfections with ERa, ER(51 and ER02 Variant
As discussed in Chapter 3, the localisation of oestrogen receptors within tissues is
very diverse. In many tissues different ER isoforms are expressed in different cells,
however co-expression of the isoforms can occur within one cell. It has been
documented that ER isoforms not only form homodimers upon ligand binding, but
also form heterodimers for example ERa/ER(31 (Cowley et al., 1997; Ogawa et al.,
1998b; Pettersson et al., 1997). These studies have looked at the binding abilities of
the receptors and analysed the effect of heterodimerisation on transcriptional
activity, however there has only been one previous publication demonstrating
dimerisation between rat ERa and ERp in live cells using FP-tagged constructs
(Matsuda et al., 2002). Studies using FP-ER|32 have not been reported previously.
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4.1.4 Fluorescent Proteins
Since the development of vectors which allow preparation of proteins linked to
fluorescent proteins (FP), it is now possible to use real time monitoring to observe a
tagged protein's distribution within the live cell. The properties of FPs make them
useful as molecular reporters to monitor patterns of protein localisation, gene
expression and intracellular protein trafficking in living cells (Ogawa et a/., 1995),
therefore avoiding potential artefacts due to cell fixation and permablisation (Tavare
et al., 2001).
The green fluorescent protein (GFP) was discovered (Shimomura, 1962) as a
companion protein to aequorin, the chemiluminescent protein from Aequorea
jellyfish. GFPs are found in a variety of bioluminescent organisms ranging from the
jellyfish Aequorea Victoria to the sea anemone relative Discosoma (Tsien, 1998).
Wild type GFPs possess the property of accepting energy by radiation-free energy
transfer process from an excited state blue fluorescent protein during the aequorin
bioluminescence reaction, with a maximum peak of absorbance at 395 nm and a
minor peak at 470 nm. Several chromophore variants have been placed into
plasmid vectors by Clontech Laboratories including the green fluorescent protein
(EGFP) from the Aequorea victoria jellyfish and the red fluorescent protein (DsRed)
derived from the Discosoma sp. The availability of different coloured FPs allows two
or more proteins to be tagged with these distinct spectral variants, thus enabling
them to be localised in cells simultaneously.
The fluorescent tag can be positioned at the N- or the C-terminus of the test protein.
Hager et al placed a GFP tag at the amino terminus of human ERa and observed
that the receptor was expressed as a stable protein and that it retained
transactivational properties similar to those of the untagged receptor (Hager et al.,
2000). This was supported by Price et al who found that the GFP tag positioned at
the N-terminus of the ER, does not alter the binding characteristics of ERa or ER|31,
nor the localisation of the receptors (Price et al., 2001).
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4.1.5 Aims
The aim of the experiments described in this chapter was to assess the subcellular
distribution of oestrogen receptors (ERa, ER|31 and ERp2) using fluorescently
tagged constructs. The redistribution of the fluorescently tagged ERs in the
presence and absence of different ligands was studied to evaluate the activation
potential of the ligands. Two different fluorescent tags were used during the study to
be able to visualise the receptor isoforms co-transfected together and to assess
whether they could co-localise following addition of ligand with the formation of
heterodimers.
4.2 Methods
4.2.1 Generation of ERp Fluorescent Constructs
To be able to observe the behaviour of human ER(31 or ER|32 proteins expressed in
living cells, full length cDNAs were cloned into fluorescent protein vectors (EGFP
and DsRed) purchased from Clontech. These vectors were chosen so the human
ER cDNAs were inserted into the vector in frame with the 3' end of the EGFP or
DsRed. The resulting protein was therefore tagged with an N-terminal EGFP or
DsRed protein. The position of the tag was chosen to avoid disturbing the ligand
binding or AF-2 domains of the steroid receptors.
4.2.1.1 Preparation of the Fluorescent Plasmid Vectors
EGFP- and DsRed-containing plasmid vectors (Clontech) were transformed into XLI
Blue cells, plated out onto kanamycin-containing plates and propagated in LB with
kanamycin (section 2.8). A CsCI preparation was performed to ensure the vectors
were pure prior to cloning (section 2.9.2.3).
4.2.1.2 Preparation of the ER cDNAs and the Fiorescent Vectors
Human ER|31 and hER(32 were amplified up from pUni and pRSET vectors
(respectively) by PCR with AGS Gold Taq as discussed in section 2.5 and 2.7. The
PCR products were purified by elution through a High Pure Purification column
(section 2.7.2).
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4.2.1.3 Cloning of ER01 and ERf}2 into the Fluorescent Vectors
The hER(31 and hER[32 cDNAs and the fluorescent vectors were digested with
Hindlll and BamHI (section 2.8.2) and the cDNAs ligated into the vectors (section
2.8.3). Once the constructs had been generated the plasmids were screened by
restriction digestion and sequenced to ensure the cDNAs had been cloned correctly
(section 2.8.5). The plasmids containing the correct constructs were prepared by the
CsCI method prior to transient transfection studies being performed (section
2.9.2.3).
4.2.2 Human ERa -pDsRedNI
Human ERa cloned into the pDsRed-N1 vector was a gift from F. Schaufele
(Department of Medicine, University of California, San Francisco, USA.
(Weatherman et al., 2002)). The plasmid was propagated and purified using the
CsCI method (section 2.9.2.3).
4.2.3 Transient Transfections for Confocal Microscopy
Transfections were performed as described in section 2.10.2.5, Hek 293 or Hep G2
cells were plated onto 35mm glass bottom microwell dishes (Plastik® Corporation).
For each dish used, 2^g of DNA was transfected into the cells using JetPEI (section
2.10.2.2). In the co-transfection experiments a total of 2^g ER (1 pig of each ER) was
used. After 48 hours the media was removed and the cells washed in PBS at room
temperature. To maintain the cells during analysis, 1ml PBS with 25mM Hepes
buffer (Sigma) was added to the dish. The ligand used was diluted to 10"8M in
PBS/Hepes and added to the dish that was already in place on the warm plate
(37°C) on the confocal microscope (LSM510, Zeiss). Images were captured at 10
minute intervals for 1-3 hours and exported into Photoshop 7.0 (Adobe).
The confocal pictures obtained correspond to the FP colours and the yellow regions
represent co-localised ERs tagged with the green and red FPs in the co-transfection
studies. The intensity profiles were obtained using the confocal software; a line was
drawn through the length of a selected nuclear image and the profile generated.
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4.2.4 Transient Transfections for Western Analysis
Cells were plated out into 60mm dishes (Cellstar®) as described in section 2.10.2.6
and transfected with 6^ig of plasmid DNA. The cells were incubated for 48 hours
prior to being harvested using the crude whole cell protein extraction method
(section 2.10.2.6.1.3).
4.2.5 Western Analysis
The protein samples obtained from the ER|3-EGFP transient transfections were
separated on a Western gel as described in section 2.10.2.6.3. The anti-EGFP
mouse monoclonal antibody was purchased from Clontech (Catalogue Number;
8367-2), used at a 1:500 dilution and was incubated with the membrane overnight at
4°C. The secondary antibody used was a mouse anti- rabbit IgG (Diagnostics
Scotland) used at 1:5000, incubated with the membrane in TBST at room
temperature for 2 hours. The Western membrane was developed with ECL Plus
Detection Kit (Amersham Life Sciences) as described in section 2.10.2.6.3.4.
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4.3 Results
4.3.1. Western Showing ERp Protein Present
The Western blot (Figure 4.1) shows that the transiently transfected FP-tagged ERs
were present in the transfected cells, giving a band at approximately 86.2 kDa for
ERpi and at 82.5kDa for ER|32. Results are consistent with the expected sizes of
ERpi protein (59.2 kDa) and ERp2 (55.5 kDa) tagged with the EGFP (27 kDa). The
protein was detected within the "supernatent" (cytosol and nuclear protein) extract,
whereas the "pellet" (residual nuclear debris) did not contain any protein.
Figure 4.1. Western analysis of extracts prepared from cells transfected with EGFP-tagged
ERp. Samples run were (1) Blank, (2) ERpi-EGFP; pellet, (3) ERpi-EGFP; supernatant, (4)
ERP2-EGFP; pellet, (5) ERP2-EGFP; supernatant. The proteins were detected using an anti-
EGFP antibody (Clonetch). The molecular weight marker was run alongside the samples to
determine the band size.
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4.3.2 Treatment of Cells with E2
Following transient transfection ERa-DsRed was localised to the nucleus in both
Hek 293 and Hep G2 cells (Figures 4.2a & 4.3a). In the absence of E2 the protein
was diffusely distributed with a slight speckled "focal" arrangement (Figures 4.2a &
Figure 4.3a t = 0). Addition of the ligand resulted in relocation of the ERa-DsRed to
form bright regions (foci) representing a high intensity of the ERa, within 10 minutes.
The number and brightness of the foci increased and appeared to be maximal at 30
minutes, with a decrease in the diffusely distributed receptor. The effect of the ligand
lasted until 60 minutes, after which the foci started to disperse and the receptor
began to relocate into a diffuse pattern again. The intensity profiles (Figures 4.2b &
4.3b) illustrates the focal pattern of the receptor, showing the greatest intensity
peaks where foci are brightest (arrows). The peaks of the intensities and their
frequency as well as the speckled background varied between cells and between
the two cell lines. In Hep G2 cells the intensity profiles demonstrate peaks in
intensity to a greater extent and the foci were more discrete than in Hek 293 cells.
In the absence of E2 (t = 0), ER|31-EGFP transiently transfected into Hek 293 and
Hep G2 cells (Figures 4.4a & 4.5a) showed a diffuse pattern. Typically a couple of
discrete foci were observed in both cell lines, which developed into brighter foci
upon addition of 10"8M E2. Redistribution of ERpi-EGFP into bright discrete foci was
observed after 20 minutes incubation with 10"8M E2. Thereafter the number of foci
increased and the diffuse ER(31-EGFP reduced. At 60 minutes the greatest number
and brightness of discrete foci was observed with the least diffuse ER|3-EGFP
present. From the intensity profiles it can be deduced that not all the cell nuclei have
the same intensity and there is a difference in the number and appearance of foci.
It was noted that ERa and ER(31 tagged to the FP had a different focal appearance.
ERa was observed to form regions of bright foci upon addition of ligand whereas
ER|31 formed more discrete foci in both of the cell lines used. Results are
summarised at the end of the results in Tables 4.1 & 4.2.
ER|32-EGFP transiently transfected into Hek 293 and Hep G2 cells (Figures 4.6a &
4.7a) adopted a diffuse pattern in absence of ligand (t = 0) and remained in a diffuse
distribution after incubation with E2 for one hour irrespective of the cell line used.
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Figure 4.2a. ERa-DsRed expression in Hek 293 cells with addition of 10"8M E2. ERa-DsRed
transiently transfected into Hek 293 cells, maintained in culture for 48 hours and analysed
under a confocal microscope. Cells were washed and treated with 10"SM E2. Confocal
images taken over 70 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.2b. ERcx-DsRed expression in Hek 293 cells with addition of 10'8M E2 for 60
minutes. Images are of three cell nuclei showing a graph of the intensity profile of the
fluorescent ER. The graph demonstrates the intensity of the fluorescence (y axis) along the
length of the line drawn through the nucleus, in the direction of the arrow (x axis). All graphs
shown have the same y axis values. Arrows indicate peaks in intensity.
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Figure 4.3a. ERa-DsRed expression in Hep G2 cells with addition of 10"8M E2. ERa-DsRed
transiently transfected into Hep G2 cells, maintained in culture for 48 hours and analysed
under a confocal microscope. Cells were washed and treated with 10"8M E2. Confocal
images taken over 60 minutes from time (t) 0, at 10 minute intervals.
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Figure 4.3b. ERa-DsRed expression in Hep G2 cells with addition of 10"8M E2 for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
Chapter 4 FP tagged ERs 131
t = 0 t = 10 t= 20
t = 30 t = 40 t= 50
t= 60
Figure 4.4a. ERpi-EGFP expression in Hek 293 cells with addition of 10"8M E2. ER|31-EGFP
transiently transfected into Hek 293 cells, maintained in culture for 48 hours and analysed
under a confocal microscope. Cells were washed and treated with 10"8M E2. Confocal
images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.4b. ERp1-EGFP expression in Hek 293 cells with addition of 10" M E2 for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.5a. ER(i1-EGFP expression in Hep G2 cells with addition of 10"8M E2. ER|31-EGFP
transiently transfected into Hep G2 cells, maintained in culture for 48 hours and analysed
under a confocal microscope. Cells were washed and treated with 10"8M E2. Confocal
images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.5b. ER|31-EGFP expression in Hep G2 cells with addition of 10" M E2 for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.6a. ER|32-EGFP expression in Hek 293 cells with addition of 10"8M E2. ERfS2-EGFP
transiently transfected into Hek 293 cells, maintained in culture for 48 hours and analysed
under a confocal microscope. Cells were washed and treated with 10"SM E2. Confocal
images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.6b. ER(32-EGFP expression in Hek 293 cells with addition of 10"8M E2 for 60
minutes. Images are of two cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.7a. ERP2-EGFP expression in Hep G2 cells with addition of 10"8M E2. ER|32-EGFP
transiently transfected into Hep G2 cells, maintained in culture for 48 hours and analysed
under a confocal microscope. Cells were washed and treated with 10"8M E2. Confocal
images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.7b. ER|32-EGFP expression in Hep G2 cells with addition of 10"8M E2 for 60
minutes. Images are of two cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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4.3.3 Treatment of Cells with 3pAdiol
In the absence of ligand ERa-DsRed adopted a diffuse distribution within the
nucleus in Hek 293 and Hep G2 cells (t = 0) (Figures 4.8a & 4.9a). Upon addition of
10"8M 3f5Adiol for 10 minutes, large foci were observed and these increased in
number and brightness with time. At 30 minutes these bright foci clustered together
in both cell lines, appearing as a large bright area which did not contain individual
foci, as well as individual bright foci present and a decrease in the diffusely
distributed ERa-DsRed (Table 4.1 & 4.2). The bright focal pattern was maintained in
both cell lines at 60 minutes. The intensity profiles (Figures 4.8b & 4.9b) show that
there are differences between individual cells and the redistribution pattern indicated
by the number and size of foci, with Hep G2 cells containing more discrete foci
compared to Hek 293 cells.
ERpi-EGFP was transiently transfected into Hek 293 and Hep G2 cells and treated
with 10"8M 3[3Adiol (Figures 4.10a & 4.11a). The ERpi-EGFP remained in a diffuse
pattern in the nucleus until after 40 minutes of incubation with 3(3Adiol, at which time
faint discrete foci appeared in Hek 293 cells. This redistribution was not observed in
Hep G2 cells until 60 minutes after addition of 3|3Adiol. Once ER|31-EGFP foci
appeared their brightness increased reaching a maximum at 90 minutes (Hep G2).
Analysis of the intensity profiles of different cells demonstrated that at 60 minutes
the number, intensity and size of the foci varied and not all of the cell nuclei that
contained ER|31-EGFP showed a redistribution of receptor following addition of
3pAdiol (Figures 4.10b & 4.5b). Results are summarised in Table 4.1 and Table 4.2.
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Figure 4.8a. ERa-DsRed expression in Hek 293 cells with addition of 10"8M 3pAdiol. ERa-
DsRed transiently transfected into Hek 293 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M 3|1Adiol.
Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.8b. ERa-DsRed expression in Hek 293 cells with addition of 10"8M 3f5Adiol for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.9a. ERa-DsRed expression in Hep G2 cells with addition of 10"8M 3|3Adiol. ER«-
DsRed transiently transfected into Hep G2 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M 3f5Adiol.
Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.9b. ERa-DsRed expression in Hep G2 cells with addition of 10"8M 3(1Adiol for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.10a. ERpi-EGFP expression in Hek 293 cells with addition of 10"8M 3(1Adiol. ERp1-
EGFP transiently transfected into Hek 293 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M 3(1Adiol.
Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.10b. ER|31-EGFP expression in Hek 293 cells with addition of 10"8M 3pAdiol for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.11a. ER(11-EGFP expression in Hep G2 cells with addition of 10"8M 3|1Adiol. ER(11-
EGFP transiently transfected into Hep G2 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M 3(3Adiol.
Confocal images taken over 90 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.11b. ERfi1-EGFP expression in Hep G2 cells with addition of 10"8M 3(1Adiol for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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4.3.4 Treatment of Cells with Genistein
ER a-DsRed transiently transfected into Hep G2 cells (Figure 4.12a) showed
redistribution upon addition of 10~8M genistein. Prior to the addition of ligand, ERa-
DsRed was in a diffuse pattern with slightly brighter/darker areas within the nucleus.
After 10 minutes with genistein, the receptor redistributed and brighter areas
appeared, however it was not possible to observe individual foci. After 40 minutes
there were definite bright areas and a reduction in the diffuse ERa-DsRed. The focal
areas were most defined between 40 to 90 minutes after addition of genistein (see
Table 4.2). After 110 minutes the foci migrated to the edge of the nucleus and the
nucleus appeared to reduce in size, possibly due to nutrient depletion. The intensity
profile (Figure 4.12b) indicates that the time lapse redistribution pattern at 60
minutes is typical for other cells and that individual foci are difficult to pick out.
ER(31-EGFP transiently transfected into Hep G2 cells (Figure 4.13a) redistributed
upon the addition of 10"8M genistein. With no ligand present, ERpi-EGFP was
uniformly distributed within the Hep G2 cell nucleus. After 20 minutes the ERpi-
EGFP redistributed into darker areas and faint discrete foci appeared. After 30
minutes the foci increased in number and intensity, reaching a maximum at 60
minutes. The intensity profiles (Figure 4.13b) demonstrate variations between cells
and their number of visible foci, ERa-DsRed redistributed into large bright foci
whereas ERpi-EGFP redistributed into more discrete foci. Results are summarised
in Table 4.2.
Chapter 4 FP tagged ERs 149
t = o t= 10 t = 20 t = 30
t = 40 t = 50 t = 60
t= 120 t = 130 t = 140 t = 150
t= 160 t= 170
Figure 4.12a. ERa-DsRed expression in Hep G2 cells with addition of 10'8M genistein. ER«-
DsRed transiently transfected into Hep G2 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M genistein.
Confocal images taken over 170 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.12b. ERa-DsRed expression in Hep G2 cells with addition of 10"8M genistein for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.13a. ERp1-EGFP expression in Hep G2 cells with addition of 10"8M genistein.
ER|31-EGFP transiently transfected into Hep G2 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M genistein.
Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.13b. ERpi-EGFP expression in Hep G2 cells with addition of 10"8M genistein for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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4.3.5 Treatment of Cells with PPT™
The commercial ERa agonist PPT™ activated transiently transfected ERa-DsRed in
Hep G2 cells (Figure 4.14a). In the absence of ligand the ERa-DsRed was diffusely
distributed with a few brighter areas. Upon addition of 10"8M PPT™ these brighter
areas increased in intensity and at 30 minutes large but discrete foci were observed,
with a decrease in the diffuse ERa-DsRed present in the nucleus. After 50 minutes
the maximum redistribution of ERa-DsRed was observed with the least amount of
diffuse ERa and maximal numbers of bright foci. The intensity profiles (Figure
4.14b) demonstrates the redistribution of the ERa into either bright areas or more
discrete foci. Results are summarised in Table 4.2.
ER|31-EGFP transiently transfected in Hep G2 cells (Figure 4.15a) did not
redistribute from a diffuse pattern on addition of 10"8M PPT™ after 60 minutes.
4.3.6 Treatment of Cells with DPN™
Addition of the commercial ER(31 agonist DPN™ altered the distribution of ERa-
DsRed transiently transfected into Hep G2 cells (Figure 4.16a). Prior to 10"8M
DPN™ being added to the cells, ERa-DsRed had a mainly diffuse pattern of
expression within the nucleus, with the exception of a few brighter areas present.
Once 10"8M DPN™ had been added to the cells more foci appeared, increasing in
number and intensity to reach a maximal difference between foci and diffuse ERa-
DsRed after 40 minutes (Table 4.2). At this time point the uniform ERa-DsRed
distribution was not observed, instead ERa-DsRed appeared as bright and dark
areas where very little diffuse ERa-DsRed was present. After 100 minutes there
were still very bright large foci present, but these started to re-locate to a more
uniform distribution. The redistribution of ERa upon addition of DPN™ varied
between cells as shown in the intensity profiles (Figure 4.16b), the individual foci
were either visible or appeared as a larger bright area.
ER|31-EGFP in Hep G2 cells (Figure 4.17a) redistributed upon addition of 10"8M
DPN™, however the formation of discrete foci did not occur until after 50 minutes of
incubation. The number of foci increased in number and brightness with time,
reaching a maximum at 70 minutes, after which they remained the same. The
intensity profiles (Figure 4.17b) showed the ER|31-EGFP redistributed to different
extents in different cells and very discrete foci were observable unlike with ERa.
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Figure 4.14a. ERa-DsRed expression in Hep G2 cells with addition of 10"8M PPT™. The
ERci-DsRed construct transiently transfected into Hep G2 cells, maintained in culture for 48
hours and analysed under a confocal microscope. Cells were washed and treated with 10"8M
PPT™. Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute
intervals.
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Figure 4.14b. ERa-DsRed expression in Hep G2 cells with addition of 10~°M PPT™ for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.15a. ER|31-EGFP expression in Hep G2 cells with addition of 10~8M PPT™. The
ER(31-EGFP construct transiently transfected into Hep G2 cells, maintained in culture for 48
hours and analysed under a confocal microscope. Cells were washed and treated with 10"8M
PPT™. Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute
intervals.
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Figure 4.15b. ERp1-EGFP expression in Hep G2 cells with addition of 10"8M PPT™ for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.16a. ERa-DsRed expression in Hep G2 cells with addition of 10"8M DPN™. The
ERa-DsRed transiently transfected into Hep G2 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M DPN™
Confocal images taken over 130 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.16b. ERa-DsRed expression in Hep G2 cells with addition of 1CT°M DPN™ for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
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Figure 4.17a. ER(31-EGFP expression in Hep G2 cells with addition of 10"8M DPN™. The
ERp1-EGFP transiently transfected into Hep G2 cells, maintained in culture for 48 hours and
analysed under a confocal microscope. Cells were washed and treated with 10"8M DPN™.
Confocal images taken over 90 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.17b. ERpl-EGFP expression in Hep G2 cells with addition of 10"8M DPN™ for 60
minutes. Images are of three cell nuclei showing a graph of the intensity of the fluorescence
along the red line drawn through the nucleus.
Chapter 4 FP tagged ERs 162
4.3.7 Summary of ER distribution with Different Ligands
In the absence of ligand, ERa, ER(31 and ER(32 tagged to an FP were distributed in
a uniform diffuse pattern within the nucleus. Upon addition of ligand ERa and ER(31
redistributed to form bright foci, either as discrete foci or larger bright regions. ER|32
failed to redistribute with E2 due to its lack of an AF-2 region and therefore inability
to bind ligands. The redistribution of the ERa-DsRed or ER|31-EGFP upon addition
of different ligands in Hek 293 and Hep G2 cells varied and is summarised in the
tables below.




Punctate? Time Max. difference
hERpl-EGFP
Punctate? Time Max. difference
e2 Yes 10 40 Yes 10 60
3|3Adiol Yes 10 50 Yes 40 50
Time given in minutes.






Punctate? Time Max. difference
e2 Yes 10 30 Yes 10 60
3|3Adiol Yes 10 30 Yes 40 80
Genistein Yes 20 80 Yes 20 60
PPT™ Yes 10 50 No
DPN™ Yes 20 50 Yes 50 70
Time given in minutes.
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4.3.8 Co-transfections of ERa, ERpi and ERp2
4.3.8.1 Co-transfection of ERa and ERfi1
ERa-DsRed and ERpi-EGFP were co-transfected into Hek 293 (Figure 4.18a) and
Hep G2 (Figure 4.19a) cells. In some cells both ERa and ERpi were present in the
same nuclei, however in other cells only one of the ERs was present (data not
shown). ERa-DsRed and ERpi-EGFP are represented by the colours of their FP
tags, overlapping of the red and green FPs resulted in a yellow colour thus
representing regions of co-expression of the two ER subtypes. In cells that had both
ERs expressed the distribution of each receptor was altered by addition of ligand;
ERa-DsRed redistributed into bright and darker regions with 10"8M E2 and ERpi-
EGFP formed more discrete foci however redistribution was not to the same extent
as ERa. The intensity profiles (Figures 4.18b & 4.19b) show that ERa-DsRed and
ERpi-EGFP did possibly heterodimerise, shown in yellow and formed foci together
(arrows) however not on every occasion (Figure 4.18b). Formation of foci was more
obvious in Hep G2 cells compared with Hek 293 cells. On some occasions it was
easier to determine ERa-DsRed and ERpi-EGFP co-localisation from the nuclear
image rather than the intensity profiles (Figure 4.19b).
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Figure 4.18a. ERa-DsRed and ER|31-EGFP co-expression in Hek 293 cells with addition of
10"8M E2. ERa-DsRed and ER(31-EGFP transiently transfected into Hek 293 cells,
maintained in culture for 48 hours and analysed under a confocal microscope. Cells were
washed and treated with 10"8M E2. Each time point shows the red (ERa-DsRed) channel, the
green channel (ER|31-EGFP) and both channels together (yellow). Confocal images
taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.18b. ERa-DsRed and ERp1-EGFP co-expression in Hek 293 cells with
addition of 10"8M E2 for 60 minutes. Images are of three cell nuclei (red and green channels
together) showing a graph of the intensity of the fluorescence along the red line drawn
through the nucleus.
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Figure 4.19a. ERa-DsRed and ER|11-EGFP co-expression in Hep G2 cells with addition of
10"8M E2. ERa-DsRed and ERp1-EGFP transiently transfected into Hep G2 cells, maintained
in culture for 48 hours and analysed under a confocal microscope. Cells were washed and
treated with 1Cf8M E2. Each time point shows the red (ERa-DsRed) channel, the green
channel (ER|11-EGFP) and both channels together (yellow). Confocal images taken over 60
minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.19b. ERa-DsRed and ERpi-EGFP co-expression in Hep G2 cells with addition of
10"8M E2 for 60 minutes. Images are of three cell nuclei (red and green channels together)
showing a graph of the intensity of the fluorescence along the red line drawn through the
nucleus.
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4.3.8.2 Co-transfection of ERa and ERfi2
ERa-DsRed and ER(32-EGFP were co-transfected into Hek 293 (Figure 4.20a) and
Hep G2 (Figure 4.21a) cells. Both of these receptors were diffusely distributed within
the same nucleus of some cells, indicated in yellow, and their distribution altered
upon addition of 10"8M E2. In Hek 293 cells (Figure 4.20a) ERa-DsRed relocated to
form a focal distribution after 10 minutes with 10~8M E2, however ER(52-EGFP
remained in a diffuse distribution. The intensity profiles (Figure 4.20b) demonstrate
that ERp2-EGFP remained in a fairly uniform distribution with a couple of peaks in
fluorescence possibly indicating ER|32-EGFP formed heterodimers with ERa-
DsRed, appearing as yellow foci. In one of the intensity profiles there was a green
peak without a red peak, possibly indicating ER|32/ERp2 homodimers occurred,
although ERp2 lacks the functional AF-2 domain.
In Hep G2 cells (Figure 4.21a) the ERa-DsRed redistributed into foci after 10
minutes with 10"8M E2, ERp2-EGFP distribution also altered. ER|32-EGFP changed
from a diffuse distribution to darker and lighter green regions rather than specific
observable foci. The intensity profiles (Figure 4.21b) show in different cells the
redistribution of ERp2-EGFP differs and that it can form foci with ERa-DsRed
(shown in yellow) and therefore heterodimers may have formed. The intensity
profiles show clear peaks and troughs with ERa-DsRed and ER|32-EGFP, some of
which appear coincidental (arrows), although they did not appear as a very distinct
yellow (red/green) overlap when viewed under the confocal.
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Figure 4.20a. ERa-DsRed and ER(52-EGFP co-expression in Hek 293 cells with addition of
10"8M E2. ERa-DsRed and ER|32-EGFP transiently transfected into Hek 293 cells,
maintained in culture for 48 hours and analysed under a confocal microscope. Cells were
washed and treated with 10"8M E2. Each time point shows the red (ERa-DsRed) channel, the
green channel (ER|32-EGFP) and both channels together (yellow). Confocal images taken
over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.20b. ERa-DsRed and ERP2-EGFP co-expression in Hek 293 cells with addition of
10"8M E2 for 60 minutes. Images are of three cell nuclei (red and green channels together)
showing a graph of the intensity of the fluorescence along the red line drawn through the
nucleus.
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Figure 4.21a. ERa-DsRed and ER02-EGFP co-expression in Hep G2 cells with addition of
10"8M E2. ERa-DsRed and ER|32-EGFP transiently transfected into Hep G2 cells, maintained
in culture for 48 hours and analysed under a confocal microscope. Cells were washed and
treated with 10"8M E2. Each time point shows the red (ERa-DsRed) channel, the green
channel (ER|12-EGFP) and both channels together (yellow). Confocal images taken over 60
minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.21b. ERa-DsRed and ERf52-EGFP co-expression in Hep G2 cells with addition of
10"8M E2 for 60 minutes. Images are of three cell nuclei (red and green channels together)
showing a graph of the intensity of the fluorescence along the red line drawn through the
nucleus.
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4.3.8.3 Co-transfection ofERfil and ERfi2
ER|31-DsRed and ER(32-EGFP were co-transfected in Hek 293 (Figure 4.22a) and
Hep G2 (Figure 4.23a) cells. These two receptors were present in the same nuclei,
and responded to 10~8M E2. ER|31-DsRed redistributed to a focal pattern in both cell
lines, however ER|32-EGFP only redistributed to a noticeably focal pattern in the
Hep G2 cells (Figure 4.23a) forming foci in the same areas as the ER(31-DsRed foci.
The intensity profiles for the Hek 293 (Figure 4.22b) demonstrate that the two
receptors show a similar distribution with possible focal regions of both ERs together
(yellow areas). The peaks of intensity of ER(31-DsRed were consistent with the
peaks of ER|32-EGFP (arrows) although discrete foci were not visible. In Hep G2
cells (Figure 4.23b) the intensity profiles for ERpi-DsRed and ER|32-EGFP were
similar and it could be observed that ER|31-DsRed and ER(32-EGFP may have co-
localised in the same foci within the nucleus as shown in the intensity profile
(arrows).
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Figure 4.22a. ER|31-DsRed and ER|32-EGFP co-expression in Hek 293 cells with addition of
10"8M E2. ER(31-DsRed and ER|32-EGFP transiently transfected into Flek 293 cells,
maintained in culture for 48 hours and analysed under a confocal microscope. Cells were
washed and treated with 10"8M E2. Each time point shows the red (ER|11-DsRed) channel,
the green channel (ERp-EGFP) and both channels together (yellow). Confocal images taken
over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.22b. ER(31-DsRed and ERp2-EGFP co-expression in Hek 293 cells with addition of
10"8M E2 for 60 minutes. Images are of three cell nuclei (red and green channels together)
showing a graph of the intensity of the fluorescence along the red line drawn through the
nucleus.













Figure 4.23a. ERpi-DsRed and ERP2-EGFP co-expression in Hep G2 cells with addition of
10"8M E2. ERp1-DsRed and ERP2-EGFP transiently transfected into Hep G2 cells,
maintained in culture for 48 hours and analysed under a confocal microscope. Cells were
washed and treated with 10"8M E2. Each time point shows the red (ERpi-DsRed) channel,
the green channel (ERP2-EGFP) and both channels together (yellow). Confocal images
taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 4.23b. ER(31-DsRed and ER(32-EGFP co-expression in Hep G2 cells with addition of
10"8M E2 for 60 minutes. Images are of three cell nuclei (red and green channels together)
showing a graph of the intensity of the fluorescence along the red line drawn through the
nucleus.
Chapter 4 FP tagged ERs 178
4.4 Discussion
These results have demonstrated that human ERa and ERpi proteins tagged at
their N-terminal using a fluorescent protein have a diffuse distribution within the cell
nucleus and that upon addition of an oestrogenic ligand, the receptor redistributes
into bright foci. Similar findings have been reported previously by several
laboratories following studies using FP-hERa and E2 (Htun et al., 1999; Stenoien et
a!., 2000; Stenoien et al., 2001a; Weatherman et al., 2002). And a single report has
investigated the behaviour of FP-hER(31 (Matsuda et al., 2002).
Attempts at defining the two biologically distinct states of ER by immunocytology
have failed to reveal any differences in the localisation of the loosely and tightly
bound forms (Greene and Press, 1986; Yamashita, 1995). The advent of FP-tagged
receptors and high resolution microscopy has allowed FP-ER localisation and
redistribution to be examined in live cells. This is advantageous as it avoids the
artefacts caused by fixation methods or antibody labelling. For the first time it has
been possible to observe the differences in intranuclear distribution of the receptor
that reflected the type of ligand, agonist or antagonist, bound to the receptor. Htun
et ats work represented the first report of the importance of ligand in affecting the
distribution of a nuclear receptor within the nucleus (Htun et al., 1996).
The EGFP protein is 27 kDa and the DsRed protein is 28 kDa, it was originally
thought that these proteins may have interfered with the function and localisation of
the tagged ER, however this has not been reported. When an ER is tagged to an FP
the receptor remains functional within the nucleus and it is capable of transcriptional
activation of the ERE-reporter gene upon addition of E2 with similar activity to that of
the untagged ER (Htun et al., 1999; Stenoien et al., 2000; Weatherman et al., 2002).
During the course of the current investigations, fluorescently tagged ERa and ER|31
activated an ERE-Luc reporter when they were incubated with E2. The observed
dose response was comparable to the fold increases observed with the untagged
ER constructs (Chapter 5) (FP data not shown). Western analysis using proteins
extracted from cells transiently transfected with the FP tagged-ER constructs have
shown the ER proteins are expressed and that their apparent molecular weight is
consistent with the expected size of the full length ER plus the FP tag. Therefore it
can be assumed that the FP tag does not disrupt the expression of a functional ER
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within a cell, or the receptor's ability to activate gene expression via an oestrogen
response element.
In the current series of experiments differences in the subcellular localisation of
ERa, ER|31 and ER|32 in the different cell types were observed following exposure
to ligand. Furthermore, the pattern of intranuclear redistribution was influenced by
the ligand used. In the absence of ligand ERa and ERpi proteins tagged to the FP
were mostly distributed in a diffuse manner throughout the nucleus (but not
observable in the nucleolus of some cells). A few brighter "foci" were also observed
in the absence of ligand, this may have been due to active redistribution initiated by
endogenous ligand or co-activators. This was more apparent with ERa-DsRed than
with the ER|31-EGFP protein.
Htun et al were the first to report the redistribution of hERa-GFP in the presence of
E2, from a reticular (network) pattern evenly distributed throughout the nucleus, to a
focal or punctate pattern (Htun et al., 1999). In the current studies both FP-hERa
and FP-hER(31 altered their nuclear distribution following addition of ligand with
discrete foci appearing. ERa-DsRed redistributed with all of the ligands tested
including E2, 3|3Adiol and the synthetic PPT™. The commercial agonist DPN™ sold
as a more potent activator of ERp 1 than ERa also activated ERa-DsRed, as did
genistein which has also been shown to be a more potent activator of ER|31 than
ERa (An et al., 2001). ER(31-EGFP was activated to redistribute into punctate foci
by all the ligands except the ERa-specific ligand PPT™. The redistribution of ER|32-
EGFP was not altered by exposure to E2 and the FP tagged protein remained in a
diffuse distribution. Upon addition of ligand ER|31-EGFP formed more discrete foci
compared to the larger foci of ERa-DsRed. This was more apparent in the Hek 293
cells compared to the Hep G2 cells. This difference in focal pattern may be due to
the DsRed protein tag or the ERa construct, therefore more work is required using
the ERp 1 -DsRed construct to determine whether the observed effect is due to the
different tags or due to the different ER subtypes.
FP-ERa has been shown to activate a reporter gene in a dose dependent manner
(Htun et al., 1999). In those studies maximal activation of ERa-GFP by E2 was
observed using a concentration of 10nM (10"8M). Increasing the concentration of
ligand from 1nM to 100nM has been reported to decrease the time for an ER-GFP
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to redistribute into a speckled pattern (Price et al., 2001). In the experiments
presented here, 10"8M of each ligand was used as this was found to be the optimum
concentration required to stimulate ERa and ER(31 induced reporter gene activation
using an ERE-Luc reporter (Chapter 5).
It has previously been demonstrated that the ER associates with the nuclear matrix
(Htun et al., 1999). However, Stenoien et al demonstrated using fluorescent
recovery after photobleaching (FRAP) that nuclear receptors, whether bound to
chromatin or any other type of nuclear structure, are much more dynamic than
previously thought (Stenoien et al., 2001b). The rapid exchange rates observed with
these receptor proteins has led to conflicting interpretations of the mechanism of
intranuclear mobility. Agonist bound ERs form nuclear matrix bound intranuclear
foci, the individual receptors within these foci are able to undergo rapid exchange as
observed using FRAP. However, another report suggested that a reduced mobility
of the nuclear proteins upon ligand binding and redistribution is thought to be due to
interactions with immobilised components of the nuclear architecture (McKenna et
al., 1998). The size of the receptor complexes does not significantly change when
ligand is added, therefore indicating the observed reduction in mobility is not due to
the increased molecular interactions that reduce brownian motion, but rather the
reduction in mobility is probably due to interaction with a nuclear substrate. Stenoien
et al have demonstrated that ERa-GFP can exhibit different rates of mobility upon
addition of different agonists or antagonists due to conformational alterations. For
example the antioestrogen ICI 182,780 renders ERa-GFP immobile, even if the cell
has been treated with E2 (Stenoien et al., 2001a).
However it has been demonstrated, using Br-UTP and/or antibodies to RNA
polymerase II, that that there is less co-localisation between RNA synthesis foci and
transcription factors than previously expected (Stenoien et al., 2000). High
resolution microscopic analysis has revealed that most FP-hERa foci do not overlap
with transcription sites (Stenoien et al., 2000). These data suggest that complexes
containing transcription factors are in a dynamic state of assembly/disassembly and
that the time spent actively transcribing genes may be minimal.
Several laboratories have already demonstrated that FP-ERa develops a focal
distribution upon addition of E2 (Htun et al., 1999; Stenoien et al., 2000; Stenoien et
al., 2001a; Weatherman et al., 2002). By following individual cells after addition of
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ligand they demonstrated that re-organisation occurs on a rapid timescale of 10 to
20 minutes. In the current studies the time it took for the ERa-DsRed to redistribute
into a focal pattern following addition 10"8M E2 was also 10 minutes, however the
time scale differed using other ligands. In general ERa-DsRed was activated in the
presence of ligand and redistributed to a focal pattern in a shorter time period than
ER|31-EGFP in both cell lines. With 10*8M 3|3Adiol and the commercial ERpi-specific
agonist DPN™, ERpi-EGFP took at least 40 minutes to redistribute. However this
was only demonstrated over a 60 minute time period with one cell and as observed
with the intensity profiles there are differences between cells. The oestrogen
receptors ability to redistribute varied within the same experiment between different
cells and different cell lines.
Co-transfection studies were performed as it has been proposed that hERa and
hERp can form heterodimers upon ligand binding (Cowley et al., 1997) and this has
also been demonstrated using in vitro gel shift assays (Moore et al., 1998). To date
only one co-localisation study has been published using FP-tagged human ERa and
ERpi (Matsuda et al., 2002). In the current studies human ERa-DsRed and ERpi-
EGFP did appear to co-localise in the same bright foci in both Hek 293 and Hep G2
cells, consistent with the recent publication using rat ERa and ERp (Matsuda et al.,
2002).
ERa-DsRed and ERP2-EGFP co-transfected in Hek 293 cells did not appear to co-
localise in foci in the presence of E2 although they were present in the same
nucleus, however, intensity profiles showed peaks consistent with both ERs. In Hep
G2 cells the intensity profiles suggest that ERa-DsRed and ERp2-EGFP foci were
co-localised and therefore suggest the receptors may have formed heterodimers. As
discrete foci containing ERP2-EGFP were visible only when ERa-DsRed was
present it could be postulated that upon heterodimerising with ligand-activated ERa,
ERp2 is "pulled" into the foci together with ERa. This is marked contrast to the
behaviour of single transfection studies where ERp2-EGFP remained in a diffuse
distribution within the nucleus even after exposure to E2.
When ERpi-DsRed and ERp2-EGFP were co-transfected the ERs formed a focal,
yellow pattern which was more marked in Hep G2 cells compared with Hek 293
cells. The intensity profiles of the ERpi-DsRed and ERp2-EGFP suggest that
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heterodimers were formed in both cell lines, although more experiments are
required to confirm this.
Therefore, for the first time, it has been demonstrated in live cells that the truncated
ER|32 variant protein may form heterodimers with either ERa or ER(31 in the
presence of E2 (ERa/ER(32, or ER(31/ER(32), although this does not exclude the
possibility that homodimers also form in the same nucleus.
In agreement with these results, Matsuda et al showed that rat FP-ERa and FP-
ER(31 co-localised in clusters within the nucleus in the presence and absence of
ligand (Matsuda et al., 2002). This co-localisation of FP-ERa and FP-ER(31
suggests that FP-ERa/FP-ER(31 heterodimers were formed rather than homodimers
of each subtype. This is in agreement with biochemical studies which have shown
that heterodimers are preferentially formed over each type of homodimer (Pace et
al., 1997; Pettersson et al., 1997).
One problem encountered in the present study was the level of transfection
efficiency. On average 30% of the cells transfected showed FP-ER clearly visible in
the nucleus, some variation in the fluorescent intensity of individual nuclei was also
observed. This is in agreement with findings of Htun et al who reported a difference
in the level of ERa-GFP expression and the overall brightness in different cells and
attributed it to cell-to-cell variation (Htun et al., 1999). Therefore in my studies a
number of cells were analysed in the same dish, as well as on different occasions
so that a more definite conclusion could be made.
These variations between the fluorescence observed in individual cells were
exaggerated in co-transfection studies as many cells contained just one of the
receptors and those that did contain both sometimes had different levels of
fluorescence even though the same amount of plasmid DNA was added to the cell
monolayer. These differences may be due to a number of factors including
transfection efficiency of the individual cells, the phase of the cell's cycle, physical
characteristics, local external environment, co-activators and other regulators
present in the cell. The stochastic nature of some of the biological regulatory
processes may also contribute to unique nuclear appearance (Htun et al., 1999).
For example, Htun et al examined the distribution of ERa-GFP in various breast
cancer cell lines and noticed that there was a small but significant difference in the
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intranuclear distribution of the receptor in the different cells even in the absence of
ligand (Htun et al., 1999). In MCF-7 cells (ERa-positive), ERa-GFP was localised in
a reticular pattern evenly distributed throughout the nucleus, excluding the nucleous.
However, in the ERa-positive T47D cells the ERa-GFP had a composite pattern due
to the accumulation of the receptor in a reticular pattern and to a low level of
concentration at numerous nuclear sites present throughout the nucleus. In the
ERa-negative cell lines, MDA-MB-231 and MDA-MB-435A, ERa-GFP was slightly
patchy in appearance therefore indicating that the receptor was unevenly
distributed. In these cell lines the extent of redistribution of ERa-GFP to form a focal
pattern in the presence of ligand was found to also vary (Htun et at., 1999).
Differences in endogenous expression levels may explain the lack of oestrogen
dependent changes in nuclear matrix association reported by Htun et at.
In this study, in the absence of ligand the transfected FP-ERs were in a mainly
diffuse distribution which appeared similar in both the Hek 293 and the Hep G2
cells. This similarity may be due to both cell lines having no detectable ERa or ER|3
mRNA or protein prior to transfection (Chapter 3). However in the presence of ligand
the receptor redistribution observed varied between the cell lines, this was more
notable in the co-transfection studies. This data and previously published data
therefore demonstrates differences in the FP-ER distribution that occur in different
cell lines in the presence and absence of ligand.
Stenoien et aI reported that it is necessary to avoid over expression in transiently
transfected cells as this leads to incorrect, un-reproducible results (Stenoien et at.,
2000). However, in the current studies the concentration of ER tagged to the FP
constructs transiently transfected into the cells was comparable to the concentration
Stenoien et al have used (Stenoien et at., 2000).
In this study, the Hep G2 cells transfected with ERa-DsRed incubated with 10"8M
genistein in PBS/Hepes showed a reduced nuclear size and migration of the foci to
the nuclear membrane after 130 minutes. Stenoien et al demonstrated that the
depletion of ATP levels has no effect on the intranuclear mobility of the proteins
associated with the splicing speckles and nuclei components (Stenoien et al.,
2001a). Therefore in these current studies the change in ER distribution observed
after extended incubation in PBS may not be due to ATP depletion but due to
depletion of other nutrient factors.
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In conclusion, from these studies with FP-tagged ERs it was observed that the
addition of ligand induced a redistribution of ERa and ER(31 from a diffuse to a focal
pattern and that this occured rapidly (10 minutes in the presence of 10"8M E2). In
single transfections, ERa and ERpi formed foci in the presence of oestrogenic
ligand but the truncated ER|32 which lacks a functional AF-2 domain did not.
Co-transfection of ERa and ER(31 demonstrated that these ERs can form foci
together consistent with previous reports that they heterodimerise as well as
homodimerise. ER(32 has also been shown to form a focal pattern when it is co-
expressed with ERa or ER|31, suggesting that after formation of heterodimers the
ERa or ER|31 has the ability to "pull" the ER|32 into the foci. The idea that ER(32
might act as a regulator of ERa and ER(31 is therefore supported by these findings.
These investigations were extended to include functional studies to determine the
impact of different ligands on the ability of these receptors to activate ERE-reporters
and to determine whether the formation of ERa, ER(31 and ER|32 heterodimers
affected the ability of the ERs to activate gene transcription.
Chapter 5
Analysis of the Functional Competence of ER using ERE
Reporter Constructs in Cell Transfection Assays
5.1 Introduction
Oestrogens exert profound effects on the physiology of diverse target cells and
these effects appear to be mediated by two oestrogen receptors; ERa and ER|31
(wild type). As observed in Chapter 4, different ligands have the potential to bind to
and activate ERa and ER|31, causing the receptors to redistribute within the nucleus
to form a focal or highly concentrated distribution. Functional transient transfections
have been performed to ascertain whether this observed redistribution is consistent
with an increase in gene transcription.
The pharmacology behind oestrogen action is tripartite (Kraichely et a!., 2000).
Transcriptional activities of ERa and ER(31 are influenced not only by ligands, but
also by the coregulator proteins with which they associate and the EREs to which
they bind to in order to initiate gene transcription.
Figure 5.1. The tripartite nature of nuclear hormone receptor actions involving ligand,
receptor and effector interactions. Adapted from Katzenellenbogen et at., (2000).
Interactions
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In this chapter different oestrogen response elements, ligands and co-activators and
the effect of co-transfection of ERa and the ERp variants is examined.
5.1.1 Oestrogen Receptor Interaction with Different Oestrogen Responsive
Elements
Stimulation of target gene expression in response to E2 or other agonists, can be
mediated through a "classical pathway" in which the ER binds to a specific
oestrogen response element (ERE) on the DNA. This ER-ERE complex then
interacts with co-activators and components of RNA polymerase II transcription
initiation complex resulting in enhanced transcription (Klinge, 2001). Alternative
transcriptional activation pathways, such as the AP-1 mechanism discussed in brief
in the literature review, also exist.
It has been documented that differences in ERE sequence impact on ER binding
affinity and transcriptional activation (Klinge, 2001). The minimal consensus ERE
sequence, present in the Xenopus laevis vitellogenin A2 gene (referred to here as
Vit ERE), is a 13 bp palindromic inverted repeat; 5'-GGTCAnnnTGACC-3' where "n"
is any nucleotide (Wood et a!., 2001). It has previously been demonstrated that if the
ERE sequence deviates from the consensus sequence by even a single base pair,
the receptor exhibits a reduced affinity for the ERE and a decreased transcriptional
activity (Wood etal., 2001 and reviewed in the literature review).
Previous studies have shown that ERa and ER|31 bind to the consensus vitellogenin
A2 ERE GGTCAnnnTGACC (Klein-Hitpass et al., 1988) and activate transcription.
Human ER(3 has a lower affinity for the A2 ERE and a decreased ability to activate
transcription of promoters containing the A2 ERE compared with the ERa (Cowley
et al., 1997; Kuiper et al., 1996; Mclnerney et al., 1998b). Although the vitellogenin
A2 gene has been extensively used to study oestrogen-regulated gene expression it
is important to remember that most endogenous genes contain EREs that differ
from the A2 ERE by one or more base pairs and that these differences in nucleotide
sequence most likely influences the ability of individual EREs to mediate
transcriptional activation. Previous studies have suggested that the ability of
individual EREs to modulate receptor conformation may partially account for the
differences in transactivation observed with the imperfect EREs (Loven et al., 2001).
Chapter 5 Functional Studies 187
In this study reporter constructs containing either the single oxytocin (OT) ERE, the
single perfect vitellogenin A2 (Vit) ERE or a three ERE repeat; Vit ERE (3x ERE)
were used to assess the different transcriptional activities of ERa and ERp in
response to E2.
5.1.2 Different Ligands which Activate ERa and ER01
It has been shown in Chapter 4 that FP tagged ERa and ERp 1 proteins respond to
addition of different ligands in transiently transfected cells by redistributing into a
focal nuclear pattern. To follow on from these observations, functional studies were
performed to assess whether these changes in ER distribution upon addition of
ligand initiated gene transcription via an ERE reporter.
Previous studies have analysed the binding abilities and the transcriptional
activation of the ERs with different ligands (Barkhem et al., 1998; Kuiper et al.,
1996). As the sequence of the LBD of the ER isofoms is not identical and different
conformational changes are initiated upon ligand binding, the activation of gene
transcription is proposed to vary.
Some of the ligands used in this chapter have been shown to bind to the LBD of
ERa and ER(31 and cause initiation of gene transcription to different extents
(Barkhem et al., 1998; Kuiper et al., 1998). E2 binds to both ERa and ERpi whereas
3pAdiol, a metabolite of DHT, is proposed to work as an antagonist for ERa but an
agonist for ERp 1 (Weihua et al., 2003). Genistein is a phytoestrogen which is
reported to activate ERpi to a greater extent than ERa (Liu et al., 2003; Pettersson
and Gustafsson, 2001; Pike et al., 1999). The novel ligand PPT™ is ERa-specific,
whereas DPN™ is proposed to be an ERpi -specific ligand (Kraichely et al., 2000;
Meyers et al., 2001).
Dose response studies were performed to assess the concentration required to
stimulate ER activation and the concentrations which resulted in maximal
transcriptional activation. Human ERa, ER|31 and ER(32 as well as ERpi cloned
from macaque and marmoset were investigated to assess their ability to initiate
gene transcription with different ligands using a 3x ERE-Luc reporter. To my
knowledge there is no literature published on primate ERp responses to different
ligands.
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5.1.3 The Effects of Co-transfection with ERa, ER01 and ER02 Variant
Immunohistochemical analysis described in Chapter 3 has demonstrated that the
ERa and ER01 isoforms and the ER(32 splice variant can be expressed within the
same tissues. If the receptors are expressed together in the same nucleus they
have the ability to form heterodimers and under experimental conditions these
appear to form in preference to homodimers (Cowley et al., 1997). The behaviour of
combinations of FP tagged ERa and ER0 following co-transfections in the same cell
nucleus has been investigated in Chapter 4. It was observed that when ER02 was
co-transfected with ERa or ER01 it was able to redistribute into a focal pattern
together with either ERa or ER0 full length receptor. This observation is consistent
with reports that ER02 can heterodimerise with ERa or ER01 in gel shift assays
(Cowley eta!., 1997; Moore etai, 1998).
ER a and ER01 have been shown not to be functionally equivalent (Hall and
McDonnell, 1999; Pettersson et al., 1997). For example in many contexts ERa is
significantly more transcriptionally active than ER01 and it has been proposed that
ER01 could act as a modulator of ERa transcriptional activity (Cowley et al., 1997;
Hall and McDonnell, 1999; Weihua et al., 2000). Previously, co-transfection studies
have been carried out to analyse the effects of ER01 on the transcriptional activity of
ERa (Cowley et al., 1997; Ogawa et al., 1998a; Pettersson et al., 2000). However,
more recently, the identification of the ER02 variant lacking part of the LBD including
the AF-2 region (Moore et al., 1998; Ogawa et al., 1998c) has led to suggestions
that ER02 may act as a dominant negative regulator of ERa activity (Ogawa et al.,
1998c). Inoue ef al co-transfected an ER0 isoform lacking all of the LBD (A5) with
ERa or ER01 wild type and reported a slight dominant negative effect on ERa, but
an increase in ER01's activity (Inoue et al., 2000). As the ERp isoforms are co-
expressed in cells in many tissues, including the testis and endometrium (Chapter 3
and Saunders et al., 2000; Saunders et al., 2002a; Saunders, 2003) it is important
to investigate the functional competence of the ER0 isoforms. Therefore in this
chapter functional studies were performed to assess transcriptional activity of ERa,
ER01 and the ER(32 variant as well as the effect of co-expression of these receptors
in the same cells.
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5.1.4 Steroid Receptor Co-activators (SRC)
A number of previous studies have identified co-activator and co-repressor proteins
capable of interacting with nuclear receptors and influencing their transcriptional
activity (McKenna and O'Malley, 2002; Onate et a/., 1995). The steroid receptor co-
activator (SRC) was the first co-activator to be identified (Onate et al., 1995) and
has been found to influence ERa or ER(3 gene transcription (Gee et al., 1999; Wong
et al., 2001) and to be affected by different EREs (Hall et al., 2002).
Three members of the SRC gene family have been identified in human and rodents;
SRC-1, -2, and -3 (Xu and O'Malley, 2002). All three members of the SRC family are
able to interact with ERs in a ligand dependent manner and significantly enhance
ER transcriptional activity (Xu and O'Malley, 2002). The SRC-1 isoform acts to
initiate reporter gene transcription by binding to ERa and ER(31 following ligand
binding and dimerisation. In addition to ERs, SRC co-activators can also interact
with and activate other members of the steroid hormone receptor superfamily
including androgen and progesterone receptors (Lee et al., 1998; Leo and Chen,
2000). Human proteins encoded by the SRC gene family are approximately 160 kDa
in size and have an overall sequence similarity of 50 to 55% and sequence identity
of 43 to 48%. Their most conserved region is the N-terminal domain which is
involved in DNA binding and heterodimerisation between proteins containing similar
motifs.
Two functionally distinct SRC-1 isoforms have been identified, SRC-1 e and SRC-1 a,
which contain unique C-termini therefore suggesting that alternative splicing may
regulate SRC function (Kalkhoven et al., 1998). The two human SRC isoforms are
identical up to residue 1385 but differ at their C-termini. SRC-1 a (1441 amino acids;
156.7 kDa) contains 56 unique residues and lacks 14 of the most C terminal amino
acids present in SRC-1e (1399 amino acids; 152.3 kDa) (Kalkhoven et al., 1998).
Both isoforms contain three nuclear receptor binding motifs (LXXLL) and an
activation domain which co-localises with the CBP-binding domain, whilst SRC-1 a
contains a unique LXXLL motif in its C-terminus. The relative expression of the two
SRC isoforms has been studied by RNase protection assays (Kalkhoven et al.,
1998) and both were detected in all the cell lines tested, including the Hek 293 and
Hep G2 cells used in the current study.
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5.1.5 Aims
The aims of this chapter were to examine the functional differences between
different EREs and to examine the dose responses of ER proteins with different
ligands using transient transfections, in the presence of an ERE-reporter construct.
The effect of co-transfecting the different ER isoforms and the co-transfection of
SRC-1 with the ERs, to alter gene transcription was also assessed.
5.2 Methods
Transient transfections were carried out as in section 2.10 using the Hek 293 or the
Hep G2 cell lines.
5.2.1 Plasmids
All the plasmids used in transient transfection studies were purified using CsCI
preparations described in section 2.9.2.3.
5.2.1.1 Oestrogen Receptors in pcDNA3.1 Vector
Human, macaque and marmoset full length ERpi and ER(32 cDNAs and human
ERa cDNA were cloned into the pcDNA3.1 (Invitrogen) vector (section 2.7.3.5).
5.2.1.2 Oestrogen Receptor Reporter Constructs
The EREs used were tagged to the luciferase promoter construct so their response
to ER activation in transient transfections could be analysed using the Luciferase
assay (section 2.10.2.4). The sequences of the EREs are detailed in Table 5.1.






Vit ERE (PGL) AGGTCAcagTGACCt
The significant differences in sequence are underlined.
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The bovine oxytocin (OT) ERE, mutated to resemble rat ERE, was obtained from
Norbert Walther (Institute for Hormone and Fertility Research, University of
Hamburg, Germany. (Adan et al., 1991)). The OT (approximately 160 bp) was
already tagged to the luciferase promoter and had been cloned into pGL2 Basic
Vector (Promega) between Smal and Hindlll restriction sites (Figure 5.2).
Figure 5.2. Diagram with details of the pGL2-basic vector used for the OT ERE and Vit ERE.
The A2 vitellogenin ERE sequence was cloned into pGL2-Basic-Luciferase vector
(Promega) (Figure 5.2) and the pTAL-Luciferase vector (Promega) (Figure 5.3) to
form Vit ERE (pGL) and pTAL ERE respectively (Table 5.1). The work was
performed by Graeme Scobie (MRC Human Reproductive Sciences Unit).
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Figure 5.3. Diagram with details of the pTAL-basic vector used for the Vit ERE.
Hind III
MCS (192)
1 10 20 30 40
GGTACCGAGCTCTTACGCGTGCTAGCCCGGGCTCGAGATCT
Kpn I Sac I Mlu I Nhe I Xma I Xho I BglU
Sma I
The 3x ERE-TK-Luc reporter construct was a gift from S.C. Nagel and D.P.
McDonnell (Department of Pharmacology and Cancer Biology, Duke University
Medical Centre, North Carolina, USA. (Nagel et ai, 2001)). It contained three
tandem copies of the vitellogenin ERE that had been ligated into the TK-Luciferase
vector (Ligand Pharmaceuticals) using Bgl II and Hind III.
5.2.1.3 Steroid Receptor Co-activator-1 (SRC-1)
SRC-1e and SRC-1 a constructs were a kind gift from Professor M. Parker
(Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, London, UK.
(Kalkhoven et al., 1998)) and had been inserted into the pSG5 vector. The SRC-1
constructs were supplied on blotting paper so the spots were reconstituted in TE,
transformed in XLI Blue cells (Stratagene) and plated onto amplillicin-containing
agar plates (section 2.9.1). Prior to use in transient transfection studies the plasmids
were purified using the CsCI technique (section 2.9.2.3).
5.2.1.4 Renilla Internal Control
The pRL-CMV vector (Promega) contains the CMV enhancer and early promoter
elements which provide a high level expression of Renilla luciferase. When co-
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transfected with the ERE-luciferase constructs this provides an internal control for
the Luciferase assay. The pRL-CMV construct was transformed in XLI Blue cells
(Stratagene), plated out and propagated in LB (section 2.9.1). A CsCI preparation
(section 2.9.2.3) was performed so that the constructs were prepared for
transfection.
5.2.2 Luciferase Assay
The Dual-Luciferase® Reporter Assay (Promega) was used to measure the level of
transcriptional activity as described in section 2.10.2. The experimental ERE-Luc
reporter activity was corrected against the Renilla internal control. This
normalisation of the luciferase activity was essential as it minimises the
experimental variability caused by the differences between cell viability or
transfection efficiency. The results were expressed as a fold increase in activity over
the control, ie. the luciferase value given for constructs transfected into the cells in
the absence of ligand.
5.2.3 Transient Transfection Studies
The transfections were carried out as described in section 2.10.2. For every
experiment, each condition was performed in duplicate and the experiment
performed a minimum of three times in a 12 well plate.
JetPEI transfection reagent (Cambridge Biosciences) was used for transfecting the
cells (section 2.10.2.2) in all of the experiments except for the Hek 293 E2 dose
response and the Hek 293 co-transfection studies. In these experiments Gene
Porter (Gene Therapy Systems) was used (section 2.10.2.1).
5.2.3.1 Activation of ERE-Luciferase Reporters
For a comparison of different ERE-Luc reporters in Hek 293 and Hep G2 cells, 1 pig
of the ER, 0.1 pig pRL-CMV and 0.25|^g of the ERE-Luc was used in each well in a
12 well plate. To each either ethanol vehicle, 10"8M or 10"7M E2 was added 4 hours
after transfections (see Table 5.2).
For a comparison of different concentrations of the 3xERE, three conditions were
used. Either 0.125p,g, 0.25p,g or 0.5ng 3xERE were added to 0. Vg pRL-CMV only,
or to 1p,g ER and 0.V9 pRL-CMV in each well. Vehicle or 10"8M E2 was then added
to the transfected cells 4 hours later (see Table 5.2).
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Table 5.2. Details of the different EREs used and their concentrations.
ER ERE pRL-CMV E2 Cone.
Different EREs ipg 0.25pg 3xERE, OT ERE,
pTAL EREorVitERE
0.1 pg Vehicle, 10"8M & 10"7M
3xERE
Concentrations
ipg 0.125pg, 0.25pg & 0.5pg 0.1 pg Vehicle & 10"8M
5.2.3.2 Dose Response Studies
Using the Hek 293 and the Hep G2 cells, 1pg ER, 0.5pg 3x ERE and 0.2pg pRL-
CMV was used in each well of the 12 well plate. Different ligands were added to the
cells four hours after transfection. E2 and 3(3Adiol ligands were added to Hek 293
cells; E2, 3|3Adiol, genistein, ppt™ and dpn™ were added to Hep G2 cells, with
concentrations ranging from 10"14M to 2.5x10"5M.
5.2.3.3 Co-transfection Studies
Using Hek 293 and Hep G2 cells, 200ng of the first ER was added, with either
200ng (1:1 ratio), 600ng (1:3) or 1200ng (1:6) of the second ER, 0.25pg 3x ERE and
0.1 pg pRL-CMV. Four hours after transfection, different concentrations ranging from
10"13M to 10"7M, of E2 were added to the cells.
5.2.3.4 Impact of SRC-1 in Single ER Transfections or ER Co-transfections
Co-transfections were carried out in Hep G2 cells. In each well, 1pg ER, 0.25pg 3x
ERE and 0.1pg pRL-CMV were added, with 1pg of the SRC-1e or SRC-1a
constructs. Four hours after transfection, either an ethanol vehicle, 10~8M or 10"7M
E2was added to the wells.
In co-transfection studies using two ERs and SRC-1 e in Hep G2 cells; 200ng of the
first ER was transfected with either 200ng, 600ng or 1200ng of the second ER along
with 1 pig SRC-1 e, 0.25pg 3xERE and 0.1 pg pRL-CMV. Either an ethanol vehicle or
10"8M E2was added four hours after transfection.
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5.3 Results
Each luciferase value was normalised to the internal pRL-CMV Renilla internal
control value and fold activation was calculated by dividing the values by the vehicle
control (set at 1). Each data point is the average of duplicate experiments performed
on at least three occasions. The standard error is shown for all data.
5.3.1 Activation of ERE-Luciferase Reporter
5.3.1.1 Comparison of the Different ERE Reporter Constructs
Hek 293 cells (Figure 5.1) or Hep G2 cells (Figure 5.2) were co-transfected with the
luciferase reporter plasmids containing the different ERE sequences. The results
were normalised and expressed as a fold increase compared to the ERE-Luc alone
(Figure 5.1A) or ERE-Luc and hER without E2 (Figures 5.1B & 5.2).
In the presence of E2 the fold induction of the luciferase reporter was influenced by
the promoter sequence and by whether human ERa or hER(31 was introduced into
the cells. Overall, the 3x ERE-containing reporter construct showed the greatest fold
increase compared to the single EREs and the OT ERE (Table 5.3) in both Hek 293
and Hep G2 cells.
In Hek 293 cells (Figure 5.1A) the OT ERE co-transfected with hERa induced a high
level of transcriptional activity, resulting in increased activity greater than that of the
3x ERE, notably at 10"7M ligand. A similar level of induction was not observed with
hER(31 in the Hek 293 cells or by hERa and hER(31 in the Hep G2 cells. In Hek 293
and Hep G2 cells transfected with hERa, the pTAL ERE and Vit ERE (pGL2
reporter) showed a similar, minimal increase in transcriptional activity in the
presence of 10"7M E2.
Therefore the 3x ERE-Luc reporter construct was used in all subsequent studies as
it initiated the greatest transcriptional response with hERa and hERpi in the
presence of E2 in both cell lines as shown in Table 5.3.
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Figure 5.1. Comparison of the different EREs and their ability to activate gene transcription
in Hek 293 cells. Hek 293 cells were co-transfected with the luciferase reporter plasmid
containing the 3x ERE, pTAL, OT or Vit ERE and the pRL-CMV internal control, ERa (A) or
ER|31 (B) were added. The cells were treated with vehicle, 10"8M or 10"7M E2. Each value
was normalised to the internal pRL-CMV Renilla control and fold activation was calculated
by dividing values by the vehicle control (set at 1). NB in (A) the control is the ERE alone, in
the absence of ERa, (B) control includes ER|31. Each data point is the average of duplicate
determinations from three representative experiments. Scales presented are different.
Standard errors are calculated from the means of the three experiments.
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Figure 5.2. Comparison of the different EREs and their ability to activate gene transcription
in Hep G2 cells. Hep G2 cells were co-transfected with the luciferase reporter plasmid
containing the 3x ERE, pTAL, OT or Vit ERE and the pRL-CMV internal control, ERa (A) or
ERpi (B) were added. The cells were treated with vehicle, 10"8M or 10"7M E2. Data are
displayed as fold induction of luciferase activity over the pRL-CMV internal control, scales
presented are different. Data are the mean +/- SEM of 3 experiments.
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Table 5.3. Summary of the effect of different promoter sequences on induction of the
reporter expression in the presence of E2. Values given as the mean fold increase over the
control. This being the selected ERE in the absence of ligand but with addition of the
appropriate constructs.








Hek293 ERa 17.7 20.8 3.5 3.7 19.7 26.0 2.7 3.5
Hek 293 ER(3 2.7 2.9 1.1 1.6 1.1 1.1 1.2 1.1
Hep G2 ERa 12.4 106.3 1.7 16.1 1.0 7.5 1.5 16.0
Hep G2 ERp1 4.0 8.1 1.6 2.1 1.0 1.4 1.2 1.4
5.3.1.2 Comparing Different Concentrations of 3xERE with ERa and ERp1
Increasing concentrations of the 3x ERE-Luc reporter construct co-transfected with
a fixed amount of human ERa or hER(31 in Hep G2 cells was assessed. The higher
the concentration of the 3x ERE-Luc reporter construct used for transient
transfections, the greater the transcriptional activity detected by the luciferease
assay and the higher the observed fold increase (Figure 5.3 & Table 5.4).
Table 5.4. Summary of the effect of different concentrations of the 3x ERE-Luc reporter
construct on gene transcription with 10"7M E2 in Hep G2 cells. Values given as a mean fold
increase over the normalised condition in the absence of ligand.
3x ERE 0.125(.ig 0.25pg 0-5pig
ERa 12.0 35.3 47.0
ER|31 1.8 5.0 10.0
Therefore, in the subsequent studies the ER constructs were co-transfected with
0.5pg of the 3x ERE-Luc reporter construct.
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Figure 5.3. Assessing the impact of different amounts of 3x ERE-Luc co-transfected with
hERa or hERp. Hep G2 cells were co-transfected with the hER« (A) or hERpi (B), the pRL-
CMV internal control and either 0.125pg, 0.25pg or 0.5^g 3x ERE-luciferase reporter
plasmid. The cells were treated with vehicle or 10"8M E2. Data are displayed as fold induction
of luciferase activity over the pRL-CMV internal control, scales presented are different. Data
are the mean +/- SEM of 3 experiments.
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5.3.2 Impact of Steroid Hormones on Transcriptional Activity of ERs
5.3.2.1 17p-Oestradiol Dose Response
In Hek 293 and Hep G2 cells the 3x ERE-Luc reporter construct transiently
transfected together with human ERa or human, macaque or marmoset ERpi,
showed a dose response curve in activity in the presence of increasing
concentrations of E2 (10~14M to 10"6M) (Figures 5.4 & 5.5).
The different ER constructs in the Hek 293 and the Hep G2 cells showed similar
ERE reporter gene activation potential. The hERa construct activated the greatest
increase in activity of the 3x ERE-Luc reporter gene compared to the ERpi
constructs and required a lower concentration of E2 to activate maximal activity (Hek
293 cells). However the E2 concentration required to give maximum activation of the
3x ERE-Luc reporter varied. For example, maximal activation was achieved when
10"7M E2 was added to hERa in Hek 293 cells, but was reached when 10~6M E2 was
added to ERa transfected into Hep G2 cells.
The hERp2-containing construct failed to induce transcription of the 3x ERE-Luc
reporter gene in the presence of E2 (from 10"14M to 10"6M) in the Hek 293 or the Hep
G2 cells.
Transcriptional activity of macaque and marmoset ER|31 (Figures 5.4D, E & 5.5.D,
E) was similar to hERpi in both cells lines (see Tables 5.4 & 5.5).
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Figure 5.4. 17p-Oestradiol dose response with ER transfected Hek 293 cells. Hek 293 cells
were transiently transfected using Gene Porter transfection reagent, with hERa (A), hERpi
(B), hERp2 (C), Mac ERpi (D) or Marm ERpi (E), the 3x ERE-Luc reporter and the pRL-
CMV internal control. Cells were treated with an ethanol vehicle or increasing concentrations
of 17p-oestradiol (E2), ranging from 10"14M to 10"6M. Data are displayed as fold induction of
luciferase activity over the un-stimulated cell. Data are the mean +/- SEM of 3 experiments.
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Figure 5.5. 17|3-Oestradiol dose response with ER transfected Hep G2 cells. Hep G2 cells
were transiently transfected using the JetPEI transfection reagent with hERa (A), hERa;
reduced scale (Ai), hER|31 (B), hER|32 (C), Mac ERp1 (D) or Marm ERpi (E), the 3x ERE-
Luc reporter and the pRL-CMV internal control. Cells were treated with an ethanol vehicle or
increasing concentrations of 17p-oestradiol (E2) ranging from 10"14M to 10"6M. Data are
displayed as fold induction of luciferase activity over the un-stimulated cell. Data are the
mean +/- SEM of 3 experiments.
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5.3.2.2 3/3Adiol Dose Response
In both Hek 293 and Hep G2 cells 3|3Adiol induced transcription of the 3x ERE
reporter gene by hERa and human, macaque and marmoset ERpi in a dose
dependent manner (Figures 5.6 & 5.7).
In the Hek 293 cells transfected with hERa, transcriptional activity of the ERE
reporter increased gradually to reach a maximum with 10"7M 3(3Adiol. In the Hep G2
cells transfected with hERa, low concentrations of 3|3Adiol (10"14M to 10"8M) induced
minimal reporter gene activation. However the addition of 10"7M and 10"6M 3{3Adiol
induced a large increase in activation of the reporter gene (67.6-fold and 415.8-fold
respectively) with ERa. This large increase in the reporter gene activation was not
observed with any of the ER|31-containing constructs in either cell line. This high
induction of transcriptional activity may be due to a downward trend of Renilla
expression at high 3|3Adiol concentrations. At lower concentrations (10"14M to 10"8M)
human, macaque and marmoset ER(31 initiated ERE reporter gene transcription
greater than hERa (see Tables 5.4 & 5.5) in both cell lines. The marmoset and
especially the macaque ER|31 initiated a greater increase in ERE reporter gene
activation compared to hER(31 in Hep G2 cells. The macaque ERpi was observed
to increase the ERE activity to a greater extent at lower concentrations (10"14M to
10"7M) of 3(3Adiol than the marmoset ER(31 in both cell lines.
The hERp2-containing construct failed to induce transcription of the 3x ERE-Luc
reporter gene in the presence of 3(3Adiol (10"14M to 10"6M) in either the Hek 293 or
the Hep G2 cells.
5.3.2.3 Genistein Dose Response
Genistein induced a dose responsive induction of the 3x ERE reporter gene
transcription when hERa or ER(31 were transiently transfected into Hep G2 cells
(Figure 5.8). Transfection of hERa initiated the lowest fold induction compared to
the ERpi constructs with all doses of genistein (10"14M to 10"7M). The human and
marmoset ER(31 initiated the greatest level of ERE reporter gene activation at high
(10"7M to 10"6M) doses of genistein (see Table 5.5). The human ERp2 construct did
not induce reporter gene activity when it was expressed in Hep G2 cells and
exposed to increasing concentrations of genistein (10 "14M to 10"6M).




1 o-1410131 o-12101110 10109 10-8 10-7 10-6
Adiol Concentration








0 (3l , , fli








0 a ,a ,fl jLJl
Figure 5.6. 3(3Adiol dose response in Hek 293 cells. Hek 293 cells were transiently
transfected with hERa (A), hER|31 (B), hER(32 (C), Mac ER|31 (D) or Marm ERpi (E), the 3x
ERE-Luc reporter and the pRL-CMV internal control. Cells were treated with a vehicle, or
increasing concentrations of 3(3Adiol, ranging from 10"14M to 10"6M. Data are displayed as
fold induction of luciferase activity over the un-stimulated cell. Data are the mean +/- SEM of
3 experiments.
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Figure 5.7. 3pAdiol dose response in Hep G2 cells. Hep G2 cells were transiently transfected
with hERa (A), hERa; reduced scale (Ai), hERpi (B), hERp2 (C), Mac ERpi (D) or Marm
ERpi (E), the 3x ERE-Luc reporter and the pRL-CMV internal control. Cells were treated
with a vehicle, or increasing concentrations of 3pAdiol, ranging from 10"14M to 10"6M. Data
are displayed as fold induction of luciferase activity over the un-stimulated cell. Data are the
mean +/- SEM of 3 experiments.
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Figure 5.8. Genistein dose response in Hep G2 cells. Hep G2 cells were transiently
transfected with hERo (A), hERpI (B), hERp2 (C), Mac ERp1 (D) or Marm ERp1 (E), the 3x
ERE-Luc reporter and the pRL-CMV internal control. Cells were treated with a vehicle, or
increasing concentrations of genistein (Ge), ranging from 10"14M to 10"6M. Data are
displayed as fold induction of luciferase activity over the un-stimulated cell. Data are the
mean +/- SEM of 3 experiments.
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5.3.2.4 PPT™ Dose Response
The ERa-specific agonist ppt™ induced reporter gene transcription in the presence
of human ERa, macaque or marmoset ERpi using Hep G2 cells (Figure 5.9).
Transcriptional activity of the 3x ERE reporter was upregulated in a dose dependent
manner. With hERa, transcriptional activity of the reporter became apparent when
1CT9M ppt™ was present and the greatest fold increase in activity was
demonstrated with 10"6M ppt™. Human ER|31 and ER|32 did not initiate gene
transcription in the Hep G2 cells with any concentration of ppt™. However,
macaque ER|31 induced reporter gene activation with ppt™ at 10"8M and marmoset
stimulated reporter activity slightly with 10~6M ppt™ (see Table 5.5).
5.3.2.5 DPN™ Dose Response
The ERpi -specific agonist DPN™ activated hERa and ER(31 in Hep G2 cells (Figure
5.10). Human ER|31 showed an increase in ERE-Luc reporter gene activity when the
cells were treated with 10"9M DPN™. When 10"8M DPN™ was added to the cells
transfected with hER|31, the 3xERE reporter gene activation reached a maximum
and remained at a constant level of transcriptional activation. Human ERa induced
gene transcription when DPN™ was added to the cells at concentrations of 10"6M
and higher and initiated a greater level of reporter gene activity compared to ERpi
with concentrations of 10"6M and above (see Table 5.5).
The marmoset and macaque ERpi-containing constructs stimulated gene
transcription in a dose dependent manner in the presence of DPN™, with marmoset
ER(31 showing the greatest increase in reporter gene activation.
None of the concentrations of DPN™ tested were able to induce reporter gene
activation by the hER|32 construct.
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Figure 5.9. PPT™ dose response in Hep G2 cells. Hep G2 cells were transiently transfected
with hERa (A), hERa; reduced scale (Ai), hER|31 (B), hERp2 (C), Mac ER(31 (D) or Marm
ERpi (E), the 3x ERE-Luc reporter and the pRL-CMV internal control. Cells were treated
with a vehicle, or increasing concentrations of PPT™, ranging from 10"14M to 10"6M. Data are
displayed as fold induction of luciferase activity over the un-stimulated cell. Data are the
mean +/- SEM of 3 experiments.
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Figure 5.10. DPN™ dose response in Hep G2 cells. Hep G2 cells were transiently
transfected with hERa (A), hERa; reduced scale (Ai), hER(31 (B), hER(32 (C), Mac ER(31 (D)
or Marm ER(31 (E), the 3x ERE-Luc reporter and the pRL-CMV internal control. Cells were
treated with a vehicle, or increasing concentrations of DPN™, ranging from 10"14M to 10~4M.
Data are displayed as fold induction of luciferase activity over the un-stimulated cell. Data
are the mean +/- SEM of 3 experiments.
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5.3.2.6 Summary of Results using Single Transfections and Different Ligands
The transcriptional activity of hERcx, hER(31 and hERp2 in the presence of
oestrogenic ligands was receptor subtype dependent in both Hek 293 cells and Hep
G2 cells and transcriptional activity depended upon the ligand added (Tables 5.4 &
5.5). Highest levels of reporter gene activation were observed using hERa in Hep
G2 cells, the most marked induction was achieved using the ERa-selective ligand
PPT™ (169-fold using 10"7M). However, E2 stimulated the greatest level of
transcriptional activation overall through the 3x ERE reporter with ERa and ERpi.
ERp2 failed to stimulate ERE-Luc reporter gene activation with any concentration of
the ligands tested.
Table 5.4. Summary of reporter gene activation in Hek 293 cells with E2 and 3|3Adiol.
ER 10"SM E2 10"7M E2 10"®M Adiol 10"7M Adiol
hERa 22.1 30.3 13.6 14.0
hERpi 9.7 11.1 13.3 17.6
McER|31 6.2 16.8 14.5 14.7
MmER|31 11.3 15.2 8.3 9.8





















hERa 31.5 59.4 4.4 67.6 2.3 3.7 72.7 169.1 2.5 5.3
hERpi 8.5 11.7 2.5 5.4 1.9 4.9 1.0 1.2 7.5 7.8
McERpi 5.8 12.1 8.8 12.2 3.2 2.8 7.6 7.1 10.8 9.1
MmERpi 8.9 17.1 1.2 5.5 1.0 4.8 1.6 1.2 2.6 20.1
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5.3.3 ERa and ERp Co-transfections
Results presented in the previous sections have demonstrated reporter gene
activation by ERa or ERp is not functionally equivalent and is influenced by the
concentration of E2. The impact of heterodimer formation on reporter gene activation
was investigated by co-transfection of variable amounts of ER|31 or ERp2 together
with a fixed amount of ERa or ERp1 and 3x ERE-Luc reporter. The amount of
hERpi or hERp2 were chosen to give final ratios of 1:1, 1:3 or 1:6. All results were
compared to those obtained in control transfections involving either ERa alone plus
the 3x ERE-Luc reporter (Figure 5.11A & 6 & Figure 5.12A & 6) or ERpi alone plus
the 3x ERE-Luc reporter (Figure 5.11C & Figure 5.12C).
5.3.3.1 Co-transfections of ERa and ERfil
In Hek 293 cells, co-expression of ERa/ERpi resulted in increased activation of the
ERE-Luc reporter compared to the activity seen in ERa containing controls (Figure
5.11A). The effect was independent of the ratio of ERa:ERpi although highest
levels of transcriptional activity were obtained with ERa/ER|31 (1:3) using 10"7M E2.
Results obtained using Hep G2 cells were not identical (Figure 5.12A) and addition
of ERpi to ERa-containing cells failed to enhance reporter gene activation. At ratios
of 1:6 (ERa/ERpi) some blunting of the transcription response was observed (see
Table 5.6).
5.3.3.2 Co-transfection of ERa and ERfi2
In Hek 293 cells, co-expression of ERa/ER(32 resulted in a decrease in activation of
the ERE-Luc reporter activity compared to when ERa was singly transfected with
the ERE-Luc (Figure 5.11B) with 10"9M and 10"7M E2 present. The observed
decrease in activation was similar with all concentrations of ERp2 co-transfected,
although with 1:3 and 1:6 ratios (ERa:ERp2) the rate of error increased. In Hep G2
cells a definite decrease in reporter gene activation was observed upon co-
transfection of ERp2 (Figure 5.12B). The substantial decrease in activation was
consistent with all three ratios of ERp2 (1:1, 1:3, 1:6). Although it was noted that in
the absence of E2, the co-transfected ERa/ERp2 increased ERE reporter gene
activation compared to ERa alone in both cell lines.
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5.3.3.3 Co-transfection of ERa and ERfi2
Co-transfection of ER|31 and ER|32 in Hek 293 cells resulted in an increase in ERE
reporter gene activation (Figure 5.11C). The increase in reporter activation with
addition of 10"9M and 10"7M E2 was shown to increase as the concentration of
transfected ER(32 increased. In Hep G2 cells reporter gene activation also increased
upon co-transfection of ER|32, increasing with increasing concentrations of ER|32
(Figure 5.12C). Overall, the increase in reporter gene activation in the co-
transfections was greater in Hek 293 cell compared to Hep G2 cells.
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Figure 5.11. The impact of co-transfecting different ERs in Hek 293 cells. Hek 293 cells were
transiently transfected using the Gene Porter transfection reagent, with the 3x ERE-Luc
reporter and pRL-CMV internal control. Human ERa (A & B) was transfected into the cells
together with increasing amounts of hERpi (A) or hERp2 (B). hERpI was transfected into
the cells (C) and co-transfected with hERp2. Cells were treated with a vehicle, or increasing
concentrations of E2, ranging from 1CT13M to 10"7M. Data are displayed as fold induction of
luciferase activity over the un-stimulated cell, scales presented are different. Data are the
mean +/- SEM of 3 experiments.
























10® - 10 s - 10-® - 10-®
■■ " II
ERa ERa+p. 1:1 ERa + p, 1:3 ERa+p, 1:6
1 X 1
A A A
10® - 10-® - 10® - 10-®
" ■' 11 ■
ERa ERa + p21:1 ERa + p21:3 ERa + p21:6
ERP1 ERpi + p21:1 ERp1 + p21:3 ERp1+p21:6
Figure 5.12. The impact of co-transfecting different ERs in Hep G2 cells. Hep G2 cells were
transiently transfected with the 3x ERE-Luc reporter and pRL-CMV internal control. Human
ERa (A & B) was transfected into the cells together with increasing amounts of hERpi (A) or
hER|32 (B). hERpi was transfected into the cells (C) and co-transfected with hERp2. Cells
were treated with a vehicle, or 10"8M E2. Data are displayed as fold induction of luciferase
activity over the un-stimulated cell. Data are the mean +/- SEM of 3 experiments.
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5.3.3.4 Summary ofResults using Co-transfections
The results of the co-transfection studies in Hek 293 and Hep G2 cells are
summarised in the tables below (Tables 5.6 & 5.7). The Hek 293 cells co-
transfected with ERp-containing constructs differed in transcriptional response
compared to Hep G2 cells. Hek 293 cells showed an increase in ERE reporter gene
transcription with ERa/ERpi and ERpi/ERp2 co-transfected but a decrease in gene
activation with ERa/ERp2. The Hep G2 cells demonstrated a decrease in reporter
gene activation with ERa/ERpi and a larger decrease with ERa/ERp2, however an
increase in gene activation was observed with ERpi/ERp2 co-transfected.
Table 5.6. Summary of the reporter gene activation when ERs were co-transfectioned (1:6
ratio) in Hek 293 cells.
3x ERE + + + + + + + + + +
ERa + + + + + + - - - -
ERp1 - - + + - - + + + +
ERp2 - - - - + + - - + +
10"7M E2 - + - + - + - + - +
Response 1.0 31.2 1.1 47.1 1.1 17.6 1.0 8.1 1.2 14.4
-/+ = construct absent/present, response values given as the mean fold increase.
Table 5.7. Summary of the reporter gene activation when ERs were co-transfectioned (1:6
ratio) in Hep G2 cells.
3x ERE + + + + + + + + + +
ERa + + + + + + - - - -
ERp1 - - + + - - + + + +
ERp2 - - - - + + - - + +
10"8M E2 - + - + - + - + - +
Response 1.0 26.8 5.5 15.8 2.5 10.9 1.0 12.7 7.9 22.3
-/+ = construct absent/present, response values given as the mean fold increase.
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5.3.4 Impact of SRC-1 on Transcriptional Activity of hERa, hERpi or hERp2
5.3.4.1 Impact ofSRC-1e and SRC-1a in Co-transfections with ERa and ERfi
The impact of SRC-1 e and SRC-1 a on the transcriptional activity of human ERs was
assessed using transient transfections in Hep G2 cells (Figure 1.13). Transcriptional
activation of the 3x ERE-Luc reporter by ERa stimulated by addition of 10"7M E2 was
increased by SRC-1 a but decreased by SRC-1 e compared to the activity of ERa
alone. With lower concentrations of E2 (10"8M) both SRC-1 e and SRC-1 a enhanced
transcriptional activity of hERa when compared to levels of reporter gene
expression induced by hERa without SRC-1.
Human ERpi co-transfected with SRC-1 e or SRC-1 a resulted in a slight decrease in
reporter gene activation by E2 compared to when hERpi was transfected without
SRC-1 (Table 5.8). However the overall levels of reporter gene activation were very
low.
The human ERp2 transfected into Hep G2 cells did not induce any reporter gene
activity in the presence of E2 and co-transfection of SRC-1 e or SRC-1 a did not result
in any change in activity.
Table 5.8. Summary of reporter gene activity in Hep G2 cells when co-transfecting SRC-1 e







hERa 4.9 55.3 6.5 16.9 14.8 64.4
hERpi COin COo 1.4 2.3
Values given as the mean fold increase.
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Figure 5.13. Impact of SRC1 co-transfected with hERa, hERpI or hERp2 in Hep G2 cells.
Hep G2 cells were transiently transfected with hERa (A), hERpi (B) or hERp2 (C), the 3x
ERE-Luc reporter and pRL-CMV internal control. Cells were treated with either a vehicle, E2
at 10"7M or 10"8M. Data are displayed as fold induction of luciferase activity over the un¬
stimulated cell. Data are the mean +/- SEM of 3 experiments.
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5.3.4.2 Impact of the Presence ofSRC-1e in ERa and ERfi Co-transfections
Co-transfection studies (section 5.3.3 and Figure 5.14) using Hep G2 cells
demonstrated that co-expression of hER(31 or hERp2 together with hERa resulted in
an apparent reduction in ERE-Luc reporter gene activity with 10"8M E2. In contrast,
co-expressing hER|32 with hER(31 increased activity compared to hERpi alone. Co-
expression of SRC-1e with ERa alone was found to reduced ERE reporter
activity. However when SRC-1e was co-transfected with ERa and ER(31, reporter
gene activation increased to greater than the level of activation of ERa alone with
the 3x ERE-Luc reporter construct or with ERa and ER(31. When the ERa and
ERp2-containing constructs were co-transfected the ERE-Luc reporter gene
activation decreased compared to ERa and 3x ERE-Luc alone, and the presence of
SRC-1e did not act to alter the transcriptional activation of the reporter. In co-
transfections with ERpi and ER(32 reporter gene activation increased with
increasing concentrations of ER(32. In the presence of SRC-1e the reporter gene
activation increased further (as shown in Table 5.9).
Table 5.9. Summary of the effect of SRC-1e co-transfected with the hERa, hER(31 and
hERp2 and the ERs co-transfected in a 1:6 ratio, on reporter gene activation in Hep G2 cells.
ERE + + + + + + + + + + +
ERa + + + + + + +
ERpi + + + + + +
ERP2 + + + +
SRC-1e + + + + +
10"8M E2 + + + + + + + + + +
Response 1 26.1 19.5 18.7 33.6 14.9 20.4 5.1 5.2 5.3 11.1
-/+ = construct absent/present, response values given as the mean fold increase.
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Figure 5.14. Impact of SRC1e with hERa, hER|31 and hER|32 co-transfections in Hep G2
cells. Hep G2 cells were transiently transfected with hERa and hER(31 (A), hERa and hER(32
(B) or hER|31 and hER|32 (C), the 3x ERE-Luc reporter and pRL-CMV internal control. Cells
were treated with a vehicle, or 10"8M E2. Data are displayed as fold induction of luciferase
activity over the un-stimulated cell. Data are the mean +/- SEM of 3 experiments.
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5.4 Discussion
These functional studies with different ER constructs, ERE reporter genes and
different ligands demonstrate the variability of this complex system. In these
experiments regardless of the cell type or ERE sequence, human ERa is a more
potent activator of ERE reporter gene transcription than ER|31 (wild type). The ER|32
variant did not initiate gene transcription regardless of ligand, reporter gene or cell
type. Cells were transiently transfected with the same concentrations of ERa and
ER|31, however the level of expression in indvidual cells cannot be controlled.
Studies have compared the functional activity of ER|3 from human as well as primate
and compared this with human ERa. The impact of different ligand concentrations,
promoter gene sequence, and the presence of a co-activator (SRC-1) have been
explored using transient transfections in two ER negative cell lines (Hek 293 and
Hep G2). Preliminary data has been gathered assessing the impact of receptor co-
transfection (heterodimer formation) on reporter gene activation.
5.4.1 Activation of ERa and ERpi by 17f5-Oestradiol is Influenced by the
Promoter
Ligand-activated oestrogen receptors bind with high affinity to specific DNA
sequences, known as oestrogen response elements (EREs) located within the
regulatory regions of target genes. Sequence-specific interaction between
oestrogen receptors and the EREs is dependent upon the presence of an intact
DBD (Hall et al., 2002; Tremblay et al., 1997). However, regions outside the DBD
may also play a role in formation of the stable receptor-DNA complexes (Kuiper et
al., 1997).
It has been reported that one base change in an ERE half site can cause the re¬
arrangement of a localised hydrogen bond network rather than a simple hydrogen
bond substitution and therefore result in lower affinity of ERa for the imperfect
EREs, as shown in CHO cells (Loven et al., 2001). The ERE-bound ERa or ER|3
proteins are thought to interpret the sequence and orientation of ERE half-sites in
unique manners. One consequence of variation in sequence between different
EREs will therefore be to induce distinct conformations in the ER co-activator pocket
leading to different co-factor recruitment and gene response (Loven et al., 2001).
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These differences provide a mechanism for differential gene expression by ERa and
ER|31 through the classical ERE pathway.
The OT ERE is a bovine oxytocin response element mutated to resemble a rat ERE.
It has one base change from the consensus vitellogenin ERE in the 5' half site
which can affect its affinity for ERs and therefore its ability to activate gene
transcription (Loven et al., 2001). In Hep G2 cells transfected with hERa or hER(31,
addition of E2 only resulted in 7.5- and 1.4-fold increase respectively, with OT ERE.
Hek 293 cells transfected with ER(31 showed a 1.1-fold increase in reporter gene
activation with OT ERE, in contrast ERa transfected with OT ERE resulted in a 26-
fold increase in reporter gene activity. This may be due to cell-specific factors in Hek
293 cells which aid OT ERE reporter gene activation via ERa.
My results demonstrate that in general the single consensus Vit EREs cloned into
the pGL2 and pTAL vectors induced a greater fold increase in gene transcription
than the OT ERE with ERa in Hep G2 cells. The one exception was when ERa was
expressed in Hek 293 cells where a higher level of gene transcription was induced
by the OT ERE reporter. The work shown here is in agreement with previous studies
which demonstrate that the consensus Vit ERE induces gene transcription though
hERa and hER(31 to a greater extent that the OT ERE in Hela and CHO cells (Loven
et al., 2001; Wood et al., 2001). This is also consistent with reports that hERa's
binding affinity for Vit ERE is higher than that of hER(31 (Loven et al., 2001; Wood et
al., 2001) shown by DNase I footprinting.
The single consensus vitellogenin EREs did not stimulate transcriptional activation
as much as the 3x ERE. These results are in agreement with previous published
work using ER-negative CHO-K1 and MCF-7 cells transfected with different ERa
and ERpi constructs including human ERs (Klinge, 1999; Sathya et al., 1997;
Tyulmenkov et al., 2000). Changes in binding affinity of ERs in response to the
increase in number of tandem EREs has revealed both similarities and differences
between ERa and ER(31. A mammalian ERa construct induced activation of
luciferase reporter gene activity in response to E2 from three or four tandem copies
of a consensus ERE in CHO cells but not with two tandem copies. The same was
true for ERp1 but to a lower level of activation (Tyulmenkov et al., 2000). In
electrophoretic mobility shift assays mammalian ERa binds to three ERE copies
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with high affinity closely followed by 4 copies, however with one or two copies of the
ERE the binding affinity was significantly less. The binding affinities for mammalian
ER|31 demonstrated that it bound with comparable affinity to two and four tandem
copies of ERE and with higher affinity to the three copies of the ERE. In the
presence of more than four Vit EREs linked together, the reporter activity of hERa
decreased reporter activity when assessed in MCF-7 cells (Nagel eta/., 2001).
Therefore, to summarise the published studies, the relative induction of reporter
gene activity by E2 was dependent on the number of tandem copies of the
consensus ERE, with three being optimal.
Ogawa et al have used gel shift assays to demonstrate that homodimers of human
ERa or ER(31 bind to the consensus Vit ERE with high affinity but that ER|32/cx
homodimers do not bind as effectively (Ogawa et al., 1998c). Klinge has reviewed
the available data on ERE binding and concluded that there was no significant
correlation between ERE binding and E2-induced transcriptional activation (Klinge,
2001). This suggests that differences in binding affinity assays may not be of direct
relevance to the differences in transcriptional activation of ERa and ER|31 with the
different response elements.
In my studies I found hERa and hER|3 stimulated transcriptional activation to varying
extents depending upon the different EREs used and that this also varied between
different cell lines. In general hERa-induced activation was greater than observed
using ER|31. This has been documented previously using different EREs in several
cell lines including Cos 1, CFIO and Hela (Cowley and Parker, 1999; Tremblay et al.,
1997; Tyulmenkov et al., 2000). However, in human osteosarcoma or human
endometrial carcinoma cells, the transcriptional activity of ER|31 was higher than
that of ERa (Watanabe et al., 1997). Cell-specific variation in the expression of ERa
and ER|31 suggests the individual receptors may regulate specific subsets of
oestrogen responsive genes in different cell backgrounds. Therefore, differences in
ligand binding, tissue distribution and transcriptional activation of reporter constructs
indicate that ERa and ER|3 play overlapping but different roles in vivo (Kuiper and
Gustafsson, 1997; Massaad et al., 1998).
The 3x ERE reporter was the reporter chosen to study oestrogen regulated gene
expression in these experiments as it was demonstrated to initiate the greatest
transcriptional activity. However it is important to remember that most endogenous
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genes contain EREs that differ from the consensus Vit ERE by one or more base
pairs and that these differences in nucleotide sequence most likely influence the
ability of individual EREs to mediate transcription activation.
5.4.2 ERa and ER01 Contribute Differentially to Gene Activation by
Oestrogenic Ligands
Functional studies described in this chapter demonstrate that ligands such as 17|3-
oestradiol initiate gene transcription with human ERa and ER(31 (wild type) but not
with the ER|32 variant. The ER(32 variant lacks the last coding exon which includes
amino acids involved in ligand binding and all of those involved in the AF-2 domain
and is therefore unable to bind ligands (Kuiper et al., 1996; Ogawa et al., 1998c).
These studies have also shown for the first time that macaque ER(31 and marmoset
ER|31 are able to initiate transcription of the 3x ERE reporter using a range of
ligands. ERa activated ERE reporter gene transcription more than ER(31 with all
ligands tested, except with the ER(31 -specific agonist DPN™. It was also noted that
the maximal stimulation was observed at different concentrations of ligand with the
different constructs, with ER(31 generally requiring a higher concentration of ligand
for maximal transcription to occur compared to the hERa.
The idea that ligands play an active role in ER function has been proposed by
several laboratories (McDonnell et al., 1995; Paige et al., 1999; Wijayaratne et al.,
1999). It has been demonstrated that different ligands induce distinct conformational
changes in the ER, correlating with diversity in transcriptional responses (Hall and
Korach, 2002; Hall et al., 2002). It has been demonstrated that upon binding,
different ligands induce distinct conformational changes within the receptor co-
activator-binding pockets, thus leading to differential co-factor recruitment and
biological activity (Hall et al., 2002). This agrees with my data which demonstrates
that different oestrogenic ligands induce different levels of transcriptional activity
even when the same ERE promoter is used.
The variation in ligand-induced activation shown in these results is also in
agreement with previous observations in which ER|31 consistently induced reporter
gene activity to a lesser extent than ERa (Barkhem et al., 1998; Pettersson et al.,
2000). My results have demonstrated that ER|31 is poorly activated by E2 at
concentrations below 10"9M (1nM). In contrast, ERa reaches approximately 66% of
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its maximal activation with 10"9M E2 in Hek 293 cells but only 20% in Hep G2 cells
with the same E2 concentration. However, previous saturation ligand binding assay
studies using rat ERs have demonstrated that there is very little difference in the
ERa and ER|31's binding affinity for E2 (Kuiper et al., 1997).
To my knowledge, transient transfections have not been performed previously to
investigate ER-induced transcription in the presence of 3|3Adiol. In my studies
3|3Adiol was generally found to activate gene transcription via ER|31 to a greater
extent than ERa, however there were differences observed between Hek 293 and
Hep G2 cells. Kuiper et al studied the ligand specificities of rodent ERa and ERp to
calculate their relative binding affinities and demonstrated that 3(3Adiol binds with
higher affinity to ER(3 than ERa and that the Ki (nM) was three times greater for ERa
(6nM compared to 2nM) (Kuiper et al., 1997). No data has been presented on the
ER transcriptional activity in response to addition of 3|3Adiol, but as it has been
stated that this natural agonist serves as an agonist through ER|31 in the prostate
(Weihua et al., 2002). High concentrations (10"7M) of 3(3Adiol resulted in an increase
in gene activation of over 67-fold compared to 4.4-fold at 10*6M, when ERa was
expressed in Hep G2 cells. This was not observed in Hek 293 cells, nor with ER|31
in either cell line tested. This dramatic increase in gene transcription may be due to
the ERa ligand binding pocket becoming saturated and therefore over stimulating
co-activator recruitment, although further work is required to determine the exact
explanation.
Genistein was observed to activate gene transcription via both ERa and ER|31 in
Hep G2 cells. At higher concentrations (10"7M) genistein stimulated ER|31 gene
transcription to a greater extent than ERa. Various studies have measured the
binding affinity of different ERs for genistein with different values being obtained (An
et al., 2001; Barkhem et al., 1998; Harris et al., 2002a; Kuiper et al., 1997). Despite
binding assays generally showing genistein has a more than 10-fold higher
selectivity for ER(31 versus ERa, it has been demonstrated by crystallographic
studies that genistein exhibits partial agonism on the ER|31 LBD and full agonism on
ERa LBD (Pike et al., 1999). Previous studies have found that the EC50 of ERa for
genistein is much higher than for ER(31, indicating that ER(31 requires less genistein
in the system to activate gene transcription (Harris et al., 2002b; Kuiper et al., 1997).
Therefore from my transfection results and previous published binding affinity data,
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it can be suggested that genistein binds to ER(31 and activates transcription through
an ERE to a greater extent than when it is bound to ERa.
Pettersson et al also demonstrated that genistein was a more effective activator of
mouse ER(31 than human ERa in transient transfections with a 2x ERE in Hek 293
cells, however, at higher concentrations of ligand (200nM) ER(31 and ERa were both
fully active (Pettersson et al., 2000). With a very high concentration (2pM) of
genistein, the ligand acted as a super agonist for both ER subtypes, resulting in
more than 200% of the maximal activity obtained with E2 (Pettersson et al., 2000).
The high transcriptional activity reported by Pettersson et al may be due to genistein
modulating protein kinase signalling pathways and therefore altering the
phosphorylation status of ERs. However, this high fold increase was not observed in
the present studies, nor was it observed by Barkhem et al who used stably
transfected Hek 293 cells and incubated them with genistein for 72 hours (Barkhem
et al., 1998).
In these functional studies the novel ligand PPT™, was found to activate ERa-
induced gene transcription to a much greater extent than E2, whereas human ER|31
did not activate transcription in the presence of PPT™. Similar results have been
reported previously; Kraichely et al demonstrated that PPT™ induced a high level of
transcriptional activation, similar to E2, with ERa using a 3x ERE-CAT reporter
(Kraichely et al., 2000). However, ppj™ was not found to stimulate ER|31 with a
range of reporter gene constructs even at high concentrations (10^M) of ligand
(Kraichely et al., 2000). In contrast, for the first time it has been demonstrated that
macaque and marmoset ER|31 constructs were able to activate the 3x ERE reporter
in the presence of high concentrations of PPT™ (10~8M and 10"6M respectively).
This indicates that there may be slight differences in the nucleotide sequence within
the LBD of the primate ER|31 which allows binding of PPT™ in a manner which can
initiate gene transcription, unlike the human ER|31.
The ER|3-specific agonist DPN™ induced gene transcription through ERa to a much
higher extent than via ER|31 at high concentrations (10"6M and greater). This was
unexpected as it has been proposed that DPN™ is an ER|31-specific agonist and is
170-fold more potent with ER|31 compared to ERa with a 4x ERE in HEC-1 cells
(Meyers et al., 2001). In a recent study, Ramsey et al demonstrated in CHO-KI cells
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with a 2x ERE, that DPN™ activated hER(31 induced transcription to a greater extent
than hERa at a range of concentrations (from 10"11 to 10"4M) and hERa only
became transcriptionally activated at 10"8M DPN™ (Ramsey et al., 2003). However
in my functional studies, ER|31 was more transcriptionally active than hERa only at
lower concentrations of DPN™ (10"7M) where ERa was minimally active. The
dramatic increase in transcriptional activity of ERa in the presence of high
concentrations (10"6M) of ligand may be due to saturation of the receptor's LBD
pocket and recruitment of co-activators. Marmoset ERpi induced higher levels of
gene transcription through a 3x ERE with all concentrations of DPN™ tested,
compared to macaque ER(31 or human ER|31, highlighting a possible difference
between different species and the ER conformation once the ligand has bound.
5.4.3 The Effect of Co-transfecting Two ER Isoforms
In Chapter 4 it was observed that FP-tagged human ERa, ER|31 and ER(32 can
heterodimerise within the cell nucleus and the dose response experiments (this
chapter) have shown that hERa and hER|31 are not functionally equivalent and
ERp2 is not functional in the presence of ligand. Therefore functional studies were
necessary to ascertain whether hER(31 or hER|32 could reduce hERa's
transcriptional activity by acting as a transdominant repressor or a modulator for
hERa action.
Experiments in Hek 293 cells with the 3x ERE reporter and 10~8M E2 have shown
that co-transfection of hERa with hER(31, or hER(31 with hER|32 resulted in an
increase in transcriptional activity compared with transfections of hERa or hER(31
alone. However, when hERa was co-transfected with hER|32, the fold increase in
transcriptional activity was decreased slightly. However, these results must be
considered preliminary as there were variations between experiments. This variation
in responsiveness is most likely due to the transiently transfected constructs not
being introduced into every cell, as observed in Chapter 3 using
immunocytochemistry. Therefore in the co-transfections not all the cells will express
both of the receptors.
In Hep G2 cells co-transfecting hER|31 with hERa and a 3x ERE reporter, resulted in
a decrease of gene transcription but the results were variable and depended on the
different ratios of hERa:ER|31. When hER|32 was co-transfected with hERa, gene
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transcription levels were decreased substantially. However when hER|31 and hER|32
were co-expressed transcriptional activity was increased. In the absence of E2,
when hER|31 and hER|32 were co-expressed, a slight increase in reporter gene
activation was observed. Hence indicating the possibility of an alternative, non-
classical pathway for which gene transcription maybe activated through hERp2, as
this effect was not observed with hER|31 alone. Therefore in these cells, hER|32 may
act as a transdominant repressor of hERa transcriptional activity in the presence of
10"®M E2i but may alternatively act to increase the activity of hER(31.
When Ogawa et al co-transfected human ERa or hER|31 with hERpcx (hER(32) and
an ERE-CAT reporter in Cos 7 cells at a 1:10 ratio, hERp2 inhibited ligand induced
transactivation by hERa, but did not influence transactivation by hERpi (Ogawa et
al., 1998c). They obtained similar results in Hek 293 cells. The results presented
here only demonstrate this in Hep G2 cells using a 1:6 ratio, as in the Hek 293 cells
there was a high error rate. Thus highlighting the differences between cell lines and
variations in conditions and reporters used in different studies.
Hall et al have used Hek 293 cells and the same 3x ERE reporter gene to
demonstrate that hER(31 (wild type) had the ability to act as a transcriptional inhibitor
or activator of hERa depending upon the agonist concentration (Hall and
McDonnell, 1999). In their studies they suggested that hER|31 functions as a
repressor of hERa transcriptional activity at low, subsaturating concentrations of E2
(10"1°M) and that the presence of hER(31 decreased the sensitivity of hERa-
expressing cells to oestradiol (Hall and McDonnell, 1999). However they only used a
1:1 ratio of the ERs, whereas I used a range of ratios (1:1, 1:3 & 1:6). In saturating
conditions of E2 (10"7M) transcriptional activity of the ERa/ERpi heterodimer is
indistinguishable from that of the hERa homodimer. Therefore the ability of hERpi
to switch from a transcriptional repressor to an activator as E2 levels increase may
provide cells expressing hERa and hERpi with a mechanism to control cellular
sensitivity to hormones (Hall and McDonnell, 1999). Pettersson et al also
demonstrated that ERp can act as a negative or positive regulator of ER activity
depending upon the concentration of ligand added (Pettersson et al., 2000), stating
that ERp inhibits ERa activity at E2 concentrations below the ERp activity threshold.
However they used human ERa and a mouse ERp (short form) in Hek 293 cells with
a 2x ERE reporter, therefore a direct comparision cannot be made with my results.
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In the results shown here, 10"8M and 10"7M E2 was used in Hek 293 cells and 10"7M
in Hep G2 cells, which Hall et al and Pettersson et al found to be saturating. If a
lower concentration of ligand had been used a different result may have been
obtained.
However the hER|31, hER|32 and hER|35 variants have all been reported to inhibit
transcriptional activation by hERa using an ERE promoter in Cos 1 and Cos 7 cells.
The hERp 1, hER(32 and hER(35 variants appeared to have different efficiencies;
hER(31>hER(32>hERp5 (Peng et al., 2003). Peng et al demonstrated a decrease in
activation of transcription via hERa when it was co-transfected with hER|31 or
hER(32 in a 1:9 ratio occurred with both 10"1°M and 10"7M E2 (Peng et al., 2003).
This contradicts what Hall et al demonstrated with subsaturating and saturating E2
concentrations (Hall and McDonnell, 1999). This recently published data by Peng et
al shows both similarities and differences to my data, as I demonstrated that hER|31
acted to decrease hERa transcriptional activity in Hep G2 cells, but slightly
increased activity in Hek 293 cells.
Inoue et al studied an ERp splice variant (ER|3A5) which lacked exon 5 (Inoue et al.,
2000). ER[3A5 has both an intact DNA binding domain and an AF-1 transactivational
domain, therefore being similar to ERpi, but due to a premature stop codon lacks
the LBD present in exon 5. The ER|3A5 isoform was found to have a dominant
negative effect on ER|31 or ERa in transient transfection systems (Inoue et al.,
2000). One possible mechanism for the documented dominant negative activity is
that these heterodimers are transcriptionally inactive and have no or very little DNA
binding activity. The other possibility is that the ER|3A5 competes with ERa or ER|31
for the DNA binding site and forms transcriptionally inactive heterodimers on the
ERE (Inoue et al., 2000). In the process of transactivation by ER, AF-1 and AF-2
need to interact with co-activators. Since ERpA5 lacks the AF-2 but contains an
intact AF-1, unproductive interactions with co-activators may be maintained, but the
interaction of co-activators with wild-type ER may be prevented (Inoue et al., 2000).
These data are highly relevant to ER|32 and may explain one way in which ER|32
can act as a dominant negative "receptor".
In my studies I have found that co-transfections of hER(31 and hER(32 resulted in an
increase of ERE reporter activity compared to when hER|31 was present alone in the
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Hek 293 and Hep G2 cells. This was similar to data published previously by Ogawa
et al who found that in Cos 7 cells with a single ERE reporter the level of
transcriptional activity was maintained at the same level as hER|31 in the absence of
ER|32 (Ogawa et al., 1998c). The observed increase in transcriptional activity in my
results may be due to cell specific factors in the human cell lines that increase ER(31
activity and/or act to stimulate ER|32 in an alternative manner. There is also the
possibility that ER(32 acts through a novel and as yet unidentified pathway through
more specific response elements, phosphorylation or novel binding.
It has been recently proposed that the difference in hERa and hER(31 activity may
be due to cell-type specific factors as well as the slight differences in the LBD
(Ramsey et al., 2003). ER|31 contains an N-terminal AF-1 region which is less active
than ERa's AF-1 and its activity is thought to be cell-specific. This hypothesis of cell
specificity is based on the greater activity of ERa AF-1 in Hep G2 cells whereas in
Hek 293 cells AF-1 and AF-2 activity are equal. Therefore in Hek 293 cells the N-
terminus of hER|31 has greater transcriptional activity than in Hep G2 cells. If this is
true, it may explain why in my experiments ERa transcriptional activity is 6-fold
greater than ER|31 with 10"7M E2 in Hep G2 cells, but only 3-fold greater in Hek 293
cells. This may also explain why in co-transfections in Hek 293 cell ERa and ER|31
show an increase in transcriptional activity whereas the same co-transfection in Hep
G2 cells shows a decrease in activation.
There are several hypotheses as to how ER|31 may repress ERa induced reporter
activity in co-expression studies, including (i) ER(31 binds to cognate response
elements in a constitutive manner and therefore competes with the ERa for access
to DNA (Hall and McDonnell, 1999); (ii) ER|31 does not contain a strong AF-1 within
its amino-terminus, but rather contains a repressor domain that when removed
increases overall transcriptional activity (Hall and McDonnell, 1999; Ogawa et al.,
1998b); (iii) with subsaturating concentrations of E2, inactive ER|31 binds to its ERE
and competitively blocks ERa binding to the ERE. As the E2 levels increase,
sufficient ER|31 is activated to compete with the unligand bound ER|31 and
transcription can proceed (Hall and McDonnell, 1999; Pettersson et al., 2000); (iv)
modulatory effects on the configuration of the AF-2/AF-1 interaction, where ER(3
may be repressing the AF-1 activity (Pettersson et al., 2000) and (v) the nuclear
receptors compete via transcriptional silencing or squelching (Schodin et al., 1995),
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for example, titrating out co-activators and basal transcription factors essential for
ERa. These hypotheses have previously been based on studies using ERa and aim
to explain the possible dominant negative of ER(31, however since the identification
of ER|3 splice variants, such as ER|32 (Ogawa et al., 1998c) these statements may
also apply to ERp2 containing heterodimers.
It has previously been determined that human ERa/ER|31 heterodimers are formed
preferentially over ERp1/ER(32 heterodimers in gel shifts (Ogawa et al., 1998c). And
ERa homodimers are formed preferentially in comparison with ER(3 homodimers
(Cowley et al., 1997). ERa homodimers and ERa/ER|31 heterodimers were found to
bind to the ERE with greater affinity than ER(31 homodimers (~4-fold greater Kd)
(Cowley et al., 1997) suggesting the former dimers are more functional than the
latter. Both ERa and ER|3 have been detected in many tissues by RT-PCR (Cowley
et al., 1997; Moore et al., 1998) and co-expression has been demonstrated by
immunohistochemistry (Saunders et al., 1998; Saunders et al., 2000). Recently data
have been extended to include expression of the ER(32 splice variant (Chapter 3
and (Saunders et al., 2002a; Scobie et al., 2002), however the relative amounts of
ER proteins in specific cell types has yet to be determined. Therefore in tissues
varying levels of expression of ERs, and the presence of splice variants will result in
different homo- and heterodimers forming.
5.4.4 The Ability of the SRC-1 to Alter ERa or ER01 Transcriptional Activation
in the Presence of E2
In this study the SRC-1 co-activator was co-transfected into the Hep G2 cells
together with a human ER. In the presence of E2 and it was found that the SRC-1
isoforms had a variable impact on gene transcription. At 10"8M E2, the SRC-1 e and
SRC-1 a co-activators increased human ERa's ability to initiate gene transcription,
however when 10"7M E2 was added to the cells, SRC-1 e inhibited hERa's activity
and SRC-1 a increased the activity compared to hERa without the co-activator.
Human ER|31's transcriptional activity was slightly decreased in the presence of
SRC-1 e and SRC-1 a. Therefore these results are variable with different
concentrations of ligands, hence more work is required to determine the precise
response of ERs with SRC-1 transfected into the cell. The hER|32 variant did not
activate gene transcription either with or without the SRC co-activators.
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The SRC-1a and SRC-1e isoforms not only differ in their ER-binding properties but
also in their ability to potentiate the transcriptional activity of the human ER in
transiently transfected Cos 1 cells (Kalkhoven et al., 1998). The extra LXXLL motif
in the SRC-1a isoform increases the affinity for the ER in vitro but it does not appear
to be responsible for the functional difference between the two isoforms (Kalkhoven
et at., 1998). This difference has been proposed to be due to a second activation
domain (AD2) that is CBP independent and is suppressed in the SRC-1a isoform.
Therefore SRC-1 exists as functionally distinct isoforms which are likely to play
different roles in ER-mediated transcription (Kalkhoven et al., 1998). However, this
effect was found to be cell and promoter dependent. SRC-1 e stimulated ER
mediated transcription on various reporters with SRC-1 a only enhancing activity on
an ERE-tk-Luc reporter (Kalkhoven et al., 1998) not with a 3x ERE as used in my
experiments. The inability of SRC-1 a to potentate the transcriptional activity of the
ER on simple reporters and the oxytocin reporter suggests that on some promoters
the recruitment of CBP/p300 is not sufficient for maximal ER-mediated transcription
in transiently transfected cells (Kalkhoven et al., 1998). However, it has been
documented that there are cell differences in transient transfection studies, for
example; Cos 7 cells showed a greater stimulation by SRC-1 e than HeLa cells
(Kalkhoven et al., 1998). In the current experiments using Hep G2 cells, SRC-1 a
stimulated hERa transcriptional activation more than SRC-1 e, however, with hER|31
there was very little difference between the results obtained in the presence of the
two co-activator isoforms. To support this, recently Ramsey et al have demonstrated
in CHO-KI cells with a 2x ERE, that SRC-1 can increase hERa transcriptional
activation but not hER|31 (Ramsey et al., 2003).
Co-transfection of SRC-1 and ER(31 has previously been shown to increase the
basal level of transcriptional activation of an ERE reporter even in the absence of
oestrogenic ligand in Cos 1 cells (Kalkhoven et al., 1998; Tremblay and Giguere,
2001) consistent with a ligand-independent effect of SRC-1 on ER(31. However, the
basal level of transcriptional activation was not increased when SRC-1 was added
to mouse ERa in the absence of ligand (Tremblay and Giguere, 2001). This finding
was observed in the current study but only in the co-transfection studies in which
ERa and ER|3 were co-transfected and SRC-1 e was present.
Chapter 5 Functional Studies 232
In the absence of ligand it has been demonstrated that ERa and SRC-1 both tagged
to different FPs, are diffusely distributed within the nucleus of MCF-7 cells (Stenoien
et al., 2000). Addition of E2 results in a substantial overlap between the two proteins
therefore suggesting that a significant portion of the SRC-1 is associated with ERa.
In the cells examined, E2 caused the SRC-1 to become punctate (focal) and overlap
with the distribution of ERa, whereas in the absence of ERa or presence of
antagonists, SRC-1 did not redistribute. Stenoien et al have also demonstrated that
the ER-SRC interaction system is very dynamic (Stenoien et al., 2001b).
Photobleaching studies (FRAP) show that in the absence of ligand ER and SRC-1
have a rapid complex exchange, in the presence of E2 the interactions are less
transient and the exchange rate is reduced but remains highly dynamic.
Ligand binding is known to induce conformational changes that reveal interaction
surfaces required for SRC-1 binding and different ligands bound to ERa or ER(31
are able to induce differential recruitment of co-activators (Hall et al., 2002).
Structural studies provide insight into the importance of helix 12 for co-activator
interactions. The E2 bound ER LBD exists in a specific conformation which is
different to the conformation when other ligands are bound (Stenoien et al., 2001b).
One difference is the position of helix 12 which forms a surface that is important for
AF-2 activity after binding agonists. In particular the co-activator NR box lies in the
groove formed by the agonist-induced re-positioning of helix 12 (Shiau et al., 1998).
These published studies provide a structural mechanism for the differential effects of
agonist and antagonists and highlight that re-arrangements involving helix 12 are
very important for ER activity and interactions with co-activators. Deletion
experiments have shown the importance of helix 12 in the ER's re-organisation and
therefore ER's function (Shiau et al., 1998; Stenoien et al., 2001b). Weatherman et
al used fluorescence resonance energy transfer (FRET) to determine that the
interaction of ERa with LXXLL-containing peptides was dependent on the AF-2
domain. And that the interaction, although very weak, could occur in the absence of
ligand but was dramatically stabilised in the presence of ligand (Weatherman et al.,
2002).
Kraichely et al used GST pull-down and yeast two-hybrid assays to determine the
differences in the relative strength of interaction of human ERa and hER|31 with
SRC-1 in the presence of agonist ligands, they suggested that these differences
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may prove to be physiologically important and contribute to selective activities
depending on the expression levels of the co-activator in particular cell types
(Kraichely et al., 2000). Human ERpi interacts with SRCs with lower affinities
compared to hERa (Kraichely et al., 2000; Wong et at., 2001), therefore giving a
possible reason for it's lower transcriptional activity.
In this study it has been demonstrated that the presence of SRC-1e with co-
transfections of hERa with hER(31 or with hER(32, increased transcriptional activity
and opposed any dominant negative effect observed with hER|32. The presence of
SRC-1e increased the reporter gene activation with hERa and hER|31, and ERa
with ER|32, to a greater extent than that of hERa alone. Co-transfections with hER|31
and hER(32 showed the transcriptional response was increased in the presence of
SRC-1e. This observed increase in reporter gene transcription despite the presence
of the hER|3 may be due to the cells becoming saturated with SRC-1. It has been
proposed that the decrease in reporter gene transcription when ERp forms
heterodimers is possibly due to a decrease in ability of the dimer to recruit co-
activators (Peng et al., 2003). Therefore in a system such as the one demonstrated,
over expression of the SRC-1 aids transcription. It was also shown that when the
hER|3 variants were co-transfected with SRC-1 e in the absence of E2 transcriptional
activity increased, further supporting the theory of an alternative activation
mechanism.
In these studies, RT-PCR with primers specific for SRC-1 a and SRC-1e detected
both mRNAs in Hek 293 and Hep G2 cell lines (data not shown). Needham et al
have also demonstrated that mRNAs for SRC-1 a and SRC-1 e was expressed in
these cell lines, but at a ratio of 1:2. However their relative protein concentration is
still unknown (Needham et al., 2000).
5.4.6 Conclusions
My findings, alongside other published data, suggest that in human tissues
activation of oestrogen-responsive genes will be influenced by the tissue-specific
expression of ERa and/or the ER|31 wild type and/or ER(32 variant, the ligand
present, the affinity of the receptor for individual ERE sequences, ligand and ERE-
induced changes in the receptor conformation, the presentation of transcriptionally
productive surfaces for interaction with other transcription factors and the
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contribution of numerous transactivating factors in the promoters of oestrogen
responsive genes. This level of complexity enables cells with these receptors to
exert exquisitely fine-tuned control over cellular functions in response to ligands.
Due to these complex interactions it is very difficult to generalise for a certain
receptor or a certain ligand what the response will be in vivo, therefore careful
consideration is required when applying results such as these to a more
physiological system.
Chapter 6
Impact of Activation of the MAP kinase Pathway on
Oestrogen Receptors
6.1 Introduction
It has been demonstrated in previous chapters that the different oestrogen receptors
can co-localise within the nucleus of the same cell (Chapter 4 and Stenoien et al.,
2000) and functional studies have shown that the receptor isoforms have different
transcriptional activation potential with different ligands (Chapter 5 and Hall and
Korach, 2002). Sequence analysis has revealed conservation of some amino acids
within the ligand binding domain and DNA binding domains of ERa and ER|31. Both
receptors bind to oestrogenic ligands, with some affinity differences (Kuiper et al.,
1998) and activate gene transcription to fairly similar extents. However, the ER|32
splice variant is truncated at the C-terminus and therefore lacks the specific amino
acids which encode for the AF-2 region and hence cannot be activated by ligands
(Pettersson and Gustafsson, 2001). My functional studies have demonstrated that
hER(32 can have a dominant negative effect on hERa, but acts to increase gene
activation when co-transfected with hERp 1 in Hek 293 and Hep G2 cells. Similar
results have been recently documented in Cos 1 and Cos 7 cells with an ERE
reporter (Peng et at., 2003). It has also been observed that in the absence of E2,
hER(32 sometimes shows an increase in gene transcription when present with
hER(31 and/or SRC-1e. Therefore my results have lead to the suggestion that
hER|32 is activated through an alternate, ligand-independent mechanism.
6.1.1 AF-1 Domain and Phosphorylation
ERa and ER(3 possess a constitutive N-terminal activation function (AF-1) whose
activity can be modulated by kinase signalling pathways. A serine residue (Ser118)
in the A/B domain of human ERa has been shown to mediate epidermal growth
factor signalling through the Ras/MAPK signalling cascade (Kato et al., 1995).
However, Ser118 of ERa does not seem to be involved in the recruitment of co-
activators (Webb et al., 1998). It has been demonstrated that the mouse ER|31 can
also be activated by the Ras pathway and this effect is mediated through a Serine
residue (Ser124) in the A/B domain (Tremblay et al., 1997). More recently it has
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been demonstrated ERp contains two Serine residues within the AF-1 region. These
serine residues positioned at 87 and 106, are involved in the phosphorylation of the
receptor by MAP kinase (Driggers et al., 2001; Rochette-Egly, 2003). It is also within
the AF-1 region of ER|3 that upon ER phosphorylation, co-activators such as SRC-1
can be recruited (Tremblay et al., 1999a).
6.1.2 Growth Factor Stimulation
Accumulating evidence has demonstrated significant cross-communication between
oestrogen receptors and peptide growth factor signalling pathways with some
reports suggesting that growth factors may promote activation of ERs even in the
absence of natural ligands (Marquez et al., 2001). Agents capable of exerting such
ligand independent activation of ER include epidermal growth factor (EGF) (Ignar-
Trowbridge et al., 1996; Kato et al., 1995; Kato et al., 1998) and insulin-like growth
factor (Ignar-Trowbridge etal., 1996; Kato eta!., 1998; Lee etal., 1997).
In the absence of oestrogens in vivo administration of EGF mimics the effects of
oestrogen on the mouse reproductive tract (Curtis et al., 1996; Ignar-Trowbridge et
al., 1996). In mice lacking ERa expression (aERKO) both oestrogen- and EGF-
stimulated uterine growth is blocked, although the EGF signalling pathway has not
been disrupted (Curtis et al., 1996). In addition, EGF alone can increase the
expression of the progesterone receptor in the mammary glands in an ER-
dependent manner, mimicking the effects of oestradiol. Likewise, inhibition of EGF
action in the mammary gland blocks oestradiol-induced expression of the
progesterone receptor and development of terminal end buds (Ankrapp 1998). In
EGF receptor knock out mice, the stromal but not the epithelial response to
oestradiol is severely limited in both the uterus and the vagina (Horn et al., 1998).
The conclusion drawn from these results is that the ERs may mediate transcription
of target genes by integrating signals from growth factor activated pathways as well
as from ligand binding, especially in reproductive tissues.
6.1.3 Epidermal Growth Factor Receptor (EGFr) and Activation
The EGF receptor is a 170-kDa transmembrane glycoprotein that consists of an
extracellular ligand-binding domain in its amino terminus, a transmembrane
spanning region and a cytoplasmic EGF stimulated protein kinase in its C terminus
(Marquez et al., 2001). Following binding to the EGF ligand, the receptor dimerises
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and undergoes transphosphorylation at discrete tyrosine residues. This provides
binding sites for signalling or linker/adapter molecules that contain Src-homology 2
domains and the recruitment of additional signalling molecules (Levin, 2003). Such
proteins include non-receptor tyrosine kinases such as Src, Grb or Sos members.
Signalling cascades are then triggered, as pictured in Figure 6.1, dependent on the
translocation, membrane association and activation of tyrosine, serine/threonine and
lipid kinases including ras, raf, protein kinase C and phosphotidylinositol 3-kinase
(PI3K). Kinases translocate to the nucleus where they phosphorylate and thereby
activate transcription factors, such as ERK, that induce a variety of intermediates or
effectors (Levin, 2003; Marquez et al., 2001).
Figure 6.1. EGF activating EGF and the signalling cascade resulting in activation of ERa.
Taken from Levin (2003).
6.1.4 Insulin-like Growth Factor Activation
As well as evidence for an interaction between the EGF and ER signalling pathways
there is evidence indicating cross-talk between the IGF-1 system and ER. IGF-1
binding activates its receptor, leading to PI3K/AKT activation, increased ERa
synthesis and augmented ERa transcriptional activity. This is suggested to result
from the phosphorylation of serine residue (Ser118) in the AF-1 region (Martin et al.,
2000). Similar to EGF receptor activation, IGF-1 activates aspects of uterine cell
F.GF
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proliferation in vivo, and this is dependent on ERa (Klotz et at., 2002). In addition E2
can stimulate the activity of many proteins associated with the IGF-1 signalling
cascade including insulin receptor substrate (IRS) proteins, IGF-I receptors, and
IGF-binding proteins (Lee et ai, 1999). Therefore, there appears to be an important
cooperation and cross-talk between these two systems.
6.1.5 Alternative ER02 Activation Pathways
It has been recently documented that the oestrogen receptor can become rapidly
activated within seconds, which cannot be explained by the classical steroid ligand
mechanism (Levin, 2003). Data has been published regarding the human ERa and
mouse ER|31 and their abilities to be phosphorylated (discussed in the literature
review), however relatively nothing is understood about hER|31 phosphorylation and
there are no publications concerning phosphorylation of the ERp2 variant. ERp2
lacks amino acids essential for the AF-2 region and therefore cannot be activated in
the classical ligand dependent manner as demonstrated for ERa and ER|31 (shown
in Chapters 4 and 5). Sequence alignment (Chapter 3) has shown that the amino
acid sequences of human ER(31 and ERp2 within the A/B domain are identical,
hence it can be assumed that ERp2 has the same phosphorylation sites as ERpi in
this N-terminal region. Therefore it is possible that the ERp2 could be
phosphorylated and hence be activated in the same way as ERpi.
6.1.6 Aims
The aims of this chapter were to investigate if the ERs could be activated to
stimulate gene transcription following growth factor induced phosphorylation and
whether ERp2 could be activated by this alternative pathway. It was also important
to determine the localisation of the growth factor receptor and to determine whether
it was present in the same cells that expressed ERp2 so that the alternative
pathway was physiologically viable.
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6.2 Methods
6.2.1 Transient Transfections for Confocai Microscopy
To be able to analyse human ERa, ERfM and ER|32 protein expression in living
cells, the full length cDNAs were cloned into the fluorescent protein vectors (EGFP
and DsRed) purchased from Clontech as described in section 2.9 and Chapter 4.
Transfections were performed as described in section 2.10.2.6. Hek 293 or Hep G2
cells were plated onto 35mm glass bottom microwell dishes (Plastik® Corporation).
For each dish used, 2pg DNA was transfected into the cells using JetPEI (section
2.10.2.2). After 48 hours the media was removed and the cells washed in PBS at
room temperature. To maintain the cells during analysis, 1ml PBS with 25mM
Hepes buffer (Sigma) was added to the dish. The epidermal growth factor used was
diluted to 10~8M in PBS/Hepes and added to the dish that was already in place on
the warm plate (37°C) on the confocai microscope (LSM510, Zeiss). Images were
captured over a period of time at 10 minute intervals for 1 hour and exported into
Photoshop 7.0 (Adobe, CA).
6.2.2 Identification of EGFr and IGFr mRNA by RT-PCR
Hek 293 and Hep G2 cells were collected, total RNA extracted and oligo DT primed
cDNA synthesis performed as described in section 2.3.
6.2.2.1 Screening Primers
Specific primers were chosen, as outlined in section 2.5.1, to amplify regions of the
human EGF receptor and human IGF receptor cDNAs in order to be able to
determine whether mRNAs with specific sequence homology were expressed in the
cell lines (Table 6.1).
Table 6.1. PCR primers used for detection of EGFr and IGFr and the GAPDH positive
control.
5' primer 3' primer Product size
EGFr GTGTGCCCACTACATTGACGC GTTGGACAGCCTTCAAGACC 237 bp
IGFr ATGCTGTTTGAACTGATGCG TCTCCATGTTCTCTGGCTCC 166 bp
GAPDH CTGCACCACCAACTGCTTAGC ATGCCAGTGAGCTTCCCGTTC 247 bp
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6.2.2.2 RT-PCR
PCR was carried out using Mega Mix (Microzone) as described in section 2.5.2.2.
The PCR reactions were annealed at 55°C for 30 seconds using the EGFr and IGFr
oligonucleotide primers (Table 6.1). DNA fragments were analysed by migration on
agarose gels (section 2.6.1).
6.2.3 Immunocytochemical Analysis of EGFr in Cell lines
Immunocytochemical analysis was performed on the cell lines (Hek 293 and Flep
G2) that were used in the transient transfection studies. The cells were plated out as
in section 2.10 onto chamber well slides (Nalgene Nunc International). The cells
were left to grow for 48 hours changing the media after 24 hours.
After 48 hours the cells were fixed in ice-cold methanol (section 2.10.6.4) and
immunocytochemistry performed as section 2.11, without the de-waxing and antigen
retrieval stages. The cells were incubated in 3% hydrogen peroxide in methanol for
30 minutes and then blocked with Avidin/Biotin in NRS/TBS/BSA as described in
section 2.12. The monoclonal anti-EGF receptor antibody (Sigma) was added at a
1:50 dilution and the cells incubated overnight at 4°C. After washing the cells, they
were incubated with Envision secondary HRP complex (DAKO) for 30 minutes at
room temperature. The cells were then washed and developed with DAB to
visualise receptor localisation (section 2.12). The slides were counter stained with
haematoxylin, dehydrated and mounted with pertex, then photographed as
described in section 2.13.
6.2.4 Transient Transfections
The ERa, ER|31 and ERp2 constructs and the 3x ERE-Luc reporter were prepared
as previously described (section 2.7). The transfections were carried out as
described in section 2.10.2.3 and Chapter 5. For every experiment, each condition
was performed in duplicate, and the experiment performed a minimum of three
times.
JetPEI (Cambridge Biosciences) and Gene Porter (Gene Therapy Systems)
transfection reagents were used for transfecting the cells (section 2.10.2) in the
experiments. Using the Hek 293 and the Hep G2 cells, Vg ER, 0.5g 3x ERE-Luc
and 0.2^ig pRL-CMV was used in each well of the 12 well plate. The growth factors
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were added to the cells four hours after transfection. EGF and IGF were added at
concentrations ranging from 10"14M to 2.5x10"5M.
The Luciferase Assay (Promega) was carried out as described in Section 2.10.2.4.
The results were normalised and are presented as a fold increase over the control
ER.
6.2.5 EGF Activation of the MAP Kinase Pathway
6.2.5.1 Transient Transfections for Western Analysis
Cells were plated out into 60mm dishes (Cellstar®) (section 2.10.2.7) and
transfected with 6^g plasmid DNA using JetPEI (section 2.10.2.2). The cells were
incubated with either media containing 10% charcoal stripped fetal calf serum, or
media containing 10% serum replacement (Sigma, Catalogue Number; S-9388).
After 48 hours the cells were harvested using the Nuclear Extraction method
(section 2.10.2.7.1.2).
6.2.5.2 Western Blot Analysis
The collected protein samples were mixed with SDS/|3-mercaptoethanol, boiled and
loaded onto the "SDS" polyacrylamide gel (section 2.10.2.7.3.1). Once the proteins
had migrated through the gel they were blotted on an Immobilion membrane
(section 2.10.2.7.3.3). After the protein had been transferred onto an Immobilon
membrane the gel was Coomassie stained (section 2.10.2.7.3.4) to ensure that the
proteins had transferred properly. Membranes were blocked with 5% milk/TBST as
discussed in section 2.10.2.7.3.4 prior to overnight incubation with the primary
antibody.
6.2.5.3 The MAP Kinase and Phosphorylated MAP Kinase Antibodies
Polyclonal antibodies directed against p44/p42 MAP kinase and phosphorylated
MAP kinase, were purchased from Cell Signalling Technology. The MAP kinase
p44/p42 antibody detects total (phosphorylation-state independent) p44 and p42
MAP kinase proteins without cross-reacting with JNK/SAPK or p38 MAP kinase
homologues. The MAP kinase and phosphorylated MAP kinase antibodies were
incubated with the membrane overnight at 4°C at a 1:1000 dilution.
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The following day the membranes were washed and an HRP conjugated anti-rabbit
IgG (SAPU) secondary antibody (1:5000) was incubated with the membranes for 2
hours, prior to ECL developing (section 2.10.2.7.3.4).
6.2.6 Immunohistochemical Analysis of EGFr Localisation in Tissues
Human, macaque and marmoset tissues were previously collected as described in
Chapter 3. The tissues had been fixed and embedded in paraffin wax blocks and
were held in an archive in the histology section at the MRC Human Reproductive
Sciences Unit (Edinburgh).
Immunohistochemical studies were carried out on tissues using an EGFr specific
monoclonal antibody using methods described in section 2.11. Slides were
subjected to 5% hydrogen peroxide in methanol for 30 minutes at room
temperature. The Avidin-Biotin blocking stage was excluded and instead the
sections were blocked in NRS/TBS/BSA for 30 minutes at room temperature. The
primary anti-EGFr antibody was diluted in NRS in a 1:50 dilution and added to the
sections, which were then incubated overnight at 4°C.
The following day, one drop of Envision secondary complex (DAKO) was applied to
the sections for 30 minutes at room temperature to amplify the signal. The sections
were washed and DAB was used to develop the signal. The slides were counter
stained with haematoxylin, dehydrated and mounted with pertex, then photographed
as described in section 2.13.
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6.3 Results
6.3.1 Confocal Microscopy
To be able to visualise ERa, ER01 and ER02 in Hek 293 and Hep G2 cells and the
effect of treatment with EGF, the ER0 constructs were tagged with the EGFP and
the ERa to DsRed. In Hek 293 cells the FP-tagged ERa, ER01 and ER02 were all
distributed in a diffuse pattern within the nucleus of the live cell in the absence of
EGF. Addition of 1CTSM EGF induced the receptors to redistribute into discrete foci
after 60 minutes (Figure 6.1 & 6.2a). The intensity profiles (Figure 6.2b) detail the
focal distribution of the ER02-GFP receptor in three individual cells.
In Hep G2 cells, ERa, ER|31 (data not shown) and ER02 remained in a diffuse
distribution in the presence of EGF, even after 60 minutes (Figure 6.3a & Figure
6.3.b).
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Figure 6.1. Human (a) ERa-DsRed, (b) ERp1-EGFP and (c) ER|32-EGFP expression in Hek
293 cells with addition of 10"8M EGF. ER constructs were transiently transfected into Hek
293 cells, maintained in culture for 48 hours and analysed under a confocal microscope.
Cells were washed and treated with 10"8M EGF. Confocal images after 60 minutes in the
presence of EGF.
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Figure 6.2a. ERf$2-EGFP expression in Hek 293 cells with addition of 10"8M EGF. The
ER|32-EGFP construct transiently transfected into Hek 293 cells, maintained in culture for 48
hours and analysed under a confocal microscope. Cells were washed and treated with 10"8M
EGF. Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 6.2b. ER|32-EGFP expression in Hek 293 cells with addition of 10" M EGF for 60
minutes. Images are of three cell nuclei showing a graph of the intensity profile of the
fluorescent ER. The graph demonstrates the intensity of the fluorescence (y axis) along the
length of the line drawn through the nucleus, in the direction of the arrow (x axis). All graphs
shown have the same y axis values.
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Figure 6.3a. ER|32-EGFP expression in Hep G2 cells with addition of 10"8M EGF. The ERf52-
EGFP construct transiently transfected into Hek 293 cells, maintained in culture for 48 hours
and analysed under a confocal microscope. Cells were washed and treated with 10"8M EGF.
Confocal images taken over 60 minutes starting from time (t) 0, at 10 minute intervals.
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Figure 6.3b. ER|}2-EGFP expression in Hep G2 cells with addition of 10"8M EGF for 60
minutes. Images are of two cell nuclei showing a graph of the intensity profile of the
fluorescent ER. The graph demonstrates the intensity of the fluorescence (y axis) along the
length of the line drawn through the nucleus, in the direction of the arrow (x axis). All graphs
shown have the same y axis values.
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6.3.2 Detection of EGFr and IGFr mRNAs in Cell Lines
Primers specific for EGF and IGF receptors were used to perform PCR analysis on
pools of cDNA prepared from different cell lines (Figure 6.4). Following PCR
amplification products of the expected sizes were observed on gels: EGFr gave a
band at 237 bp, IGFr at 166 bp and GAPDH at 280 bp. EGFr was detected in Hek
293, Ishikawa, LnCap and Hela cells, but was absent from Hep G2 and Cos 7 cells
(Figure 6.4\ top panel). IGFr mRNA expression was detected Hek 293, Hep G2,
Ishikawa, LnCap and Hela cell lines, but was absent from Cos 7 cells (Figure 6.4\
middle panel). The positive control, GAPDH, was detected in all cell lines but was
absent in the negative control.
6.3.3 EGFr Expression in Cell Lines Identified by Immunocytochemistry
Immunocytochemical evaluation of the Hek 293 and Hep G2 cell lines confirmed
RT-PCR results. There was no detectable EGF receptor protein staining in Hep G2
cells, but immunopositive staining was present in some Hek 293 cells (Figure 6.5)
within the cytoplamsic and membrane regions.
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Figure 6.4. Detection of EGF receptor and IGF receptor mRNAs in cDNAs pools prepared
from cell lines. RT-PCR was performed using specific primers to detect EGFr (top panel; 237
bp) and IGFr (middle panel; 166 bp) and GAPDH (lower panel; 280bp) as a positive control.
The cell lines tested were (1) blank, (2) Hek 293, (3) Hep G2, (4) Cos 7, (5) Ishikawa, (6)
LnCap, (7) Hela. 100pb marker was run on all gels.

















Figure 6.5. Immunocytochemical analysis of EGFr protein expression in Hek 293 and Hep
G2 cell lines. Hek 293 cells (a) and Hep G2 (b) were stained with specific EGFr antibodies.
In some Hek 293 cells the cytoplasmic and plasma membrane regions stained
immunopositive for the EGFr protein, Hep G2 cells did not stain immunopositive for the EGFr
protein. Magnification is x20.
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6.3.4 EGF Transient Transfections
In transient transfection studies using Hek 293 cells, human ERa, ER(31 and ER(32
were stimulated to activate gene transcription via a 3x ERE-Luc reporter, in the
presence of EGF (Figure 6.6). A dose response increase in ERE activation was
observed for ERa, ER(31 and ERJ32 with 10"9M and 10"8M EGF, however at higher
concentrations (10~7M to 10"5M) activation was reduced and showed no increase in
activation compared to the control. ERa showed a slightly greater maximum fold
increase (reaching 5.7-fold) whereas ERpi (4.2-fold) and ER(32 (4.1-fold) showed a
similar extent of activation. In Hep G2 cells, EGF did not activate ERa, ER|31 nor
ER(32 (Figure 6.7).
6.3.5 IGF Transient Transfections
RT-PCR has detected IGF receptor mRNA within Hek 293 and Hep G2 cell cDNA
pools, therefore transient transfections in Hep G2 cells with ERa, ERpi and ER|32
and a 3x ERE-Luc reporter were performed with IGF treatment. These transfections
have demonstrated that IGF has the potential to activate gene transcription through
ERa (Figure 6.8). A maximal activation in gene transcription by the ERE reporter
was observed with 10"7M IGF (4.5-fold increase). However, no increase in gene
transcription was observed with ER(31 or ER|32 constructs.
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Figure 6.6. EGF dose response with ER transfected Hek 293 cells. Hek 293 cells were
transiently transfected using JetPEI transfection reagent, with hERa (A), hERpI (B) or
hER|32 (C), the 3x ERE-Luc reporter and the pRL-CMV internal control. Cells were treated
with a vehicle, or increasing concentrations of EGF, ranging from 1CT9M to 10"5M. Data are
displayed as fold induction of luciferase activity over the un-stimulated cell. Data are the
mean +/- SEM of 3 experiments.
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Figure 6.7. EGF dose response with ER transfected Hep G2 cells. Hep G2 cells were
transiently transfected using JetPEI transfection reagent, with hERa (A), hERp 1 (B) or
hERp2 (C), the 3x ERE-Luc reporter and the pRL-CMV internal control. Cells were treated
with a vehicle, or increasing concentrations of EGF, ranging from 10"14M to 10~6M. Data are
displayed as fold induction of luciferase activity over the un-induced cell. Data are the mean
+/- SEM of 3 experiments.

































Figure 6.8. IGF dose response with ER transfected Hek 293 cells. Hek 293 cells were
transiently transfected using Gene Porter transfection reagent, with hERa (A), hER(J1 (B) or
hERp2 (C), the 3x ERE-Luc reporter and the pRL-CMV internal control. Cells were treated
with a vehicle, or increasing concentrations of IGF, ranging from 10"14M to 10"6M. Data are
displayed as fold induction of luciferase activity over the un-induced cell. Data are the mean
+/- SEM of 3 experiments.
Chapter 6 Alternative Pathways 256
6.3.6 p44/p42 MAP Kinase Detection
Hek 293 and Hep G2 cells were incubated for 48 hours in media containing either
10% charcoal stripped fetal calf serum or 10% serum replacement and then
analysed for their MAP kinase content (Figure 6.9). A nuclear protein extract was
prepared from the cells. On Western blots Hek 293 and Hep G2 cells both showed
strong bands for p44 and p42 MAP kinases in extracts from cells incubated in both
serum or serum free extracts. The phosphorylated forms of MAP kinases are also
present in both cell lines, although the bands are stronger for the extracts incubated
with the serum replacement. The bands shown on the Western correspond to 44
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Figure 6.9. Western analysis for the presence of MAPK and Phosphorylated MAPK from the
extracts obtained from Hek 293 and Hep G2 cells. Samples tested with the specific
antibodies were (1) positive control, (2) Hek 293 cells treated with fetal calf serum, (3) Hek
293 cells treated with serum free media, (4) Hep G2 cells treated with fetal calf serum, (5)
Hep G2 cells treated with serum free media. SDS Protein markers were run on the gel.
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6.3.7 EGFr Expression in Testes Identified by Immunohistochemistry
Immunohistochemical evaluation of human, macaque and marmoset testes (Figure
6.9) detected immunopositive staining for EGF receptor protein in spermatogonia!
germ cells for all three species. In the human testis few EGFr positive cells were
detected reflecting both the variety of spermatogonia and also poor tissue
preservation. The receptor protein was localised to the cytoplasm of the germ cells
and around the membrane, consistent with the previously published data. Germ
cells were easier to identify in fixed sections of macaque and marmoset testes
(Figure 6.9.b, c).



















Figure 6.10. Immunohistochemical analysis of EGF receptor protein expression in the testis
of the human, macaque and marmoset. Sections from human (a), macaque (b), and
marmoset (c) were stained with the EGFr specific monoclonal antibody. Immunopositive
staining was observed in the cytoplasm and cell membrane of germ cells in all three species.
Unspecific staining, possibly of the acrosome, was observed in the marmoset section.
Magnification is x 100.
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6.4 Discussion
In the present study it has been demonstrated that cells which express the growth
factor receptor can activate transfected ER constructs to induce gene transcription
from an ERE promoter in the presence of growth factors probably via the MAP
kinase signalling pathway. Confocal analysis of Hek 293 cells transfected with FP-
tagged ER(32 variant protein has shown that this "oestrogen" receptor can
redistribute from a diffuse distribution to a discrete focal pattern within 10 minutes in
the presence of EGF. However, in Hep G2 cells this activation of ER|32 was not
observed. RT-PCR analysis revealed that EGFr mRNA was present in Hek 293 cells
but absent in Hep G2 cells, consistent with EGF stimulation of a phosphorylation
cascade resulting in activation of the ER only being detectable in the Hek 293 cells.
The activation of the ERE-Luc reporter by the ER(32 in EGF treated cells was in
marked contrast to the lack of transcriptional response in the E2 treated cells.
The ER|32 variant is truncated at the C-terminus and therefore lacks vital amino
acids encoding for the AF-2 region within the LBD which is required to activate gene
transcription. However, if there is an alternative pathway such as a growth factor
induced MAP kinase signalling cascade which has the ability to phosphorylate the
ER|32 and induce gene transcription, it may explain a possible function of the ER|32
variant. To assess whether cells which endogenously express the EGF receptor can
activate an ERE-Luc reporter gene via this alternative pathway, transient
transfections were performed. Both Hek 293 cells, which express EGFr, and Hep
G2 cells which don't, were used in transient transfection studies. The ERa, ER(31
and ER|32 all initiated gene transcription of the ERE-Luc reporter with low (10"9M
and 10"8M) concentrations of EGF in Hek 293 cells. As expected due to the absence
of EGRr, the ER constructs transfected into the Hep G2 cells were unable to initiate
transcription. However, IGF mRNA was found to be present in both Hek 293 and
Hep G2 cells by RT-PCR, therefore transient transfections were performed to
assess whether IGF can activate gene transcription through the ER. In Hep G2 cells
only ERa was activated to stimulate the ERE-Luc reporter with IGF, in a dose
responsive manner.
The 3x ERE-Luc reporter gene was stimulated to activate gene transcription via the
ERa, ER|31 and ER|32 at a low level compared to when ERa and ER(31 are
activated by E2. This minimal induction in reporter activity has been described in a
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recent publication; Marquez et al used hERa and an ERE reporter in Cos 7 cells
and reported that transcriptional activity was increased by 2-fold compared to E2
stimulation which resulted in a 14-fold increase in transcription (Marquez et al.,
2001). This published increase in activation corresponds to the 4-fold to 6-fold
increase I have demonstrated with ERa, ER|31 and ER|32 in Hek 293 cells,
compared to the 30-fold increase in activity with ERa in the presence of E2.
My results have demonstrated that although there are detectable levels of EGF
receptor mRNA and IGF receptor mRNA in Flek 293 cells, the protein expression
within these cells is low. Therefore, the low levels of transcriptional activation of the
oestrogen receptors in the presence of EGF or IGF may be due to the lack of EGF
or IGF receptors within the membrane and cytoplasm of the cells transiently
transfected with the ER construct.
Fluman ERa contains a Serine residue at position 118 within the AF-1 region, which
is phosphorylated by MAP kinase signalling cascades (Marquez et al., 2001 and
reviewed by Rochette-Egly, 2003). Tremblay et al have analysed the mouse ER|31
and showed it also contains a phosphorylation site (Ser124). Sequence alignment of
the human ERa, ER|31 wild type and ER|32 variant peptides (Chapter 3)
demonstrates a Serine118 residue in ERa and two conserved Serine residues in
both ER(31 and ER(32 (positions 87 and 106). These residues in the ER(31 have
been documented previously to be phosphorylated by the MAP kinase signalling
cascade (Rochette-Egly, 2003) but no previous data has shown these residues to
be present in hERp2. Therefore both hER|31 and hER|32 are able to be
phoshorylated in the same manner, and as ER|32 contains the highly conserved
DBD and dimerisation regions that ER|31 contains (Ogawa et al., 1998c) it could be
functionally activated.
It has previously been reported that IGF induces phosphorylation differently to EGF,
as shown with ERa (Flint et al., 2002). Therefore it may be that IGF can activate
ERa, but not ER|31 or ER|32, through the phosphorylation of Ser118 or through one
of the other serine residues (104, 105, 167) that are not present in the AF-1 region
of hERp. Flint et al demonstrated that in the presence of IGF, phosphorylated MAP
kinase p44 or p42 did not increase, in contrast to the increase observed with EGF,
however they did note that there was a high endogenous level of p44 and p42 that
could be "masking" any effect (Flint et al., 2002).
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Western analysis to detect phosphorylated and non-phosphorylated MAP kinases
with the cells was performed. Both p44 and p42 MAP kinases (Erk1 and Erk2)
function in the protein kinase cascade that plays a critical role in the regulation of
cell growth and differentiation. MAP kinases are activated through a wide variety of
extracellular signalling pathways including those activated by growth factors.
Activation of MAP kinases and signalling cascades occurs through phosphorylation
of threonine and tyrosine residues by upstream MAP kinase kinase (MEK) activities
(reviewed in the literature review Figure 1.17) (Levin, 2003). One aim in this study
was to determine whether the presence of EGF could upregulate the MAP kinase
signalling pathway. However, unstimulated Hek 293 and Hep G2 showed a high
endogenous level of phosphorylated MAP kinase activity (as shown in Figure 6.9)
therefore it was not possible to determine whether the phosphorylated MAP kinase
was upregulated upon EGF stimulation. The cells were originally maintained in 10%
charcoal stripped fetal calf serum, but as these cells showed a high level of
phosphorylated and non-phosphorylated MAP kinase, a serum replacement was
used to try to reduce this, however endogenous MAP kinase activity remained at a
high level. The phosphorylated MAP kinase showed less intense bands on the
Western (Figure 6.9) but the positive control (supplied with the antibody) also
showed a less intense band, therefore indicating that it was likely due to the
antibody. Therefore, the Western results have demonstrated that the MAP kinase
pathway is active within both the Hek 293 and the Hep G2 cells, so activation of
ERs via an alternative growth factor pathway is viable. Flint et al have previously
demonstrated that phosphorylated p44 and p42 MAP kinases are increased in a
dose responsive manner by EGF (Flint et al., 2002) in stromal and endometrial cells.
They therefore was reported that p44 and p42 may be responsible for the ER
phosphorylation and activation in the cells (Flint et al., 2002).
If the oestrogen receptors are activated through an alternative steroid ligand
independent pathway such as the growth factor pathway, as demonstrated in these
results, the physiological significance needs to be addressed. Immunohistochemical
analysis was performed on the testes of human, macaque and marmoset, where it
has previously been demonstrated (Chapter 3 and Saunders et al., 2002a) that both
ERpi and ER|32 are expressed. In the present experiments EGFr was detected in
the cytoplasm and membrane of spermatogonia! cells within the testes. Data from
Chapter 3 and previous published data (Saunders et al., 2002a) has shown that
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ER|32 is present in the germ cells of the human using specific anti-human ER(32
antibodies, and that ER(3 is present in these germ cells in human, macaque and
marmoset (Saunders et a/., 2001). Therefore it is physiologically possible that EGF
can activate the EGF receptor in the cell membrane, which in turn phosphorylates
and hence activates the MAP kinase signalling cascade within the cytoplasm. This
would result in the phosphorylation of ERpi wild type and ER|32 variant in the
nucleus and induction of the classical ERE to initiate gene transcription. In future
studies it would be valuable to determine EGFr expression in tissues other than the
testes and to perform dual immunohistochemical experiments so that both ER|32
and EGFr protein expression could be observed in the same section and therefore
be assured that both receptors are localised within the same cell. However, in this
study both the ER|32 and the EGFr antibodies were raised in mouse, therefore a
different EGFr antibody needs to be optimised before dual experiments can be
carried out. The co-expression studies of ERa, ER|31 and ER|32 and the EGF
receptor is required in all tissues which have been reported to express the
oestrogen receptors.
The importance of growth factor induction of ER transcriptional activity to normal
physiological responses is not clear at the present time. It is possible that growth
factors maintain moderate levels of ER transcriptional activity when oestrogen levels
are low. Alternatively, signalling cascades initiated by growth factors binding to their
receptors may modulate transcriptional activity of ligand-occupied ER and thereby
increase the magnitude of target gene expression (Smith, 1998). Low oestrogen
levels could increase growth factor expression and together these factors may
promote a stronger or more sustained biological response in target tissue. It is also
possible that cross-talk pathways may sensitise the ER to suboptimal stimulation by
low levels of oestrogens and thereby promote biologically meaningful responses
under conditions in which the ligand stimulus alone would be unable to generate a
significant response (Smith, 1998).
Altered elements in growth factor signalling pathways, such as receptor over
expression, may directly influence steroid hormone action in human breast cancers
(Nicholson et at., 1999). Enhanced cross-communication between growth factor
receptor pathways and ER during cancer progression could contribute to ER
activation in the absence of ligand. Current findings show that the EGF receptor
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plays a leading role in the progression of breast tumours, therefore further
delineation of these complex pathways in breast cancer cells may lead to the design
of novel therapies that combine anti-growth factor signalling strategies with anti-
hormone measures. Cross-communication between peptide growth factor pathways




Oestrogens are key regulators in male and female reproductive function, as well as
playing an important role in other tissues including the cardiovascular system and
bone. Oestrogen action is mediated via high affinity nuclear receptors expressed in
target tissues. Studies in this thesis were aimed at expanding our understanding of
the impact of endogenous and exogenous oestrogenic ligands on cell function by
focusing on expression and activation by oestrogen receptors.
In human as well as other mammals, two oestrogen receptor genes; ERa and ER|3,
have been cloned. A number of splice variant isoforms of human ER|3 have been
described (Inoue et at., 1996; Lu et at., 1998; Moore et at., 1998; Ogawa et a!.,
1998c). These splice variants do not appear to exist in rodents and expression in
other species has not been investigated. In this thesis I have concentrated on the
ER|3 wild type and the ER|32 splice variant.
The aims of this thesis were several fold, to begin with it was necessary to
determine whether ER|3 wild type and ER|32 variant forms exist in primates, as well
as in human, and to determine the localisation of these receptors within reproductive
tissues. This was performed using RT-PCR from tissue and cell cDNA pools and
immunohistochemical and immunocytochemical analysis using anti-human ER(31
and anti-human ER(32 antibodies.
Once the expression was determined, fluorescently tagged ER constructs were
used to examine the localisation and redistribution of the receptors in the absence
and presence of different oestrogenic ligands using a confocal microscope. After
observing the differences in the activation potential of oestrogenic ligands, functional
studies were performed to assess the ability of these ligands to initiate gene
transcription via ERa, ER|31 or ER(32 using ERE-luciferase reporter constructs.
Sequence analysis has revealed that the ER[32 variant does not contain the AF-2
region and limited functional studies have suggested that it cannot be activated by
addition of ligand. My results extended these findings and showed that FP-tagged
hER|32 did not redistribute upon addition of ligand and was unable to activate an
ERE-Luc reporter in transient transfections studies. However immunohistochemical
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investigations have detected ER|32 protein in several tissues and therefore
investigations into alternative activation pathways were performed to determine
whether it could be activated in the absence of oestrogenic ligand.
7.1 Differential Expression of the Oestrogen Receptor beta in the
Reproductive Tract
The results described in this thesis as well as recently published data, have
demonstrated that there is differential expression of the ERa, ER|31 and ERf52
proteins in human tissues. ER|31 and ER[32 mRNAs were detected in human and
primate tissues by RT-PCR, however immunohistochemical analysis failed to detect
ER|32 protein in macaque or marmoset tissue. In this thesis the anti-hER(32 antibody
had been raised to a peptide equivalent to the C-terminus of human ER(32.
Sequence alignment of the primate ER|32 proteins, predicted from analysis of the
open reading frames, revealed that in the macaque the ER|32 protein was truncated
due to an insertion of a short intronic sequence which introduced a premature stop
codon. Although the marmoset ER(32 protein was similar in size to that found in
human, the sequence found at the C-terminus was not conserved.
In the human and primate ovary ERa and ER|3 are differentially expressed within the
granulosa cells of the developing follicles (Saunders et al., 2000). From my results it
was observed that ER|32 protein is expressed within the ovary of the human in a
similar distribution to that of ER|31, whilst RT-PCR has detected ER(31 and ERp2
mRNA in ovary cDNA pools from human, macaque and marmoset consistent with
previous studies (Henderson et al., 2003; Saunders et al., 2000).
It has previously been demonstrated that in the endometrium ERa and ER|3 are co-
expressed in multiple cell types including the stromal and epithelial cells lining the
glands, but only the ER|3 protein is present in the endothelial cells lining walls of
blood vessels (Critchley et al., 2001). During the proliferative phase ERa mRNA is
300-fold that of ER|3 mRNA (Matsuzaki et al., 1999). Henderson ef al have shown
that both ER|31 and ER(52 mRNAs are expressed in the endometrium (Henderson et
al., 2003). In the present studies ER(31 and ER|32 mRNAs were detected in human,
macaque and marmoset endometrial cDNA pools and pattern of ER|31 protein
expression was similar in macaque, marmoset and human endometrial tissues
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sections. Consistent with other studies from our laboratory (Henderson et al., 2003)
ERp2 protein was shown to be immunolocalised to human endometrium.
The immunohistochemical results from my studies have demonstrated for the first
time that primate placental tissues contain ER|31 protein, expressed within the nuclei
of perivascular cells surrounding the blood vessels and the syncyiotrophoblast. The
same pattern of expression was also observed in human placental tissue. However,
immunohistochemical analysis and RT-PCR failed to detect ER|32 protein or mRNA
in the human, macaque or marmoset placental tissues.
In human and primate testes, in contrast to rodents, ERa mRNA and protein are not
expressed (Pais et a/., 2003; Saunders et at., 2001). In the current study RT-PCR
has detected mRNA for both ER(31 and ER(32 in human, macaque and marmoset
testes cDNA pools. ER|31 protein has been shown in this study and in previous
studies (Saunders et al., 2002a) to be present in the nuclei of multiple cell types
including pachytene spermatocytes and round spermatids. Immunohistochemical
analysis showed staining was less intense in Sertoli cells than in the germ cells in
human and primates. The most intense immunopositive staining for ER(32 protein in
human testes was detected in Sertoli cells and spermatogonia, with low or variable
levels of expression in some spermatocytes.
The results from this thesis indicate that the marmoset is a good model in which to
examine the impact of oestrogens on the reproductive organs as it expresses similar
oestrogen receptors to the human and in a similar distribution. The human and
marmoset ER|31 and ER(32 peptide sequences are highly conserved, except for the
last five amino acids in the C-terminal region of the marmoset ER(32.
Within reproductive tissues the expression of ERa and ERp protein is not constant
especially in abnormal tissue. For example ER(32 expression is upregulated
whereas ER|3 wild type expression is down regulated in breast cancer tissues,
therefore suggesting that ER(31 may have a role in normal breast tissue oestrogen
signalling but in breast cancer, expression of ER|32 increases (Omoto et al., 2002).
Saji et al reported that ER|32 was expressed in breast cancer tissue, whereas ER|31
was absent (Saji et al., 2002). However, Saunders et al found no quantitative
relationship between staining for the two ER|3 subtypes, although they did show
both receptors were present (Saunders et al., 2002b).
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Fuqua et al have demonstrated that several ER(3 variants are present in breast
cancer cell lines (Fuqua et al., 1999). A recent publication has reported that in
normal and neoplastic breast tissues the level of expression of the C-terminally
truncated ERp variants; ER(32 and ER|35, is markedly higher than the full length
ER|31. These data suggest that the ER|32 and ER|35 variants may have a role in
modulating oestrogen and possibly anti-oestrogen action in human breast cells
(Peng et al., 2003).
Another example of a tumour tissue in which expression of ERp 1 may modulate
oestrogen responsiveness is prostate cancer. There have been many conflicting
reports of ERa or ERp expression being upregulated in cancer progression
(Pasquali et al., 2001; Royuela et al., 2001; Tsurusaki et al., 2003). Overall the
results demonstrate that both ERa and ERp are present within the prostate and that
oestrogens exert their effects on human prostate through ERpi (Pasquali et al.,
2001). In benign prostatic hyperplasia and prostate cancer both ERa and ERp are
upregulated, but ERp to a greater extent (Royuela et al., 2001).
Anti-oestrogens, for example, tamoxifen, are agonists when signalling through the
AP-1 element with ERp and therefore over expression of ERpi in tumours may
explain a lack of effectiveness of anti-oestrogen therapy in some cancer patents
(Speirs et al., 1999). Hence, in cancers such as breast cancer appropriate ERp-
specific ligands, perhaps in combination with ERa-specific ligands may be useful in
improving therapy.
7.2 Functional Analysis of the Oestrogen Receptors
The localisation studies proved an important initial step in determining the sites of
oestrogen receptor expression and an indication of cell types that oestrogenic
ligands could be expected to target. Subsequent studies focused on the ER
isoforms and their ability to activate gene transcription with various oestrogenic
ligands. In addition to transient transfections of individual receptors, transcriptional
activity of co-transfected ERs (ERa/ERpi, ERa/ERp2, ERpi/ERp2) was assessed
as this would reflect the ER expression in cells within the reproductive tissues. To
do this two experimental strategies were employed, firstly observation studies using
FP-tagged ERs and secondly, assessment of transcriptional activity using ERE-
luciferase reporter constructs.
Chapter 7 General Discussion 268
In the absence of ligand the ERs tagged to the fluorescent proteins were diffusely
distributed within the cell nucleus. Upon addition of oestrogenic ligands receptors
had the capacity to redistribute into discrete foci as demonstrated in previous
studies (Htun et a/., 1999; Stenoien et al., 2001a). Transient transfections with an
ERE-luciferease reporter were also performed to ascertain whether the ER
redistribution to focal regions was consistent with an increase in reporter gene
activation.
Ligand-activated oestrogen receptors bind with high affinity to specific DNA
sequences, known as oestrogen response elements (EREs), located within the
regulatory regions of target genes. The sequence of the EREs are reported to
influence receptor activity (Klinge et al., 1997). It has been shown that if the ERE
sequence deviates from the consensus sequence by a single base pair, the receptor
exhibits a reduced affinity and decreased transcriptional activity (Wood et al., 2001).
Similar results were observed in the present study and additionally the cell types
used for transfections were also found to influence the results obtained. For
example, the single oxytocin ERE (OT) which has one base change compared to
the consensus vitellogenin (Vit) ERE, activated gene transcription minimally with
ERa and ER|31 in Hep G2 cells, although in Hek 293 cells ERa was able to activate
the OT ERE to a greater extent than a single consensus ERE. Highest levels of
reporter gene activation were observed with the construct containing three tandem
copies of the ERE consensus sequence. This high level of gene transcription is
consistent with previous published data (Klinge, 1999; Tyulmenkov et al., 2000) and
was observed in both cell lines using either ERa or ER|31. This construct was used
throughout the rest of the studies described in the thesis.
It is well documented that different oestrogenic ligands have the ability to activate
ERa and ER(31 to different extents and this has been attributed by their differential
binding affinity, ability to alter the ER conformation and thereby influence co-factor
recruitment (Barkhem et al., 1998; Kuiper et al., 1997). In this study I analysed the
redistribution and transcriptional activation of the ERs in response to different
concentrations of the natural oestrogenic ligands 17|3-oestradiol, 3(3Adiol and
genistein. The recently developed synthetic ligands PPT™ and DPN™ which are
specific to ERa and ER|31 respectively, were also used. The results demonstrated
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that a redistribution of FP-ERs upon addition of ligand was consistent with an
increase in ERE-Luc reporter gene activation.
However, differences in the subcellular distribution pattern of the FP-ERs were
observed. For example, following exposure to ligand FP-ER(31 tended to form
discrete foci whereas more diffuse foci were observed using FP-ERa. Addition of
different oestrogenic ligands also resulted in variations in the time it took for the ER
to redistribute. The functional studies correspond to these differences and have also
demonstrated that the ligands have a dose dependent impact on activation of hERa
as well as human, macaque and marmoset ER[31. As expected the human FP-ER(32
which lacks the AF-2 region, did not redistribute following exposure to ligand nor did
it activate gene transcription.
In summary, E2 initiated redistribution of the FP-ER most rapidly and initiated the
greatest transcriptional activation of the three natural ligands tested. Human ERa
stimulated ERE reporter gene activation to a greater extent that hER(31 in the
presence of E2 and was shown to redistribute more rapidly.
The DHT metabolite, 3|3Adiol was found to activate ERE reporter gene transcription
greatest with ER|31 compared to ERa, in a dose response manner. Both ERs were
observed to redistribute within the nucleus in Hek 293 and Hep G2 cells. However,
ERa transfected into Hep G2 cells and stimulated with 10"7M or 10"6M 3(3Adiol
activated ERE reporter gene activation dramatically, possibly due to over stimulation
of the ERa.
Exposure to 10~8M of the ER|3-specific phytoestrogen genistein resulted in a slower
redistribution of FP-ERa compared to FP-ERpi. In addition, at higher
concentrations of genistein (10~8M to 10"6M) ERpi stimulated ERE reporter gene
activation to a greater extent than did ERa. These findings are consistent with
previously publications that report genistein is an ER|31-specific ligand with a much
higher binding affinity for ER|3 than ERa, although it exhibits only partial agonism
with ER|31 but full agonism with ERa (Pike eta/., 1999).
In line with previous data (Kraichely et a/., 2000) the synthetic ligand PPT™
activated ERa but not human ER(31. However both macaque and marmoset ER(31
were stimulated to activate reporter gene transcription by PPT™. This result has not
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been previously published and I propose the reason why the primate ER(31 proteins
can be activated by PPT™ may be due to slightly different conformational changes
in their LBD and AF-2 regions upon ligand binding compared to human ER|31.
The ER|3-selective ligand, DPN™, incubated with FP-ER(31 resulted in the
redistribution of the ER into discrete foci, however unexpectedly FP-ERa
redistributed into focal regions more rapidly. Functional assays were in agreement
with the FP data and both ERs activated reporter gene transcription. Additionally, at
high DPN™ concentrations (10"6M), fold activation of ERE-Luc reporter was greater
with ERa than ER|31, whereas at low concentrations (10"7M) this was the other way
round and corresponds to previous publications (Meyers et al., 2001; Ramsey et al.,
2003).
In summary the functional assays have both demonstrated that activiation of ERa
and ER|3 is influenced by the structure of the ligand as well as its concentration. The
results have also demonstrated for the first time that macaque and marmoset ER(31
are activated in a similar manner to human ERpi, except with the novel ERa-
specific ligand PPT™.
There is a growing body of evidence that ERa and ER(3 expression may be
differential or overlapping (Dotzlaw et al., 1997; Saji et al., 2000; Saunders et al.,
2002a; Saunders et al., 2001). Depending upon whether one or both of the
receptors are present in a cell, it is possible that homodimers (ERa/ERa or
ER(3/ER(3) or heterodimers (ERa/ER|3) may be formed.
In Chapter 4 results were presented which showed that following exposure to E2,
FP-tagged hERa was present in the same foci as FP-hER|31 or FP-hER(32.
Furthermore a similar pattern was seen when FP-hER|31 and FP-hER|32 were co-
expressed. However, differences were noted in the behaviour of the receptors in
Hek 293 and the Hep G2 cells. In Hek 293 cells ERa and ER(31 co-localised in foci
and ERE reporter gene activation was increased. ERa and ER|32 did not show a
clear focal pattern and it was difficult to observe foci occurring together, functional
analysis showed a decrease in ERa's ability to activate the ERE reporter gene but
there were variations between experiments. In contrast, in the same cell type FP-
tagged hER|31 and hER|32 appeared to form heterodimers and surprisingly an
increase in ERE reporter gene transcriptional activation was detected.
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In Hep G2 cells FP-hERa and FP-hER|31 were detected in the same foci and the
ERE-Luc reporter gene expression was reduced compared with that observed with
ERa alone. Co-transfections of FP-hERa and FP-hERf52 resulted in detection of
both proteins in some foci and a decrease in transcriptional activation of the reporter
was also observed. The FP-tagged ER(31 and ER|32 were also able to redistribute
together and similar to Hek 293 cells, the presence of ER|32 resulted in an increase
in gene transcription compared to that seen with ER|31 alone.
As demonstrated in this thesis, the hER|32 construct was unable to stimulate ERE-
Luc reporter gene activity in the presence of steroids and FP-ERp2 did not
redistribute upon addition of ligand. However, in co-transfection studies FP-ER|32
was redistributed into foci with ERa or ER(31 and appeared to have an impact on
reporter gene activation. I propose that the focal redistribution of ER(32 observed
when the protein is co-expressed with ERa or ERp1 reflects heterodimerisation with
the full length receptors and that after these bind ligand they "pull" the ER(32 into
focal sites and/or bind as a heterodimer to EREs.
Previously gel shift analysis has demonstrated in an artificial in vitro context, that
ERa, ER(31 and ER|32 all have the ability to form homo- and heterodimers (Cowley
et al., 1997; Moore et al., 1998). Transient co-transfections have been performed
using hERa/ER|31, hERa/ER|32 and hER|31/ER|32 (Hall and McDonnell, 1999;
Ogawa et al., 1998c; Peng et al., 2003). All of these studies have reported that co-
expression of ERf5 has an impact on ERa activated reporter gene expression.
Ogawa et al and Peng et al showed a decrease in ERa induced reporter activation
with increasing concentrations of ER|31 (1:10 and 1:9 ratios respectively) using a 1x
ERE reporter (Ogawa et al., 1998a; Peng et al., 2003). Whereas Hall et al
demonstrated that there was no effect at high (10"7M) ligand concentrations, but at
lower concentrations (10"10M) ERp decreased ERa's activity when transfected at a
1:1 ratio with a 3x ERE reporter (Hall and McDonnell, 1999). Co-transfection of
ER(32 has been shown to decrease ERa's activity (Ogawa et al., 1998c; Peng et al.,
2003). In co-transfections with ER(31 and ER(32 it has previously been demonstrated
that the transcriptional activation remains the same as that seen with ER(31 alone
(Ogawa et al., 1998c).
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Direct comparisons between my studies and those previously published are difficult
because different cell lines, different EREs and varying ER:ER ratios have been
used. Overall I have demonstrated that ER|32 acts to decrease ERa's activity via a
3x ERE-Luc reporter which is similar to previous publications, but acts to increase
ER|31's activity which has not been previously demonstrated.
Gel shift assays have shown that the ERa/ER(31 heterodimer is capable of binding
to the DNA with a similar affinity to that of the ERa homodimer (Ogawa et al.,
1998c) and the dimers were able to bind the co-activator SRC-1 to a similar extent
in gel shift assays (Cowley et al., 1997). However as the heterodimer has less
transcriptional activity than the ERa homodimer it has been suggested that it may
be less efficient at recruiting co-activators in cells (Peng et al., 2003). In contrast to
ER|31, ER(32 was demonstrated to be incapable of interacting with the co-activator
TIF1 a due to its lack of AF-2 region which is involved in co-factor recruitment,
therefore suggesting that the lack of transcriptional activity with ER|32 heterodimers
may be partially due to ER(32's inability to bind co-activators (Ogawa et al., 1998c).
Although it has been postulated that the ability to bind co-activators is not directly
associated with the ability of the ER(31 and ER|32 variants to inhibit ERa activity
(Peng et al., 2003). The ER(32 variant has a markedly reduced ability to bind to DNA
(Moore et al., 1998) and it is possible the ERa/ER|32 heterodimers bind less well
than the ERa/ERa homodimers to the ERE (Moore et al., 1998; Ogawa et al.,
1998c). Therefore the reduced transcriptional activity may be due to a combination
of factors including the reduced ability of the ER|3 variants to form stable
heterodimers and complexes at individual promoters compared with ERa
homodimers.
If ERs are expressed together they form heterodimers, which under experimental
conditions, are preferred over homodimers (Cowley et al., 1997). Therefore, if it can
be concluded that the presence of ER|3 and the variants are able to modulate
activity of ligand bound full length ERa or ER|3, it has physiological significance in
conditions such as altered oestrogen sensitivity, for example in tumours as
previously discussed.
The ER is not the only nuclear receptor with splice variants that are thought to
possess a dominant negative ability. Alternative splicing of the human glucocorticoid
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receptor (GR) generates a non-hormone binding receptor (hGRp) that differs from
the wild type receptor (hGRa) only at the C-terminal. It has been demonstrated that
hGR|3 inhibits the transcriptional activity of hGRa and has physiological
consequences in patients with generalised and tissue-specific glucocorticoid
resistence (Hecht et al., 1997; Oakley et al., 1999; Yudt and Cidlowski, 2001).
The steroid receptor co-activator (SRC-1) is one of a number of transcriptional
modulators that are capable of potentiating the activity of ligand activated nuclear
receptors including the oestrogen receptors (Klinge, 2001). The ER-co-activator
interaction stabilises the formation of a transcription pre-initiation complex and
facilitates the remodelling of chromatin at the target gene promoter (Leo and Chen,
2000).
There are two isoforms of the SRC-1; SRC-1 e and SRC-1 a, which diverge at their
C-termini and are functionally distinct. The difference in activation between the two
isoforms is thought to be due to a second activation domain that is CBP-
independent and is suppressed in the SRC-1a isoform (Kalkhoven et al., 1998). In
these studies in Hep G2 cells I demonstrated that SRC-1 a activated transcription by
human ERa and ER|31 to a greater extent than did SRC-1 e. In previous publications
SRC-1 e was demonstrated to enhance hERa and hER|3 activity to a greater extent
than SRC-1 a in Cos 7 cells (Kalkhoven et al., 1998). The difference between the
two sets of findings may be due to a number of cell-specific differences and the
constructs used.
In co-transfection studies in Hep G2 cells the addition of SRC-1 e stimulated gene
transcription and appeared to oppose the dominant negative effect on ERa induced
by the presence of ER|31 or ER{32. In co-transfection studies with ER|31 and ER|32,
SRC-1 e was observed to increased gene activation in the absence of ligand. This
ligand-independent activation of the reporter may be due to alternative pathways
being activated through the ER(32.
7.3 Alternative Activation Pathways
The ER|32 splice variant does not contain a fully functional ligand binding domain
due to the lack of an AF-2 region, therefore the receptor cannot bind to ligands and
become activated. It was previously thought that ER(32 did not have a function in the
regulation of oestrogen regulated genes, however in this thesis it has been
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demonstrated that the expression of ER|32 can enhance reporter gene activation in
the absence of ligand when it is co-transfected with ER(31. Therefore I proposed that
it could be activated through a non-steroidal pathway such as via the MAP kinase
signalling pathway which has been shown to activate ERa (Pettersson and
Gustafsson, 2001) and mouse ER|31 (Tremblay et at., 1999a). This would be
consistent with the presence of intact AF-1, DNA binding and dimerisation domains.
In this study I have demonstrated for the first time that phosphorylated MAP kinases
(p44 and p42) are present in Hek 293 and Hep G2 cells even when they were
cultured without serum or exogenous growth factors. I have also demonstrated that
both cell lines express IGF receptor and Hek 293 cells express the EGF receptor
(mRNA and protein) and therefore activation of the MAP kinase signalling cascade
following the addition of growth factors is possible. In Hek 293 cells transfections
using the FP-tagged ER have shown that ERa, ER|31 and ER(32 all redistribute from
a diffuse distribution to a focal pattern in the presence of EGF. Functional studies
have been performed and have demonstrated that the addition of EGF to Hek 293
cells transiently transfected with ERa, ER(31 or ER(32 and an ERE-Luc reporter
construct resulted in increased gene activation. This result indicates that ERs,
including ER(32, are activated by phosphorylation from the MAP kinase pathway.
This alternative pathway of ER|32 activation is most likely most due to the
phosphorylation of serine residues in the AF-1 domain. It has previously been
demonstrated that hERa (Kato et at., 1995) and mouse ER(31 (Tremblay et at.,
1999b) are phosphorylated via the MAP kinase pathway at serine residues in the
A/B domain, specifically Ser118 in ERa (Kato et at., 1995) and Ser87 and Ser106 in
ER|3 (Rochette-Egly, 2003). These two serine residues in ER[31 have been
proposed to be phosphorylated by MAP kinases (Rochette-Egly, 2003) and peptide
sequence alignment shows that human ER|32 contains identical residues to human
ERpi within the A/B domain.
7.5 Future work
Further studies on cell-specific expression of ERp2 in the primate will require
development of new antibody reagents. RT-PCR analysis has detected mRNA for
ER(32 within cDNA pools taken from the same range of primate tissues as those
examined from human, suggesting that the primate ER|32 protein may be expressed
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in a similar pattern to the human. In human tissues it would be very interesting to
perform dual or triple immunohistochemical staining for ERa, ERpi and ERp2 to
determine their differential expression in tissues and to show which cells express
both receptors. However this has not been possible to date due to poor specificity of
secondary antibodies.
In the transient transfection studies only 30% of the cells were transfected, therefore
in the co-transfection studies it was difficult to achieve transfection of both receptors
in the same cell. This low level of transfection efficiency was observed using FP-
tagged receptors where the ER proteins could be visualised and from the
immunocytochemical staining of transfected cells. This may have had an impact on
the functional studies where variation between individual experiments was
observed, most likely due to the inefficiency of dual transfections. Therefore I
attempted to produce a stable Hek 293 cell line expressing either ER|31 or ER(32
tagged to the green fluorescent protein, to obtain a uniform level of expression of
the ER. However after cloning the vectors, isolation of a stable line proved
extremely time consuming and I decided to concentrate on the transient
transfections instead. However, within our laboratory adenoviral constructs have
been prepared using the FP-ERpi and FP-ER|32 and as these result in more
efficient transfection of cells future work using these adenoviral constructs in co-
transfection studies will be undertaken to extend the current findings.
Since cloning the ERpi and ER(32 constructs with the fluorescent tags, I think it
would be extremely interesting to be able to observe the co-localisation of these
receptors with the co-activator SRC-1. Stenoien et al have previously demonstrated
that SRC tagged with the green fluorescent protein co-localised to the same nuclear
matrix bound foci as ERa tagged with the yellow fluorescent protein, in response to
E2 (Stenoien et al., 2000). Similar experiments have not been performed using ERpi
or co-transfections with ERa and ERp. Therefore future studies with the tagged
SRC-1 and ERa or ERp would be valuable in assessing the ability of ER(3
homodimers or ERa/ERp heterodimers to recruit SRC-1.
Preliminary data (Moore et al., 1998; Scobie et al., 2002) suggests that human
tissues also express other ERp variants (ERp3, ERp4 and ERp5) different to the
ERp2 splice variant studied in this thesis. For example, in tissues such as the
testes, ERp4, which lacks a DNA binding domain, is abundant and therefore may
Chapter 7 General Discussion 276
alter oestrogen regulation. These ER(3 variants may therefore add to the complexity
of the oestrogen and growth factor responsiveness of reproductive tissues.
Additional studies are required to determine if co-expression of ERp variants can
alter ligand-dependent gene activation via full length ERa or ER(31 and to determine
whether they have significant physiological effects.
Future work into the activation of a non-steroidal pathway is required. I have only
looked at one of the phosphorylation cascades and more work is required using
techniques such as immunoprecipitations with specific antibodies to determine the
phosphorylation status of the ER|31 and ER|32 in the presence and absence of EGF.
Further work is also required to determine the precise pathway of activation of the
ERp2 and whether this activation pathway plays a large or a basal role in the
transcription of genes. It would be interesting to block the MAP kinase pathway to
determine whether other pathways are involved in ER activation. There are also
other interacting proteins such as co-activators that are recruited upon the
phosphorylation of the oestrogen receptor which need to be analysed.
I have shown that the EGF receptor is present in the testis within the membrane of
germ cells in humans and primates, therefore demonstrating that the receptor is
present in the same cell type as ER(31 and ER|32. It is necessary to now perform
dual immunohistochemical studies on a wider variety of tissues to determine the
exact localisation of these receptors and to establish whether this alternative
phosphorylation pathway is feasible.
7.5 Conclusions
In summary the results obtained demonstrate that ER(31 and ER|32 are expressed in
a variety of cells within reproductive tissues of females and males, in human and in
two primates. Human ERa and human, macaque and marmoset ERpi are activated
by a variety of oestrogenic ligands. The ER|32 variant cannot be activated by binding
of oestrogens due to the lack of an AF-2 region, but appears to be a target for
phosphorylation via growth factor stimulated pathways. The ability of the ER|32
"receptor" to form heterodimers with ERa and ERp 1 and thereby altering target cell
responsiveness to oestrogens may have an impact on cell function. Further studies
are now required to elucidate the relative contributions of ERa, ERp 1 and ER|32
variants in the response of tissues to oestrogens and growth factors.
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